Upload
infomedia18
View
233
Download
0
Tags:
Embed Size (px)
DESCRIPTION
Modern Pharmaceuticals is a leading monthly business magazine in India, catering to the pharmaceutical industry. Published by Network 18 Ltd., it covers the latest industry trends & technologies, business strategies & management issues, views & visions of industry leaders in the Indian and global context. In addition, this magazine acts as a useful platform for effective interaction between several producer and user fraternities.
Citation preview
Als
o av
aila
ble
in S
ri La
nka,
Mal
aysi
a, S
inga
pore
, Tha
iland
, Tai
wan
, Chi
na &
Hon
g K
ong
Editorial
5March 2012 I Modern Pharmaceuticals
W
Budget 2012: Reforms on fast track?
EditorialAdvisory Board
Ajit SinghChairman, ACG Worldwide
& Head, ISPE
Dr Abraham PataniPast President, IDMA & CMD, Inga Laboratories
Dr Gopakumar G NairIPR Consultant & Advisor
Dilip G ShahChairman, IGPA &
Secretary General, IPA
Daara PatelSecretary General, IDMA
ith this year’s Union Budget around the corner, and more importantly, its
potential upshots for the near future, it will be pertinent to do a dipstick
on some of the recent developments – both global and national – that can
significantly impact the pharmaceutical sector. Also, it will be prudent to
take strategic steps for the road ahead.
First, let’s touch upon the global scenario. The macroeconomic deceleration of
recent times is primarily owing to sovereign debt issue in certain geographies rather
than industry/company-specific financial meltdown as was experienced in 2008-09.
This means there are good as well as bad news. The good part is that the extent of
the meltdown pulling down businesses may not be as globally widespread as it was the
last time; hence, there will still be some emerging growth markets, albeit with a slow
pace of progress. However, the bad news is that no one is yet clear
about how long this business dampener will draw out, and what
if this malignancy spreads to other geographies.
As far as India is concerned, the government’s policy paralysis
seems to drag on with some of the crucial misses being the deferral
in implementation of Goods and Services Tax (GST) and Direct
Tax Code (DTC). However, recently things have picked up
some pace as the government has reportedly been able to
obtain in-principle approval from all state governments
on implementation of GST.
From a sectoral perspective, it is expected on the part
of the government to undo preferably all the benefits
that were withdrawn in the last year’s Budget, in order
to ensure a level playing field in the market atleast for
a certain period. Besides, the Finance Ministry will do
well in keeping overall policies stable and by making
growth-centric tax amendments. All these should be in line with
the Pharma Vision 2020 for India wherein it is envisioned to
become one of the most attractive destinations for end-to-end
drug discovery and innovation.
That said, the forthcoming Union Budget will be an opportune
moment for the policy-makers to make a decisive beginning,
perhaps the second phase of economic liberalisation, and leave a
long-lasting impression on the economy as well as the industry.
Read on and stay tuned for more on this in the next edition.
Manas R [email protected]
Contents
7March 2012 I Modern Pharmaceuticals
5 Editorial
10 News, Views & Analysis
22 Technology & Innovation
26 Technology Transfer
69 Projects
71 Event List
75 Book Review
76 Products
86 List of Products
87 List of Advertisers
Special Focus
REGULAR SECTIONS
Details on page no.30
In Conversation With Manish Doshi President, Indian Drugs Manufacturers Association and MD, Amoli Organics Pvt Ltd
28
Tax incentives ...............................................................32R&D incentives ............................................................34Interface - Dr Rajesh Jain ...............................................36Roundtable ....................................................................38
Budget Wishlist ..............................31
Insight & Outlook
SMEs growth story ........................................................44Role of bankers and government .....................................46SMEs in South India .....................................................48SMEs in spotlight ..........................................................50Interface - Jagdeep Singh ................................................52Roundtable ....................................................................54Th yroid cancer therapeutics market .................................55Case Study - Fighting counterfeits ..................................56
Pharma SMEs ...................... 43
Facility Visit IKA India Pvt Ltd Capitalising on the India advantage
40
Automation Trends Process Analytical Technology
Th e less explored opportunities ...................................58
Energy Management Carbon neutrality
Inching closer to the green dream ..............................60
Policies & Regulations Policies governing drug counterfeiting
Rigorous implementation: Th e way forward ...............64
Strategy What’s new in pharma marketing?
Selective pampering ...................................................66Dr Rajan T D, Pharma Consultant & Practising Dermatologist
Tips & Tricks Patent prosecution tips
Factors to be considered before fi ling a patent ............68Kamakhya Srivastava, Head-Group on Research Publication and Programme, LEX ORBIS IP Practice
Note: ` stands for Indian rupee, $ stands for US dollar and £ stands for UK pound, unless mentioned otherwise
Highlights of Next Edition
Special Focus: IT in pharma
Insight & Outlook : Cleanrooms
Event Report BioAsia 2012
Targetting the vaccine and drug discovery market ......73
9March 2012 I Modern Pharmaceuticals
FOUNDER & EDITOR, NETWORK 18Raghav Bahl
PRESIDENT & EDITORIAL DIRECTOR, TV 18Senthil Chengalvarayan
SENIOR EDITORManas R Bastia
FEATURES EDITORArshia Khan
EDITORIAL TEAMChandreyee Bhaumik, Parita Dholakia, Michael Anthony, Abha Mishra,
Paskaline Sebastian, Titash Roy Choudhury (Delhi), Jasleen Kaur Batra (Bengaluru)
ASSISTANT ART DIRECTORVaruna Naik
DESIGNSachin Bhogate
CHIEF PHOTOGRAPHERMexy Xavier
PHOTOGRAPHYNeha Mithbawkar, Joshua NavalkarBUSINESS CONTROLLERS
Pukha Dhawan, Lovey Fernandes, Akshata Rane, Deepak Bhatia, Shwetha ME, Jayashree N, Sugandha Kulkarni, Shefali Mahant
PRINTINGEXECUTIVE VICE PRESIDENT
Ananth R IyerASSISTANT GENERAL MANAGER - PPC
Shekhar KhotPRODUCTION TEAM
Dnyaneshwar Goythale, Surekha Karmarkar, Ravikumar Potdar, Ravi Salian, Sanjay ShelarOVERSEAS CONTACT
Ringier Trade Media Ltd CHINA1001 Tower 3, Donghai Plaza, 1486 Nanjing Road, West, Shanghai 200040, China
Tel: +86-21 6289 – 5533 Ext. 368, Fax: +86-21 6247 – 4855 (Craig Shibinsky) Email: [email protected] Trade Media Ltd HONG KONG
9/F, Cheong Sun Tower, 118 Wing Lok Street, Sheung Wan, Hong Kong Tel: +852 2369 – 8788 Ext. 21, Fax: +852 2869 – 5919
(Octavia Au-Yeung) Email: [email protected] Trade Media Ltd TAIWAN
Room 3, Fl. 12, No. 303, Chung Ming S. Rd., Taichung, TaiwanTel: +886-4 2329 – 7318 Ext. 16, Fax: +886-4 2310 – 7167
(Sydney La) Email: [email protected] Trade Media Ltd GERMANY, AUSTRIA, SWITZERLAND
Tel: +41-44 734 0472, Fax: +41 44 734 0680Email: [email protected]
USA Tel: (513) 527-8800 Fax: (513) 527-8801
Email: [email protected]
USA Alfredo Domador, 6505 Blue Lagoon Drive, Suite 430 Miami, FL. 33126, USA
Tel: (305) 448-6875, Fax: (305) 448-9942
GROUP CEO, NETWORK 18B Sai Kumar
CEO-PUBLISHING, INFOMEDIA 18Sandeep Khosla
EVP-HUMAN RESOURCESSanjeev Kumar Singh
ASSOCIATE VICE PRESIDENTSudhanva Jategaonkar
ADVERTISING SALESShashin Bhagat (Ahmedabad)[email protected] B (Bengaluru)[email protected] Hara Subramaniam (Chennai)[email protected] N (Coimbatore)[email protected] Kalyan Chakravarthy (Hyderabad)[email protected] Gokhale (Indore)[email protected] Bidawat (Jaipur)[email protected] Abhik Ghosal (Kolkata)[email protected] Dhingra (Ludhiana)[email protected] Yadav (New Delhi)[email protected] Dass (Pune)[email protected] Pathak (Vadodara)[email protected]
MARKETING TEAMGanesh Mahale, Prachi Mutha, Varsha Nawathe, Abhay Borkar
NEWSSTAND AND SUBSCRIPTIONSDISTRIBUTION HEADSunil NairDEPUTY GENERAL MANAGERManoj PalsaySENIOR MANAGER - SUBSCRIPTIONSSheetal Kotawdekar
CO-ORDINATORSRahul Mankar, Anant Shirke, Sarita Quadros,Chaitali Parkar, Kamlesh Mathkar, Vaibhav Ghavale
SERVICESSUBSCRIPTION SERVICES For subscription queries, write [email protected] or call +91 22 30034631-34 or toll free 1800 200 1021PERMISSIONS For subscription to copy or reuse material from Modern Pharmaceuticals,Write to [email protected]
• Monthly Issue Price: ` 100 • Annual Subscription: ` 799
Views and opinions expressed in this magazine are not necessarily those of Infomedia 18 Ltd, its publisher and/or editors. We at Infomedia 18 Ltd do our best to verify the information published but do not take any responsibility for the absolute accuracy of the information. Infomedia 18 Ltd does not accept the responsibility for any investment or other decision taken by readers on the basis of information provided herein. Infomedia 18 Ltd does not take responsibility for returning unsolicited material sent without due postal stamps for return postage. No part of this magazine can be reproduced without the prior written permission of the publisher. Infomedia 18 Ltd reserves the right to use the information published herein in any manner whatsoever.
Infomedia 18 Ltd is the publishing arm of Network 18.
Printed by Mohan Gajria and published by Lakshmi Narasimhan on behalf of Infomedia 18 Ltd.Senior Editor: Manas R BastiaPrinted at Infomedia 18 Ltd, Plot no.3, Sector 7, off Sion-Panvel Road, Nerul, Navi Mumbai 400 706, and published at Infomedia 18 Ltd, ‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai - 400 028. Modern Pharmaceuticals is registered with the Registrar of Newspapers of India under No. MAHENG / 2008 / 27125. Infomedia 18 Ltd does not take any responsibility for loss or damage incurred or suffered by any subscriber of this magazine as a result of his/her accepting any invitation/offer published in this edition.
News,Views & Analysis
10 Modern Pharmaceuticals I March 2012
To emphasise the need for
selecting the right people
to man the innovation-
led pharma industry, the
Indian Institute of Health
Management Research
(IIHMR) conducted a
National Conclave on ‘Human
Resource Management in
Pharmaceutical Industry:
Challenges and Future
Directions’. Th e Organization
of Pharmaceutical Producers
of India (OPPI) lent active
support for this step taken
to analyse the importance
of Human Resources in a
start-up, budding or a well-
established pharma company.
S D Gupta, Director, IIHMR,
said, “By introducing courses
such as hospital and pharma
management, IIHMR strives
to resolve the issue of talent
crunch by producing well-
qualifi ed students capable of
making a real diff erence in the
fi eld of pharma, by preparing
them for the corporate roles,”
added Gupta.
Th e goals for human resources
are talent development,
employee retention and
confl ict management.
Mumbai-based Aanjaneya Lifecare Ltd, a leading manufacturer of bulk drugs, recently announced that the company has acquired Apex Drugs and Intermediates Ltd (ADIL), an integrated API and pharma intermediates manufacturing company based in Hyderabad. Th e acquisition was valued at ` 250 crore; with debt of ` 185 crore and equity dilution of ` 65 crore.
Aanjaneya Lifecare Ltd has acquired ADIL’s assets, businesses, clients, licensees, employees and has merged both the companies’ operations, becoming a fully integrated formulation company. Th e company will also leverage the strong relations of ADIL developed in Asia, Europe, UAE & Latin America for exports. Th e acquisition also gives Aanjaneya an entry in Hyderabad market.
Post acquisition, Aanjaneya Lifecare will have approximate sales of ` 700 crore with EBITDA of ` 130 crore and total long term debt in books of about ` 220 crore against net worth of ` 365 crore.
Aanjaneya Lifecare acquires Apex Drugs and IntermediatesIIHMR and OPPI organise conclave on human resource strategy in pharma sector
Indoco Remedies has recently announced a
change of leadership with the appointment
of Aditi Kare Panandikar as the Managing
Director (MD) and Sundeep Bambolkar as
joint MD of the company. Aditi took over
the coveted position from Suresh Kare who
has stepped down from the post. However
he informed that he would be retaining the
position as the Chairman of the company.
Suresh Kare has been handling the
responsibilities of the company for the last
fi ve decades and has been instrumental in
positioning the company as one of the top
pharma companies in the country today.
He informed that seeing Indoco’s growth
over the years and the swift changes that
is taking place in the industry it was high
time to hand over the responsibilities to
a younger and competitive generation.
Commenting on the changing roles,
Aditi Kare Panandikar said, “I am very
happy with this decision as it had been my
dream to take up this position, wherein I
can contribute my share in the company’s
growth and development.” She added, “Th e
company has plans to expand its business
and explore new business ventures focussed
on propelling and pushing the company
towards its growth trajectory. Bambolkar,
Joint MD, Indoco Remedies, informed
that the company aims to grow the
domestic formulations business accounting
for about 65 per cent of the revenues and
aggressively to expand its presence. “Our
vision is to grow the international business
by more than 50 per cent year on year
in the next four to fi ve years. For this the
peripheral support systems such as trained
technical manpower and manufacturing
facilities approved by the most advanced
regulatory agencies are already in place,”
informed Bambolkar.
Suresh Kare steps down as the MD, Indoco
Ranbaxy opens manufacturing facility in MoroccoRanbaxy Morocco has announced the
opening of its new manufacturing facility at
Casablanca, Morocco, paving the way for a
direct business presence in North Africa.
With the successful audit of the facility
by the Moroccan Health Authorities,
Ranbaxy Morocco is now authorised to
commence manufacturing of its products at
its Casablanca facility. Th e achievement of
this milestone positions Ranbaxy to access a
$1 billion pharmaceutical market in Morocco.
Mahendra Bhardwaj, Head, Africa,
Ranbaxy, said, “Ranbaxy has a signifi cant
presence in Africa with its own ground
operations in key markets. Morocco is
one of the important markets and this
manufacturing facility further reinforces
our commitment to the people of Morocco
and the African continent.” In addition to
servicing the Morocco market, Ranbaxy
also plans to extend the supply from this
manufacturing unit to other African
countries, in the coming years. Ranbaxy
has a strong presence in Africa.
With the addition of Morocco, the
Company now has three manufacturing
facilities in Africa; the other two located
in Nigeria and South Africa respectively.
With fi ve subsidiaries, fi ve representative
offi ces and a strong workforce of nearly
a 1,000 people, Ranbaxy’s distribution
network caters to 44 of the 54 countries in
this continent.
L-R: Bambolkar, Kare and Panandikar
News,Views & Analysis
12 Modern Pharmaceuticals I March 2012
Sudhir Valia, Director, Sun
Pharma, was awarded the
Best Performing CFO in the
pharma/healthcare sector in
an award ceremony hosted
by CNBC-TV18. Th e event
witnessed many prominent
names from the industry
such as Y M Deosthalee-
Chairman & Managing
Director-L&T Finance
Holdings; Keki Mistry,
Vice Chairman & Chief
Executive Offi cer, HDFC Ltd
among others.
Speaking on the occasion,
Udayan Mukherjee, Managing
Editor, CNBC-TV18 said,
“It takes intuition, leadership
and vision to guide India’s
corporates through the current
turbulent phase.”
Sun Pharma honoured at CNBC-TV18 CFO Awards 2012
Dr K Anji Reddy honoured with Lifetime Achievement awardDr K Anji Reddy, Founder and Chairman, Dr Reddy’s
Laboratories Ltd, has been honoured with the Lifetime
Achievement in Health Award in the Asian Voice
Political & Public Life Awards for 2012 at London
for his lifetime commitment to medical research and
improving the lives of others. Voted by a committee
of Members of Parliament in Britain, this award is
an annual event hosted by Th e Asian Voice, a weekly.
Th e award ceremony was hosted at the Members’
Dining Room in the House of Commons, London.
Satish Reddy, MD & COO, Dr Reddy’s
Laboratories Ltd, who collected the award on
behalf of his father, also shared a note of thanks by
Dr Reddy on the occasion. On receiving the award,
Dr Reddy said, “I thank Keith Vaz, Member of
Parliament, Britain and host and the organisers
of this event for the recognition. I consider myself
to be fortunate that my country had given me the
opportunity to participate in the advent of aff ordable
medicine in India.”
Sourabh Mishra joins Sorento Healthcare as Business Strategy Consultant
IPC holds symposium for global quality standards for biologics and SCMIndia’s role as a leading fi gure in
global pharma manufacturing brought
together regulators, manufacturers and
other stakeholders in global public
health at the 11t IPC-USP Science
& Standards Symposium on February
22–23 in Mumbai. Hosted by the Indian
Pharmacopoeia Commission (IPC) and
the US Pharmacopoeial Convention
(USP), the nearly 400 attendees explored
ways in which science and quality standards
can help ensure good quality medicines in
India and throughout the world.
Symposium co-sponsors were the
Association of Biotechnology Led
Enterprises, the Bulk Drug Manufacturers
Association, the Indian Drug
Manufacturers Association, the Indian
Pharmaceutical Association, and the
Organization of Pharmaceutical Producers
of India. “When it comes to medicines,
good quality begins with good science,” said
Dr Praveen Tyle, Executive Vice President
and Chief Science Offi cer, USP. Topics of
discussion included therapeutic proteins,
another important class of drugs for India’s
growing biologics manufacturing sector;
strategic perspectives on biotechnology
products in developing countries; the
role of bioassays in biosimilars; and the
replacement of animal studies for potency
testing of human vaccines.
Dr V Srini Srinivasan, Executive
Vice President, International Sites and
Standards, USP and moderator for
the symposium’s opening session, said,
“Increasingly sophisticated discoveries
in science are leading to dramatic
insights into health and disease, and the
pharma community plays a key role
in translating those advances into
medical solutions that will help patients
worldwide. At the same time, those in
pharma and regulatory circles in India—
and throughout the world—must look to
increasingly robust measures to protect
the quality of pharma products sourced
and developed through a complex
network of global partnerships and
supply chains.”
-Chandreyee Bhaumik
Sorento Healthcare
Communications Pvt Ltd has
brought Sourabh Mishra on
board as Business Strategy
Consultant. Mishra meanwhile
also continues as Chief
Strategy Offi cer at Saatchi &
Saatchi, India. Talking about
his new association, Mishra
said, “Th e opportunity to
enhance the value of Sorento’s
communication solutions in healthcare by better
integrating the strategic planning process is exciting.
Sorento has already moved much beyond conventional
mass media-based communications. In that context, the
task is also to see how we can better integrate the various
off erings it has, in order to provide more holistic solutions
to clients.”
Dr Reddy’s Laboratories has launched ziprasidone hydrochloride
capsules, a bioequivalent generic version of Geodon® in the US market
following the approval by the US FDA of Dr Reddy’s ANDA for
ziprasidone hydrochloride capsules. Th e Geodon® brand had US sales
of approximately $ 1.34 billion for the most recent twelve months
ending December 2011 according to IMS Health.
Dr Reddy
Mishra
Dr Reddy’s launches of ziprasidone hydrochloride capsules
News,Views & Analysis
14 Modern Pharmaceuticals I March 2012
Espicom Business Intelligence, has recently
announced the launch of Espicom Interactive.
For many companies the cost of business
information represents a signifi cant investment. Its
practical use in defi ning commercial strategy and
in understanding market environment is critical
to success. However, the value of such investments
is really benefi cial if the service empowers staff to
greater effi ciency in its use. Espicom Interactive is a
new service that combines Espicom’s class-leading
information services with an online delivery that is
feature rich in user benefi ts saving time and money.
Eric Wigart, Chairman, Espicom, stated, “We
understand that customers need critical information
for their practical day-to-day planning and
development work. Such information is to be used,
not just read. For 30 years Espicom has been at the
forefront of meeting the informational needs of
clients, and with the launch of Espicom Interactive
we can save them a whole lot of time and eff ort in
using it.”
TAKE Solutions Ltd has announced
the availability of PharmaReadyTM
5.0, a web-based regulatory
compliance solution suite for Life
Science organisations to ensure faster
approvals for their new products.
Th e latest version introduces new
document management features,
and delivers technology framework
upgrades to enhance scalability,
response time, and ease-of-use.
PharmaReady 5.0 supports
submissions to Swissmedic (in
addition to US FDA, Heath
Canada and EMEA). It comes
with an improved dashboard for
easier navigation and management
of documents from a centralised
location, provides more visibility and
control of e-document/e-submission
processes, and introduces new
functionalities including drag and
drop for quicker document uploads.
In addition, PharmaReady 5.0
includes an enhanced, highly scalable
technology framework allowing
the suite to run seamlessly on any
Microsoft platform.
Ram Yeleswarapu, President
and CEO, TAKE Solutions, said,
“TAKE Solutions has understood
the pulse of the life sciences market
and has worked persistently towards
achieving the goal of better value to
our customers. Having used both our
IT expertise, as well as our domain
knowledge, we are proud to release
the upgraded version PharmaReady
5.0.” He added, “PharmaReady is a
stable and growing product line that
has been consistently delivering value
to our customers across the globe.”
TAKE Solutions announces global release of PharmaReady 5.0
Prayas, the social welfare initiative of
Sanofi , launched its fi rst disease awareness
programme that focusses at empowering
doctors in rural India with the latest
developments and updates in medicine. It
engages medical experts from tier I cities
to help develop a course curriculum that
is aligned to the needs of rural doctors.
Further, these experts train a select pool
of ‘mentors’ who are expert doctors from
tier II towns who in turn then coach
rural doctors or the ‘mentees’. Dr Viraj
Rajadhyaksha, Associate Director, Medical
Aff airs and Prayas initiatives, Sanofi ,
said, “We aim at bridging the diagnosis-
treatment gap through a structured
continuing education programme for
rural doctors across India.
Th e ‘Prayas’ workshops are diff erent
from other Continuing Medical Education
(CME) programmes as the focus is not on
a molecule or brand.” He added, till now,
over 6,300 Prayas workshops have been
conducted in 14 states of India. A total
of 564 mentors guide 11,500 mentees
who are registered on the programme.
Th e programme aims to cover 1,00,000
mentees by 2015. Prayas would continue
in its mission of facilitating healthcare
to rural interiors through expansion of
mentees covered in next fi ve years.
-Chandreyee Bhaumik
Prayas launches disease awareness programmes
Espicom launches Espicom Interactive
Brenntag, the global leader in chemical
distribution, inaugurated its new head
offi ce in Mumbai. Th is new offi ce represents
Brenntag’s continued commitment to
invest in India and to ensure the company
has ample room for its planned growth
over the next few years.
At the inauguration of the new offi ce, Steve
Holland, CEO, Brenntag Group, said, “India
is a key market in Brenntag’s global strategy.
By expanding our local presence in major
cities such as Mumbai, we are supporting
our strategy of being the leading chemical
distributor in both specialty and industrial
chemicals. We already have a strong foothold
in India and we expect to take advantage
of the high growth potential in the growth
market.”
Th e new head offi ce has a space area
covering 15,000 sq ft and will have room for
more than 100 employees. At present, there
are 44 employees based at the new offi ce, In
addition, Brenntag has offi ces and distribution
facilities in Baddi, Bengaluru, Chennai,
Gurgaon, Haridwar and Hyderabad.
-Chandreyee Bhaumik
Brenntag opens new head offi ce in India
Brenntag Indian team welcomes Holland
Dr Rajadhyaksha
News,Views & Analysis
16 Modern Pharmaceuticals I March 2012
Life Technologies Corporation, a
California-based company announced the
launch of its new benchtop Ion ProtonTM
sequencer powered by Ion TorrentTM
semiconductor in India that is enabled to
whole genome sequencing of both human
and plants in a day at the fraction of its
current equipment and running costs. Th is
device will be able to read an entire human
gene at ` 50,000 in about two hours, as
opposed to the earlier devices that required
days to process an entire gene and at a cost
of $5,000 to 10,000. In India, this is the
only technology present that is capable of
providing this service at such a low price
and fast speed.
“Th e Indian market is a fast growing
market and much of the worldwide
pharmaceutical industry is positioning
itself here in India,” says Gregory
T Lucier, Chairman & CEO, Life
Technologies. Th e company has spent
almost $1 billion in the development of
this semiconductor sequencer. Lucier
pointed out, “Cancer is the disease of
the DNA but mostly up until now when
somebody contracts that disease we
are not reading the DNA to fi gure out
what the right therapy is. With this
technology we will be able to read
somebody’s DNA who is suff ering from
cancer and develop a holistic approach for
his/her treatment. Th is technology will
also be useful to stop spread of infectious
disease outbreaks.”
-Titash Roy Choudhury
Sanofi Pasteur, a vaccines division
of Sanofi , has announced the
formalisation of a marketing and
distribution pact with Pune’s
Emcure Pharmaceuticals for the
anti-rabies vaccine - Verorab.
Th e product will be imported
and supplied by Sanofi Pasteur
India Pvt Ltd and then it marketed
and distributed by Emcure via its
subsidiary, Zuventus Healthcare,
according to Sanofi .
Both the fi rms will be
jointly working to increase the
awareness on rabies vaccination
at the general practitioner and
physician level, which is the fi rst
point of contact for patients and
caregivers in regard to rabies
exposure risk.
Zuventus Healthcare will be
promoting Verorab across India to
more than 60,000 physicians and
general practitioners. Verorab is a
purifi ed vero cell rabies vaccine
and it has been unveiled by
Sanofi Pasteur in 1987 in India.
Since then, over 25-million doses
of Verorab have been disbursed in
India.
Sanofi Pasteur partners with Emcure Pharmaceuticals for anti-rabies vaccine ‘Verorab’
Life Technologies introduces machine capable of genome sequencing within 2 hour and at less than ` 50,000
Panacea Biotec, India’s leading vaccine
manufacturer launched POLPROTEC
(an enhanced potency, inactivated poliovirus
vaccine) in Nigeria in collaboration with Emzor
Pharma, Nigeria.
On this occasion, Panacea Biotec and Emzor
announced a joint Planet Polio-Free Mission
statement ‘To contribute towards achieving the goal of global polio
eradication and to ensure that no child will ever again be paralysed by
WPV or Vaccine-Derived Polio Virus (VDPV) by providing complete
portfolio of Oral Polio Vaccines (OPV) & Inactivated Polio Vaccine
(IPV) & IPV-based combination vaccine at an aff ordable price’.
Dr Rajesh Jain, Joint MD, Panacea Biotec, said, “Panacea Biotec
foresaw the need of IPV during the end game of polio eradication
programme long back and launched the vaccine in India in 2008. We
are now taking this vaccine to other polio endemic countries and are
pleased to launch POLPROTEC® in Nigeria.
In 2011 till week 39, 30 cases of Acute Flaccid Paralysis (AFP) has
been reported in Nigeria.
Panacea Biotec launches polio virus vaccine in Nigeria
Ranbaxy recently took on record the audited results
for the quarter and year ended December 31, 2011.
Commenting on the business results, Arun
Sawhney, CEO & Managing Director, Ranbaxy,
said, “I am delighted to share with you that
Ranbaxy is the fi rst pharma company of Indian
origin to have surpassed sales of $ 2 billion.
We successfully launched atorvastatin, generic
Lipitor® in the US. I am satisfi ed with the progress we
are making in resolving the long standing issues with
the US regulators.
Th e settlement with the US FDA and provision
for eventual penalties that the DOJ may levy,
brings greater predictability to our business in the
US, one of our largest markets.” “During the year,
we laid emphasis on strengthening our
processes, focussing R&D eff orts on our chosen
therapies, working towards improving manufacturing
effi ciencies and costs, re-evaluating our brand
marketing strategy and directing our energies at
markets of greater importance.” Indian pharma
business recorded sales of ̀ 19,513 million ($ 412 Mn),
a growth of 7 per cent for the year. Of this, Consumer
Healthcare or the OTC business recorded sales of
` 3,110 million ($ 67 million), a growth of over
20 per cent for the year.
Ranbaxy crosses $2 billion in global sales
Pfi zer recalls Prevnar 13 pneumococcal vaccineDrugmaker Pfi zer Inc is recalling one lot of its blockbuster
vaccine against pneumococcal disease, Prevnar 13.
Th e lot is being recalled from a drug wholesaler as
the active ingredient was past its expiration date. Th e
company says none was distributed to health care
providers. Prevnar 13 protects against 13 strains of
pneumococcal bacteria, which can cause meningitis,
pneumonia and ear infections.
News,Views & Analysis
18 Modern Pharmaceuticals I March 2012
Strides Arcolab Ltd (Strides)
had announced that it has
received US FDA approval for
its ‘Brazilian Sterile Penems’
facility, which manufactures
sterile dry powder injectables
of Penems. Th e plant has
already been approved by
other international regulatory
agencies such as MHRA
and ANVISA and with this
approval the company is in
a position to commercialise
products worldwide in the
second half of 2012.
Th e approval is also the
fi rst US FDA approval for
an international facility of
Strides. Th e approval and
commercialisation of the
products, which are already
licensed to partners worldwide
are expected in the second half
of 2012.
Commenting on the
occasion, Venkat Iyer, CEO,
Agila Specialties, said, “Th is
approval for our Brazilian
Sterile Penems manufacturing
facility in the niche domain is
another milestone in positioning
Agila as a leading global
injectable player”.
Carbapenems are a class of β-
lactam antibiotics with a broad
spectrum of antibacterial activity
and one of the last resorts for
many bacterial infections. Th e
global market size for Penems
is approximately $ 2 billion.
Glenmark Pharmaceuticals had issued a voluntary
nationwide recall in the US for seven lots of its oral
contraceptive norgestimate and ethinyl estradiol tablets due
to a packaging error.Th e recall is issued by the company’s
US arm Glenmark Generics Inc for tablets in strengths of
0.18 mg/0.035 mg, 0.215 mg/0.035 mg, 0.25 mg/0.035 mg,
Glenmark Pharma said in a statement.
“Th e recall is being implemented because of a packaging
error, where select blisters were rotated 180 degrees within
the card, reversing the weekly tablet orientation and making
the lot number and expiry date visible only on the outer
pouch,” it added.
As a result of the error the daily regimen for these oral
contraceptives could leave women consumers in US at risk
for unintended pregnancy, the company said. It, however,
did not mention the fi nancial implications of the recall
exercise.”At this time, there remains suffi cient supply of
unaff ected lots of material in the marketplace to support
demand, Glenmark said.
Glenmark recalls select lot of oral contraceptive in US
Strides Arcolab announces US FDA approval for its Brazilian facility
Drug fi rm Elder Pharmaceuticals has
launched three female personal hygiene
products in India as part of its in-licensing
pact with a US based fi rm, Combe Inc.
Th e company has introduced the
‘Vagisil’ range of feminine personal
hygiene products in India, in association
with New York-based Combe Inc, a
global brand leader in feminine care,
Elder Pharma said in a statement.
Th e Mumbai-based fi rm, which has
in-licensed the range from Combe
Inc, is introducing three key solutions,
Vagisil anti-itch creme, Vagisil intimate
feminine wash and Vagisil
intimate feminine lubricant,
it added.
Commenting on the
development, Alok Saxena,
Joint Managing Director,
Elder Pharma said, “Th e
Vagisil range of feminine
hygiene products has
been launched in India keeping in
mind growing day-to-day problems of
women, including vaginal itching, dryness,
odour, irritation, burning and discharge.
It is a new segment, something which
is new to the Indian market.
So, it presents a huge opportunity
for us.”
According to the company,
Vagisil anti-itch creme acts as an
external itch reliever and soothes
irritated skin and helps reduce
further irritation.
“It contains benzocaine, a fast-
acting itch reliever that works directly
on the nerves to stop external feminine
itching, burning and irritation,” said
Roberta Bloom, Director of Product Safety
and Scientifi c Support, Combe Inc.
Elder launches three female personal hygiene products
Novozymes Biopharma wins Technology Innovation Award for ground-breaking half-life extension platformNovozymes Biopharma, part of Novozymes A/S, world leader in
bioinnovation, received the 2012 Drug Delivery Partnerships™
(DDP) Technology Innovation Award for the company’s half-life
extension platform. Th e albumin-based technology platform off ers
the potential to enhance patient quality of life through tailoring
drug circulatory half-life to meet specifi c medical needs.
“Th e albumin-based technology is adaptable and can be used for
both genetic fusion (Albufuse® Flex) or conjugation (Recombumin®
Flex), providing a unique ability to decrease or increase a
drug’s half-life. Clearly, this will help manufacturers to develop
pharmaceuticals with enhanced pharmacokinetic properties,
off ering more favorable dosing regimes and improving patient
compliance, while reducing healthcare costs,” said Dave Mead,
Business Development Director, Novozymes Biopharma. Lack of
patient adherence to prescribed medications poses a tremendous
challenge to the global healthcare community. Th e main reasons
cited for poor compliance include patients’ forgetfulness and
factors such as the route of administration. To overcome these
issues, the technology exploits the natural interaction between
albumin and the neonatal Fc receptor (FcRn).
Th is exciting half-life extension technology enables drug
manufacturers to design new effi cacious products, or life-cycle
manage existing drugs, with longer serum half-life, reduced
toxicity and improved pharmacokinetic profi les. As a result, the
frequency of injections a patient receives or even the amount of
drug delivered can be reduced.
Saxena
News,Views & Analysis
20 Modern Pharmaceuticals I March 2012
AstraZeneca Plc is considering options for its Indian
unit, including buying the remaining 10 percent of
AstraZeneca Pharma India Ltd in order to secure
full ownership in a key emerging market.
International companies have until mid-2013
under Indian regulatory rules to either reduce
their stake below 75 percent or delist their Indian
operations, after buying out minority shareholders.
“We continue to consider two options, reducing
our shareholding to the new statutory maximum
of 75 percent and delisting,” said a company
spokeswoman in London.
An earlier report in a leading newspaper citing
two people familiar with the matter, said that
AstraZeneca was planning to delist and was in
talks with top investment banks lifted shares in the
Indian unit more than 5 percent.
With a market value of around $ 1.1 billion,
buying out the rest of AstraZeneca Pharma India
would be well within AstraZeneca’s reach. Th e
company had cash reserves of $ 7.6 billion at the
end of December.
Sartorius Stedim
Biotech (SSB) has
entered into a private
label agreement with
Trace Analytics.
Th is contract grants
SSB exclusive global
rights to market,
distribute and
service BioPAT Trace,
the new online analysing system.
BioPAT Trace is a glucose-lactate
analyser used for monitoring and
controlling both pilot-scale and
process-scale fermentation and cell
cultivation processes.
Th e system measures the
concentrations of the two analytes
glucose and lactate simultaneously,
in real time and online. BioPAT
Trace can be integrated into either
single-use or reusable
stainless-steel bioreactors.
Th anks to its single-use
sensors and microfl uidic
elements, it is immediately
ready to use. Th e system
enables reliably sterile,
automated sampling, by
either fi ltration or dialysis,
from the bioreactor.
Mario Becker, Director, Marketing,
PAT and Automation, Sartorius,
said, “With BioPAT Trace, we are
expanding our PAT portfolio by
an important component. Th e new
glucose-lactate analyser provides
our customers with real-time
information about their critical
process parameters, helping them
to further optimise and automate
their processes.”
Sartorius Stedim Biotech in pact with Trace Analytics
Sanofi and the Institut Pasteur recently
announced the creation of the Sanofi -
Institut Pasteur awards to encourage
scientifi c excellence in the service of health.
€480000 will support four innovative
research projects demonstrating real
progress in the life sciences and providing
answers to major healthcare problems,
more specifi cally in four fi elds: neglected
tropical diseases, vaccine innovation, drug
resistance, and therapeutic approaches to
ageing and regenerative medicine.
Th e jury comprises seven prestigious
members: Prof Peter C Agre, John
Hopkins University, Baltimore, United
States, Nobel Prize in Chemistry - 2003;
Prof Elizabeth H Blackburn, University
of California, San Francisco, Nobel Prize
in Medicine - 2009; and many others.
“With these awards, the Institut Pasteur
confi rms its commitment to the greater
interest by encouraging research, notably
in conditions aff ecting the most vulnerable
populations and diseases sharply on the rise
in the world,” said Alice Dautry, President,
Institut Pasteur.
Candidates can submit their applications
by April 20, 2012. Th e prizes will be
awarded in November 2012 at the Institute
Pasteur in Paris.
Sanofi and the Institut Pasteur create four prestigious awards to support innovative biomedical research
AstraZeneca weighs options for Indian unit
Clinical reference laboratory strengthens its position in AsiaClinical Reference Laboratory (CRL), a
global leader in the provision of central
laboratory services for the clinical
trials industry, has announced the full
integration of its long-standing laboratory
partner Phoenix Pharma Central Services
in Singapore.
Th e integration of Phoenix’s testing
platforms into CRL’s proprietary Global
LIMSystem enhances CRL’s support of
clinical trials in Asia through improved
effi ciencies, increased quality, reduced
costs and full global project oversight.
Tim Sotos, Chief Executive Offi cer, CRL,
said, “We have a trusted relationship
with Phoenix, having worked together
for over a decade supporting a large
number of clinical trials globally. “By
incorporating Phoenix’s data into our
centralised Global LIMSystem it allows
for both sites and clinical teams to access
their data throughout the world using
CRL’s proprietary web-based ‘OASIS’
systems. Th is provides drug development
companies with direct oversight on the
status of their trial and allows them to
evaluate drug safety on a real-time basis.”
Th rough CRL’s globally implemented IT
system, every clinical trial sample drawn
anywhere in the world will immediately
be entered into its LIMSystem to assure
real time global tracking of any specimen.
Dr Yan Lee, Chief Executive Offi cer,
Phoenix Pharma Central Services,
said, “Together we are well positioned
to provide support to pharmaceutical
and biotechnological industries in the
development of drugs and medical devices.
”Tim Sotos added, “Th e partnership also
means our clients will receive the utmost
local experience working with laboratories
in every continent. Importantly the
innovative execution of a sound business
model allows us to fully streamline our
global operations.”
BioPAT Trace
Technology & Innovation
22 Modern Pharmaceuticals I March 2012
Pharmspective, a specialty therapeutics
fi rm has recently launched a syndicated
research off ering and knowledge
management application. Th e
organisiation is going to launch a
number of knowledge management
applications that will allow subscribers
to view and interact with real-time
market intelligence through state-
of-the-art user interfaces on PC and
tablets. Th e company’s syndicated
research studies will examine clinical
decision-making, drug acquisition,
access and reimbursement, and
patient administration for specialty
therapeutics in autoimmune diseases
and oncology.
“We are excited to launch the
knowledge management applications
in response to dramatic changes in
new product development within the
pharmaceutical industry,” announced
Stephen Reid, Managing Partner
and Co-Founder, Pharmspective.
Adding to this Katie Derdeyn, MD,
Managing Partner and Co-Founder,
Pharmspective, said, “In designing our
knowledge management apps, we have
examined every factor that might play a
role in the decision to develop or utilise
a specialty therapeutic. Our product
off erings follow specialty therapeutics
from drug development through patient
administration, and this focus will allow
us to help our clients build a broad
understanding of the markets in which
they wish to enter and compete.”
Pharmspective launches knowledge management apps
Th e Zeta Plus Encapsulated System (EZP) from 3M features a
unique, easy-to-use pivot action. Addressing the demand for reliable,
high-quality disposable depth fi ltration, EZP raises the bar in terms
of ergonomics; capsule design and dual zone fi lter media, which is
optimal for cell culture clarifi cation and the removal of host cell derived
impurities. “EZP is the latest addition to our industry-leading Zeta Plus
product line that has been used by customers in the biotechnology and
pharmaceutical industries for more than 35 years,” commented Lynne
Deakin, Field Applications Specialist, 3M’s CUNO Filtration business.
Adding to this he said, “It has been developed in response to requirements
for a disposable depth fi ltration solution that allows loading and unloading
at waist height so operators don’t have to lift capsules above their heads and
risk exposure to fl uid spills when handling used capsules.”
Researchers at the University of Leeds
have come up with a technology that
could help the pharmaceutical industry
in controlling crystal formation during
the process of drug development. Th e
pharmaceuticals are often received in
the crystalline form and the crystal
structure can get altered due to the
undetected fl uctuation in the system.
Th is could cause changes in the
structure and pose a threat to the safety
and effi cacy of the desired product.
Also, there are chances that the drug
might get delayed in reaching the
market. As the composition of drug
molecules are growing more complex
by each passing day the real challenge is
involved in processing the components
to obtain the desired results. According
to Dr Robert Hammond, Researcher,
“Here comes into play the potential
of their technology. It makes possible
monitoring of the crystals during their
formation inside reactor, a phenomenon
that was not thought of before.
Th e technology uses powder X-ray
diff raction, which monitors the crystal
structure while the crystalline form
passes through a temperature controlled
fl ow cell.”
New technology to monitor crystal formation
3M’s fi ltration system offers a robust convenient solution for biomanufacturing customers
DisiTest 50 disintegration tester from Dr Schleuniger®
Pharmatron incorporates innovative induction heating
technology and combines it with the benefi ts of automation
to realise cost savings by signifi cantly streamlining the
disintegration testing process.
Th e DisiTest 50 automatically detects the disintegration
time of tablets and capsules in full compliance with current
Pharmacopoeia. Visual monitoring of the disintegration
process by the operator is not required. Induction heating
technology reduces heating times to only 3-5 minutes and
completely eliminates unproductive cleaning times typically
associated with conventional water bath-based systems. DisiTest 50 ensures precise
and homogeneous temperature control. Test medium temperature is monitored
continuously by a contact-free infrared sensor and recorded for reporting purposes.
Th e DisiTest 50 can be extended to a fully automatic disintegration testing system
with up to four independent testing stations and one MediaPrep station - all
controlled via the touch screen of the master station. Because individual testing
stations are connected using state-of-the-art TCP/IP technology, system layout is
fl exible and retrofi tting additional stations is possible anytime.
Realise cost savings with the new DisiTest 50
DisiTest 50
Technology & Innovation
24 Modern Pharmaceuticals I March 2012
BMG Labtech, a leading developer and manufacturer of microplate reader instrumentation for academic and pharmaceutical research, as well as high-throughput screening applications has come up with a technology called PHERAstar FS. Th is is the ultimate multi-detection microplate reader for HTS and assay development, especially where speed and sensitivity are imperative. Th e PHERAstar FS is based on the highly successful PHERAstar
Plus with all of the outstanding features that one would expect from the ultimate HTS microplate reader.
Th e technology also incorporates unique tandem technology, using an ultra-fast UV/Vis spectrometer (220 nm – 1,000 nm) for absorbance measurements and highly sensitive, fi lter-based detection in all modes including fl uorescence intensity, FRET, fl uorescence polarisation, time-resolved fl uorescence, UV/Vis absorbance and luminescence.
Next-generation HTS microplate reader
Bio-Rad Laboratories has
launched new magnetic bead–
based multiplex immunoassays for
human T-helper type 17 (Th 17)
cytokines and cancer biomarkers.
Th e Bio-Plex Pro™ immunoassays
take advantage of the magnetic
bead workfl ow to simplify assay
preparation and reduce variability.
Th e Bio-Plex Pro human Th
17 cytokine panel is designed
to detect 16 soluble proteins
involved in the Th 17 immune
response pathway. Th e Bio-Plex
Pro human cancer biomarker
panel 1 detects 16 biomarkers
commonly associated with cancer.
Th ese assays are designed to help
preclinical and clinical researchers
investigate mechanisms of disease
and therapeutic drug action.
Th e technology features
nine new targets, including IL-
17F, IL-21, and IL-22, which
are commonly requested by
researchers, as well as IL-17 A/F,
which is unique to Bio-Rad. Th e
Th 17 cytokines are believed to
play a key role in infl ammatory
conditions such as autoimmune
diseases, antimicrobial immunity,
transplant rejection, and cancer.
Bio-Rad launches multiplex immunoassays for hum T-helper
Cryo Store and Transposafe have announced the launch of the KelvinBox
T900 series the packaging solution for all your UN3373 dry ice shipments.
Th e KelvinBox T900 packaging systems series has been developed specifi cally
for dry ice shipments of UN3373 biological substance, category B specimens,
compliant with ADR/ICAO/IATA P650 packaging instructions. Standard
UN3373 P650 sealbags are well suited for road transport (ADR), but do not
meet the tight regulations of IATA for airtransportation. For this reason,
Transposafe®, a specialist in the security sealing of valuable consignments, has
developed the Transposafe AirSealbag®, the fi rst-of-its-kind that guarantees
leak-proof shipments at temperatures of -79°C (dry ice conditions).
Th e KelvinBox T900 temperature-controlled packaging line is the result
of combined know-how and years of experience within both companies.
Available in diff erent sizes, for sending a few tubes of sample material up
to several vial boxes, with clear packaging instructions and test reports, the
KelvinBox T900 series is a complete packaging solution with a well maintained
balance between regulatory compliance and costs.
Th e KelvinBox T900 series is available in diff erent sizes, for shipping
diff erent quantities of sample material.
Cryo Store and Transposafe present the KelvinBox T900 series for UN3373 dry ice shipments
A new form of microscope which can
produce results in seconds is being
developed by researchers at the University
of Strathclyde in Glasgow. Scientists
are creating a lens which will be capable
of showing three-dimensional images
within cells and tissues at the same
time as showing the whole organism.
Th e innovative Mesolens – the only
device of its kind in the world - will
be able to capture detail in organisms
which are too big to be examined
satisfactorily by existing microscopes
and will off er a deeper insight into areas
such as cancerous tissues and the cortex
of the brain. Dr Gail McConnell, a
Reader at the Strathclyde Institute of
Pharmacy and Biomedical Sciences, a
partner in research said, “Our research
fi ts with Strathclyde’s ethos of technical
innovation with universal impact. We
already have the two-dimensional
technology for the lens in place, but a
third dimension will allow us to take
the revolutionary step of presenting
images with a range and versatility
which no single imaging platform can
currently off er.”
Lens produces hours of scientifi c work in seconds
Human fl ea
Technology Transfer
26 Modern Pharmaceuticals I March 2012
As part of our endeavour to spread the technology culture, this section provides a means to promote and facilitate exchange of select technologies. We strive to bring together suppliers of such technologies with suitable users for negotiations and industrial collaboration.
A novel process Foramides
Synthesisamides synthesis
The present technology provides with an
amidation reaction of unprotected a-amino
acids in water under neutral conditions
with various aliphatic, aromatic and
heteroaromatic amines in the presence of
coupling reagent l,l’-carbonyldiimidazole
(CDI) at ambient temperature to obtain
the corresponding a-amino acid amides.
Areas of application
Medical and pharmaceutical industry
Forms of transfer
Technology licensing
Anti-ulceritic APIs
An Indian company offers anti-ulcer drugs
like omeprazole, pantaprazole, omeprazole
sodium, omeprazole magnesium and
esomeprazole magnesium for operations
in manufacturing processes.
Areas of application
Formulation industries
Forms of transfer
Consultancy
Clorsulon and its intermediates
An Indian company offers clorsulon, a
highly potent anthelmintic drug, which is
administered to de-worm the intestines of
sheep and cattle.
Areas of application
Pharmaceutical industry
Forms of transfer
Consultancy
Detection and analysis of heavy metals
in the industrial effluents
The present technology relates to a
device and method for detecting and
also measuring the concentration
of copper in an industrial effluent.
This device comprises of an ion
selective electrode (ISE) coupled to
immobilise Bacillus sphaericus strain
characterized in producing Urease on
its one end and to a voltage measuring
device which is calibrated to indicate the
concentration of the heavy metal in the
solvent at its other end.
Areas of application
Industrial effluents, accumulates
Forms of transfer
Technology licensing
Filter cleaning system
An Indian company offers an automatic
filter media cleaning equipment with drying
system. It consists of air wash, water wash
and drying facilities.
Areas of application
Filter media cleaning
Forms of transfer
Joint venture, equipment supply
Formulation for leucoderma
It is well known that these diseases
have property of recurrence and most
of the medicines used for cure have
various side effects and also the disease
is not fully cured. The company
offers the formulation that is quite
effective in curing all the above three
diseases in short period of time. In case
of leucoderma after application of the
formulation there starts formation of
patches (natural colour of skin) within
a week.
Areas of application
Pharma and medical industry
Transfer terms
Joint Venture, technology licensing,
research partnerships
Herbal formulation for psoriasis and
eczema
An Indian company offers an innovative
herbal formulation that has the ability
to control & cure psoriasis and eczema
within one month of application of
the formulation.
Areas of application
Herbal medicine
Forms of transfer
Joint venture, technical services,
technology licensing
Natural preparation for anxiety relief
A company offers food supplement in
the form of tablets that effectively relieves
mild to moderate anxiety problems. The
ingredient is an herbal extract, which has
been scientifically proved for its efficacy.
Efficient decrease of anxiety symptoms,
quick onset of action and no side-effects
are reported to be the advantages of
this product.
Areas of application
Pharmaceutical industry
Forms of transfer
Equipment supply
Process of preparation of nanoparticles for
drug delivery system
The present invention is related to a
process for the preparation of the novel
nanoparticles of apotransferrin or transferrin
which are useful for the preparation of a
pharmaceutical composition facilitating easy
delivery of the drug.
Areas of application
Medical and pharma industry
Forms of transfer
Technology licensing
Pharmaceutical composition for the treat-
ment of ophthalmic disease
A company can offer technology for
manufacturing a drug useful in the
treatment of opthalmic disorders. A
composition comprising Lithium chloride
is the product which causes retinal cell
regeneration. Lithium chloride alone
helped in proliferation of retinal cells but is
associated with other effects.
Areas of application
Pharma and medical industry
Transfer terms
Consultancy, technical services,
technology licensing
Technology Offered
Technology Transfer
27March 2012 I Modern Pharmaceuticals
Technology Requested
Biotechnology for wastewater
treatment system
A Thailand-based company, a
wastewater service provider, is
involved in the R&D of new technology
for water, wastewater and waste treatment.
It requires new ideas related to technology
for developing its strength in the field of
wastewater.
Areas of application
Biotechnology, engineering
Forms of transfer
Consultancy
Calcium Gluconate
A company needs technology for manufacturing
of Calcium Gluconate
Areas of application
Pharmaceutical industry
Forms of transfer
Technical services, project report, others
Extract of medicinal and aromatic plants
A company is interested in putting up a
multi-purpose herbal extraction plant for the
extraction of medicinal and aromatic plants
and herbs like artemisinin/quinine sulphate
and other alkaloids.
Areas of application
Pharmaceutical industry
Forms of transfer
Others
IV fluid manufacturing as SME
An Indian company needs new and good
technology to start manufacturing of IV
fluids.
Areas of application
Medical technology
Forms of transfer
Technical services, others
Kite grading engineering
A company is looking for kite grading, which
is a subservient of genetic therapy research
particularly for the cardiovascular novice.
Areas of application
Medical research
Transfer terms
Others
Manufacture of intravenous fluids
A company requires know how and
technological requirements for the
manufacture of intravenous fluids. Know how
should include where to obtain appropriate
grade raw materials.
Areas of application
Pharma/medicalForms of transfer
Others
Manufacturing technology of hepatits B,
tetanus, diphtheria and pertussis vaccines
An Indian company is interested in
a complete technology for start up of
manufacturing of combination vaccines from
bulk to formulations including supply of
protocols for manufacturing and production
strains.
Areas of application
Human vaccines
Transfer terms
Others
Manufacturing of liquid bio fertilisers
An agro biotech company is looking for
a proven technology for manufacturing of
liquid bio fertilisers. They would like to
know the kind of technology that could be
offered (ie the product, efficacy, length of
field trial) and a procedure of buying the
technology along with the cost incurred.
Areas of application
Biotechnology
Transfer terms
Others
Manufacturing technologies for mon-
telucast, rosuvastatin, ursodeoxy cholic
acid, D-biotin
A company needs API/bulk
drug manufacturing technologies
for montelucast, rosuvastatin,
ursodeoxy cholic acid and
D-biotin
Areas of application
API/bulk drug
Forms of transfer
Others
Pharma grade mannitol know-how
A company is on the look out for a
commercially proven latest technology &
know how (turnkey) for manufacturing
pharma grade mannitol in India. The
estimated production capacity is 600
tonnes per annum.
Areas of application
Pharmaceuticals
Forms of transfer
Others
Pharmaceutical Lyophilisation plant
A Peru based company is looking
for a Lyophilisation plant for
pharmaceutical use. Capacity shall be
around 175 to 200 square feet, for the
lyophilisation of 20,000 vials of 10 mL
per day.
Areas of application
Pharma and food processing industry
Forms of transfer
Others
Share and Solicit TechnologyThe mission of Modern Pharmaceuticals is to spread the technology culture. Here is an opportunity to be a part of this endeavour by sending your technology on offer or technology
requirements. If you belong to any of these two categories, you are invited to furnish the techno-commercial details for publication. The write-up needs to be as per the format of
this section with information about the particular technology offered or requested, its areas of application and forms of transfer. Contact us: Modern Pharmaceuticals, Infomedia 18 Ltd,
‘A’ Wing, Ruby House, J K Sawant Marg, Dadar (W), Mumbai 400 028. Tel: 022-3024 5000, 3003 4695 Fax: 022-3003 4499 Email: [email protected]
Information courtesy: Dr Krishnan S Raghavan, In-Charge, Technology Transfer Services Group, United Nations - Asian and Pacific Centre for Transfer of Technology (APCTT), APCTT Building , C-2, Qutab Institutional Area, New Delhi 110 016, Tel: 011 - 2696 6509, Fax: 011 - 2685 6274, Email: [email protected], Website: www.apctt.org, For more information on technology offers and requests, please log on to www.technology4sme.net and register with your contact details. This is a free of cost platform provided by APCTT for facilitating interaction between buyers and seekers of technologies across the globe. After submitting technology offer or request to this website, you are requested to wait for at least two weeks for receiving a response from a prospective buyer / seeker through this website, before contacting APCTT for further assistance.
In Conversation With: Manish Doshi
28 Modern Pharmaceuticals I March 2012
“One should focus on growth, and on all the input factors that lead to resultant growth,”
…says Manish Doshi, President, Indian Drugs Manufacturers Association & Managing Director, Amoli Organics Pvt Ltd. Here, he reminscences his journey.
Chandreyee Bhaumik
Photo: Joshua Navalkar
Manish Doshi
29March 2012 I Modern Pharmaceuticals
Elaborate on your journey to become the President of IDMA Th e journey has been an interesting one. I had an
exciting student life. Since my family was already
into the pharma business, I was keen to join this
industry. I graduated in pharmacy and did my
post graduation in Financial Management from
Jamnanalal Bajaj Institute of Management,
Mumbai. Frankly, I was a good scorer always.
I am managing my family business since the
last 28 years. Th e Amoli Group of Companies
manufacture API and formulations. Th e group
exports to more than 80 countries. My father
has been my constant source of inspiration. He
was very active socially. Professionally, he was
in a signifi cant position. He was the President
of the Chemists and Druggists Association
and had started various businesses that I have
subsequently grown. I always believe that
starting is more challenging than taking it
further. Further, through this journey I was
privileged to interact with some of the leaders of
the pharma industry such as Dilip Shanghvi of
Sun Pharma and many other dignitaries.
With a Presidential position comes a lot of responsibilities. How does it feel?While on one side, it certainly is exciting, on
the other it is a huge responsibility. Today, the
industry is growing reasonably well by 15 per
cent and by and large the industry has been
successful in catering to the diverse needs of
the vast population. I have been associated
with IDMA for the last 15 years. I was
appointed as the Vice-President in 2007. Th us,
it has been my constant focus to create the
right environment so that the healthy growth
continues or maybe further accelerates. Th is
involves interaction with the government to
ensure a healthy environment. In this context
policies are formulated. Sometimes even at
the operational levels there are issues that
need to be brought to the attention or need
to be sorted out.
Apart from the interaction with the
government there can be other things such
as seminars, workshops that give the right
exposure to the appropriate segments of the
industry. It must be remembered that the
industry comprises diff erent enterprises ranging
from small to medium and large, and thereby
the needs also diff er. So, it is our responsibility
as an association to ensure that all needs are
attended to.
What are your views on today’s investment in R&D? Investment in the R&D of pharma industry is
much better than most other industries in India.
So by that benchmark, one cannot say that it is
less. Again, the kind of profi tability that Indian
companies can enjoy in branded generics also put
a little constraint or limitation that a company
can do. Of course, the situation is diff erent
with the global giants or innovator companies
such as Pfi zer and Glaxo. Th eir profi tabilities
are huge because of the innovation models that
they follow.
How does one live up to the legacy?Th ere are no radical new strategies as such.
One should focus on growth, and on all the
input factors that lead to the resultant growth.
Th ere should be constant seminars, workshops,
gatherings. Th ese are the aspects that empower
the members and ultimately result in the
development of industries.
Constant eff orts should be made to ensure
that the government policies are in place and
the medicines are accessible to the interiors.
When Indira Gandhi, the then Prime
Minister decided to go for Patent Act, it only
resulted in process patent protection. Product
patents were not under this purview. Th is has
resulted in so many companies introducing
products in India; developing the products,
reverse engineering the products. Th erefore, it is
always a combination of the environmental and
the inherent internal factors. Even today, if we
consider ourselves to be the emerging powers it
is important to delve deeper into the reasons.
We are fortunate to have so many effi cient
educational boards such as Delhi University,
Mumbai University and many others. Th e
leaders at that time gave importance to
education. Th is forms the strength of the nation
otherwise we would also be like any other
African country.
Th ere are few aspects that must be
remembered as far as the pharma industry
in India is concerned. In India, medicines are
most economical. Second, the industry has
been growing in 15 per cent value terms and
more in volume terms. Th ird, we are not only
catering to the vast population of this country
but India is also the exporter to more than 150
countries across the globe. So, if one looks at
these yardsticks then one can give almost 9 out
of 10 to pharma industry. Further, if one is
talking about segments such as formulations,
Active Pharmaceutical Ingredient (API) then
it is not possible to segregate the segments
on a priority basis. Th erefore, formulation
of appropriate government policies is what
deserves immediate action.
What are your views on today’s student group? Any message for them?Our industry has either pharma students
or the students from other related fi elds
such as medicinal chemistry. Th ey are
the backbone of our industry. We are a
knowledge-based industry and human
resources is the most important component.
Th ere is a large amount of talented pharma
students. Th ey enter the industry and become
major contributors. Th us, today, even if
substantial number of pharma graduates is
going abroad we are not having any shortage of
pharma professionals.
Additionally, it is true that most of the
professional courses have disconnected with
the actual job scenario. So, it would be useful
if there is six months of paid internship during
the B Pharm or M Pharm. Th ere are enough
opportunities both on the technical as well as
marketing side post graduation. On the former
side, there are scopes on production, Quality
Control, quality assurance, regulatory aff airs
and R&D is also a huge area. Patents will gain
prominence over the years. Again, over a period
of 10 years IPR will also become important.
Next 5 years?Personally our company that is in formulation
is doing quite well. We do have plans for
aggressive growth. From the overall association
(IDMA) point of view, even though my term for
President will be near completion (two years),
whatever I am supposed to contribute to I will
continue to do so.
Success mantra: Hard work and smart workFavourite book: Atlas Shrugged by Ayn RandQualities important in a professional: Caliber, sincerity and reliabilityInterests and passions: Travelling. I am fortunate to have travelled to more than 60 countries
Quick Takes
Special Focus
31March 2012 I Modern Pharmaceuticals
Tax incentives
Never too late for too much ...................................................32
R&D incentives
Will innovation and R&D get a boost?..................................34
Interface
Dr Rajesh Jain, Chairman
CII National Committee on Biotechnology &
Joint MD, Panacea Biotec Ltd ...................................................36
RoundtableWill the Union Budget 2012 be SME friendly? ......................38
Budget Wishlist
31March 2012 I Modern Pharmaceuticals
32 Modern Pharmaceuticals I March 2012
As we are gradually nearing the
Budget season, individuals
associated with the pharma
industry, directly or indirectly,
are tormented with the regular questions.
Will the 2012-2013 Union Budget
ultimately off er solutions to the frequently
faced questions or concerns of the
industry? Will the Budget this year help
the pharma industry in occupying the
front seat globally?
Since the Assembly polls in fi ve states
will be completed on March 6, the
Government of India recently declared
that the Budget session of Parliament
will be convened on March 12, and the
2012-13 Union Budget will be presented
on March 16. With the approaching
date, the fears and wishes of the pharma
fraternity reaches a high crescendo.
Budget expectationsTh ere are several demands and expectations
as far the tax incentives for the pharma
industry are concerned. Th e Central
Government may incentivise the pharma
industry by lowering the taxes and duties
on life-saving products such as drugs and
Active Pharmaceutical Ingredient (API)
to provide an impetus to the growth and
development of the industry.
Discussing his expectations and
demands from the Union Budget,
Kayvanna Shah, Chief Executive Offi cer,
J B SEZ Pvt Ltd, explains, “From Special
Economic Zones’ (SEZs) point of view,
we hope that the upcoming Budget
provides grandfathering provisions to
all existing and upcoming SEZs and
unit-holders for a prolonged period.
Let us not forget that SEZs have been
one of the growth drivers for exports
generated and various players have made
immense investments keeping in mind
the fi scal incentives and concessions
off ered earlier. Th ough certain benefi ts
were withdrawn in the previous Budget,
it would augur well for all if the Finance
Ministry at least provides a level playing
fi eld to current players till a specifi c
period.” Continuing in the same vein, he
elaborates, “We also expect that certain
extra SOPs and incentives would be
off ered for industrial zones coming up
in rural hinterland for industrialisation
of various states. Th is will have a
magnifying eff ect on various industries
since it would boost investments from
all corners and concerned entities would
consider developing in such areas.”
Chandreyee Bhaumik
Special Focus: Tax incentives
The pharma industry hopes that Budget 2012 will match its expectations and inject the much needed dose of tax incentives. While the wish list varies, the common dream remains getting good tax incentives.
Neverfor
too muchtoo late
Tax incentives
33March 2012 I Modern Pharmaceuticals
Talking about the expectations from
the Union Budget, Tapan J Ray, Director
General, Organisation of Pharmaceutical
Producers of India (OPPI), says, “Setting
up infrastructure involves substantial
fi nancial investment and a long gestation
period. Hence, tax benefi ts should be
provided for units engaged in the business
of R&D and contract manufacturing by
way of deduction from profi ts linked to
investments.” He continues, “If India has
to emerge as a low-cost healthcare medical
tourism destination then there is a greater
need to setup state-of-the-art healthcare
facilities in the metros, tier-I and
tier- II cities for which adequate direct tax
incentives are to be provided.”
Customs dutyTh ere are also expectations as far as
indirect taxes are concerned. Elaborating
on customs duty, Ray says, “Basic Customs
Duty (BCD) for health supplements
should be reduced to 10 per cent and
Countervailing Duty (CVD)/ central
excise duty to 1 per cent or 5 per cent to
make it at par with drugs. Th is would help
in making the said benefi cial products
aff ordable to the common man.” He adds
that all life-saving drugs (including medical
devices) should be exempted from customs
duty. All equipment meant for diagnostic
purposes and consumables thereof should
be completely exempted from the levy of
customs/central excise duty. CVD should
be charged at a lower rate of 1 per cent on
import of vaccines, specifi ed medicaments
and health supplements imported into
India. BCD rate on import of formulations
should be reduced to 5 per cent.
Central Excise Duty and VAT According to Ray, the central excise
duty rate of API (primary raw material
for pharma formulation manufacturers)
should be rationalised and made at par
with pharma goods, ie, excise duty on the
inputs should be reduced from 10 per cent
to 5 per cent. Further, he adds that an
abatement of 45-50 per cent is necessary
to enable pharma industry to cover its
costs while calculating the central excise
duty payable. Continuing in this vein, he
says, “Th is abatement should be increased
to 45-50 per cent as the current 35 per cent
abatement does not even cover the trade
margins, the value of R&D costs and other
costs associated with the pharma industry
such as distribution of many medicines
(eg, vaccines) through ‘cold chain’.”
Further, commenting on the Value-
Added Tax (VAT), Ray adds that the tax
rate of 4-5 per cent on medicines and
the list of tax-exempt goods and declared
goods should be uniform across all states.
Rectifying the lapse Th ere were several diverse reactions to the
previous Budget (2011-2012). Hopefully
this Budget will rectify the situation.
Signing off Shah says, “We were clearly
taken aback by the Union Budget last
year that imposed Minimum Alternative
Tax (MAT) and Dividend Distribution
Tax (DDT) on SEZ developers and
unit-holders. Th is meant that few of our
prospective clients had to rethink on their
expansion plans with regards to setting
up new units in SEZs. However, if the
Finance Ministry can spur the investment
climate by acting on reforms and off ering
incentives linked to investments, the
situation shall certainly improve from
here. We hope in respect of Direct Tax
Code, full applicability of the existing SEZ
scheme is enabled to all SEZs notifi ed till
a determined cut-off date.”
Kayvanna ShahChief Executive Offi cer, J B SEZ Pvt Ltd
Tapan J RayDirector General, Organisation of Pharmaceutical Producers of India (OPPI)
Tax benefi ts should be provided for units engaged in the business of R&D and contract manufacturing by way of deduction from profi ts linked to investments.
We also expect that certain extra SOPs and incentives would be offered for industrial zones coming up in rural hinterland for industrialisation of various states.
Pre-Budget expecta� ons
Segment
Tax incentives
in pharma
Previous Budget
Government proposed
to levy Minimum
Alternate Tax (MAT)
of 18.5 per cent on the
book profi ts of Special
Economic Zone (SEZ)
developers and units
Expectations
Provisions to all existing
and upcoming SEZs
and unit-holders for a
prolonged period
34 Modern Pharmaceuticals I March 2012
With time India has
emerged as a hub for
various collaborative
and outsourced R&D
activities. Along with this, there is a
fundamental shift in the strategies of Indian
pharma companies from ‘business-driven
research’ to ‘research-driven business.’ With
the Budget coming soon there is constant
focus whether the government will
support the pharma industry and catalyse
its growth to become global numero uno.
Needless to say, the growth chart of the
industry is dependent on extensive research
capabilities and new product development,
and major companies are looking forward
for incentives in the same.
The present scenarioLast year the Union Budget (2011-12)
did not satisfy several industry insiders,
especially pertaining to its R&D
allowances. Th ere was no extension
provided on the weighted deduction
on the in-house R&D that stands at
200 per cent and available till FY 2012.
Th is was indeed a case of disappointment
for the pharma companies that are
actively involved in R&D activities.
Weighed deduction on the in-house
R&D means an Indian pharma
company performing in-house R&D
will get tax exemption on the amount
spent. Th e exemption would be the
double of what they spend on R&D.
For example, when a company spends
` 200 crore on R&D it will have no
tax liability on a ` 400 crore income.
Th is was 150 per cent till FY 2009 and
in the last Budget it was increased to
200 per cent. Additionally, weighted
deductions for payments inter-alia made
to National Laboratory or a University
or a specifi ed person for the purpose of
approved scientifi c research programme
has increased from 175 per cent to
200 per cent. Th e Budget can provide
a new drug delivery system for such
dosage by extending weighted deduction
for R&D activity beyond 2012 and
provide incentives for the core R&D
activity players.
More importantly, there are enough
claims that India spends less on
R&D than it ought to. According to
various expert reports, in India the
spending on R&D is approximately
2 per cent of Gross Domestic Product
(GDP) compared unfavourably with
3-4 per cent in advanced countries.
Expectations for this yearIndian pharma industry aspires to
occupy the front seat with special
emphasis on innovation and R&D.
Undoubtedly, India has the potential
required to be one of the countries with
the highest levels of intelligence in its
products. Th us, there should be eff orts
to double the percentage that is spent on
R&D over the next few years. Discussing
the wish list from the Budget, Nidhi
Saxena, Founder, President & CEO,
Karmic Lifesciences, shares, “I expect
a huge thrust to be given to R&D
activities, including clinical research
and stronger promotion for scientifi c
and research infrastructure development
in this year’s Union Budget. Next, the
healthcare sector should be given an
infrastructure status with zero duty
on R&D equipment and a longer
tax-free allowance on pharma and biotech
SEZs. Additionally, R&D and clinical
research activities should be incentivised
by providing a 5-year tax holiday on all
products developed in-house, extension
of weighted deduction on R&D on all
research-related services.”
Over the past few years the pharma
industry of the country has witnessed
Chandreyee Bhaumik
Special Focus: R&D incentives
Will innovation and R&D get a boost?With the Union Budget around the corner, it is time for pharma companies to chalk out their list of expectations. R&D incentives, in different forms, top the wish list of most of the pharma companies.
R&D incentives
35March 2012 I Modern Pharmaceuticals
Nidhi SaxenaFounder, President & CEO, Karmic Lifesciences
Vikram Gupta Founder & Managing Partner, IvyCap Ventures Advisors Pvt Ltd
There are a lot of things that are required for R&D such as chemicals, raw materials and many others. So, there should be tax exemption on all the goods that are used for R&D.
R&D and clinical research activities should be incentivised by providing a 5-year tax holiday on all products developed in-house, extension of weighted deduction on R&D on all research-related services.
Pre-Budget expecta� ons
Segment
R&D in pharma
Previous Budget
Th ere was no extension
provided on the
weighted deduction
on the in-house R&D
that stands at 200 per
cent and available till
FY2012 only
Expectations
Eff orts should be made in
order to facilitate a R&D
culture and innovation
steady growth. Today, it is considered as
one of the sectors that is continuously
driving the Indian growth story.
Identifying this success story, the
Department of Pharmaceuticals has
come up with ‘Pharma Vision 2020’ in
order to make India one of the attractive
destinations for end-to-end drug
discovery and innovation.
Talking about the benefi ts that the
R&D incentives provide the pharma
industry, Saxena avers, “Currently,
life sciences companies engaged in
R&D activities do not get any tax
deductions; if the R&D lab is not
approved by Department of Scientifi c
and Industrial Research (DSIR)
even though the company spends
considerable money on such R&D
activities. Th us, there is a need to bring
in a provision of giving tax exemptions
to companies doing R&D outside
the purview of DSIR.” Continuing
in the same vein, she adds that a fl at
10 per cent income tax on gross
profi t for the fi rst fi ve years will be a
welcome step for Clinical Research
Organisations (CROs) to start-up.
She highlights, “Th e incentives
normally given to service sector
that brings in foreign exchange
need to be introduced/re-introduced
for CROs.”
Further, discussing the need of a
proper R&D culture, Vikram Gupta,
Founder & Managing Partner, IvyCap
Ventures Advisors Pvt Ltd, says,
“Eff orts should be made in order to
facilitate a R&D culture and innovation.
Further, there are a lot of things that are
required for R&D such as chemicals,
raw materials and many others. So,
there should be tax exemption on all
the goods that are used for R&D. In
this way, there can be rationalisation
of the entire R&D segment.” Further,
according to him, there are several
activities that are not falling in
DSIR and lot of rationalisation is also
required in that context. Th is is very
important for building an entrepreneurial
innovation culture in India.
Bringing a changeWith passing time, the performance of
in-house R&D centres of major Indian
institutes show that there is a defi nite
requirement for strong merges between
the in-house R&D centres and various
national laboratories and several technical
institutes in order to attain competence in
the industry. It is true that India does not
lack the scientifi c talent or the talent pool
that is required. Th erefore, it is essential
that the centre concentrates on the R&D
segment. Th is will help the country to
assume a strong position in the global
research fi eld.
With expectations comes an obvious
comparison with the last year. Th e Union
Budget 2012-2013 will hopefully fi ll the
gaps left or created in the previous Budget.
Elaborating in this vein, Saxena explains
that in Budget 2011-12, the government
made no proposals on reducing excise
duty, tax on healthcare infrastructure and
weighted deduction for expenses incurred
outside R&D facility such as overseas
trials, dossier preparation, consulting &
legal fees on healthcare and pharma sector.
Th e positives were that by considering
the need of the industry for innovation,
it enhanced the weighted deduction on
payments made to National Laboratories,
universities and institutes of technology,
for scientifi c research, from 175- 200 per
cent. She highlights, “Th is year does not
look very positive on the R&D front until
the government takes some concrete steps
to address industry requirements.”
36 Modern Pharmaceuticals I March 2012
Expectations from the Union Budget as far as the R&D incentives are concerned...Th e weighted tax exemption of 200
per cent on R&D expenses should be
continued for at least the next 10 years.
Th is will help R&D-oriented companies
to take long-term strategic decisions on
R&D projects. It will also act as a booster
for further investment on R&D. Short-
term fi scal incentives do not encourage
the industry to invest on long-term
R&D projects.
How will the Union Budget help in the tax benefi ts section?At present, 200 per cent tax exemption is
allowed on revenue and capital expenses
incurred by approved R&D centres on in-
house projects. Clinical trials conducted
through Clinical Research Organisations
(CROs) are not eligible for 200 per cent
weighted tax deduction, not even 100 per
cent. Since clinical trials conducted through
CROs are important and integral part of
overall R&D programmes and account for
2/3rd of R&D cost, therefore, weighted tax
exemption of 200 per cent should be allowed
on all clinical trials irrespective of whether
conducted in-house or through CROs. Th is
will ensure the goal of Government of India
to make drugs aff ordable.
How do you think the Budget can favour SMEs?Th ere should be Budget allocation
for capacity development in pharma
and biotechnology for concerned
Ministries to work with industry and
develop the following:
Sector Skill Council in Pharma (SSC):
CII has taken the initiative to form
the pharma/biopharma sector skill
council and currently working with all
prominent industry bodies on devising
the framework to bridge the gap between
the demand and supply of skilled human
resources in specialty area such as quality
assurance, sales & marketing, regulatory
aff airs, licensing, business development of
specialty products, etc.
Good Laboratory Practice (GLP):
CII is working with National GLP
Compliance Monitoring Authority
(NGCMA) to provide GLP training to
interested organisations.
Finishing school: CII Biotech fi nishing
school proposal has received encouraging
response from its members, organisations
and are willing to train 5-10 graduates
in various biotech streams depending
on organisations area of interest. Th is
initiative would further be strengthened
with active participation of Department
of Biotechnology (DBT) and interested
member organisations.
Expense reimbursement: SME exporters
incur expenses such as USFDA audit and
National Science Foundation (NSF). As
in many Asian countries, these SMEs
must be allowed to take reimbursement
from the Government for USFDA and
NSF expenses so as to become globally
competitive in quality and assurance.
What kind of Budget will benefi t the pharma/biotech SEZs? Government must create a budget
through which 50 per cent of the total
income tax paid by a company in the last
10 years can be paid back as a soft loan
to an R&D organisation for 20 years
re-payment terms at 1 per cent annual
interest. Th is will encourage investment
in R&D in an objective manner and
at the same time ensure availability of
economical, innovative new safe and
effi cacious medicines for all
Special Focus: Interface - Dr Rajesh Jain
“Government must uniformly exempt all life-saving medicines from GST”…says Dr Rajesh Jain, Chairman, CII National Committee on Biotechnology & Joint MD, Panacea Biotec Ltd. He talks about his expectations from the Union Budget 2012-13 for R&D segment, pharma SMEs, among others.
Chandreyee Bhaumik
Dr Rajesh Jain
37March 2012 I Modern Pharmaceuticals
Government should consider exempting all products from
sales tax and excise duty that are specifi cally used for paediatric
purposes (for all children up to the age of 12 years)
Investment in upgrading quality of infrastructure and
training and development of people should also be given
200 per cent weighted tax deduction for pharma and
biotech sector
Should there be a separate Budget for the pharma/biotech industry?If done, it will be very helpful to ensure cost-eff ective
availability of international quality medicines with skilled and
well-trained work force in our sector. On top my expectations
from the proposed Finance Budget are as follows:
Goods and Services Tax (GST)
Th e likely implementation of GST will be watched closely by
the pharma industry as the total tax rate might go up thereby
make medicines costlier.
To ensure continued availability of medicines, government
must uniformly exempt all life-saving medicines from GST.
Tax-free Zone
Th e benefi ts granted to units set up in tax-free zones should be
continued under GST.
Excise
Considering the long-term benefi ts of R&D to the economy
at large, all excisable goods used for R&D purposes, should be
exempted from Central Excise Duty as also import of all capital
goods, raw materials, consumables, and reference standards for
R&D purposes must be fully exempted from customs duty and
other related duties.
Grants & loans
Government should encourage research and product
development activities by off ering grants and soft loans at zero
interest in much bigger scale and liberal manner than today.
Registration expenses
A weighted deduction of twice the expenditure on
scientifi c research incurred by a company is allowed. With
increasing volume of exports all over the world, our companies
need to invest substantial amounts in registration of products
overseas. Hence, expenditure eligible for weighted deduction
should also include expenditure on product registration in
foreign countries and consultants’ fees for patent/product
registration overseas.
Land & Building
At present, weighted deduction is not available towards land
and building. However, several leading companies carry out the
research at the locations exclusively designated for the purpose.
Th is requires infusion of huge funds on purchase of land and
on construction of buildings especially designed for research.
Th erefore, it is imperative that such companies are also granted
the weighted deduction on the expenditure incurred on land
and building.
Special Focus: Roundtable
38 Modern Pharmaceuticals I March 2012
Will the Union Budget 2012 be SME friendly?Apart from contributing to exports and manufacturing output, pharma Small and Medium Enterprises (SMEs) provide employment opportunities in rural areas. Will this Union Budget offer positive incentives for SMEs?
SMEs form a crucial part of the pharma industry. However, even today the primary challenges that they face point towards lack of funds. In this scenario, tax incentives in any form will be a blessing for the enterprises.
Editorial take
Dr Ajit DangiPresident & CEO,
Danssen Consulting
Since pharma SMEs contribute to
over 35 per cent of the industry’s total
turnover, they play an important role not
only in nation’s economy but in making
medicines available at aff ordable prices
as well as employment generation.
While Union Budget has limitations
in resolving some of these issues, the
least Government can do is to provide
a consistent policy environment so as to
plan the business for longer term rather
than tinkering with taxes and duties
and off er SOPs to balance the budget. It
now appears almost certain that both
Goods and Services Tax (GST) and
Direct Tax Code (DTC), which were
announced, are unlikely to be made
operational in April this year, as promised
earlier. Rationalisation of the excise duty
for raw materials and fi nished product
with abatement increased to 45 per cent
will benefi t the industry. Also, the SMEs
in the bulk drug industry need special
attention as cheaper Chinese imports
have virtually brought this industry on
the brink of closure.
Chandreyee Bhaumik
Hitesh GajariaManaging Partner, KPMG
Th ere are many expectations from the
forthcoming Union Budget towards
incentivising this sector. Th e existing
provisions do not provide any benefi t
for units engaged in contract R&D.
Th e Government could provide
certain specifi c tax holidays to SMEs
engaged in contract R&D and other
manufacturing activities. Th e current
low ceiling for tax audit of ` 60 lakh
for business undertakings could be
increased to at least ̀ 1 crore. Currently,
CENVAT Credit is available where
manufacturing is undertaken by the
brand owner itself. Many SMEs are
engaged in job work arrangements
with large pharmaceuticals companies.
Th e government could extend rules
relating to CENVAT credit to such
arrangements, which will in turn reduce
the cost of the product.
It is expected that the government
should promote an encouraging
environment for growth for this sector
by keeping stable policies and by
making favourable tax amendments.
T S Jaishankar Chairman, Confederation of Indian
Pharmaceutical Industry (CIPI)
With every Budget the taxes are on
constant rise. Th us, it should be noted
that if the government is not able to
reduce the tax it should not increase
it either. Th e tax should be allowed to
be stable. One must not forget that
SMEs are important as they form the
backbone of the pharma industry. Th ey
should be given long term incentives,
investment allowance, and many such
related benefi ts. It might not have an
immediate eff ect but they will help in the
long term. Th is will help in developing
manufacturing competitiveness.
It is already a buzz that this Budget
will witness reduction in the tax of the
diesel vehicles. But the government
should not forget that this is also an
important industry. With infl ation
catching up most of the hospitals do
not have the stock of the life-saving
drugs. Th erefore, there should be
special incentives provided so that
there is fl exibility in the pricing of the
drugs. Th is will increase the supply
of drugs.
40 Modern Pharmaceuticals I March 2012
IKA, a German company by origin,
has been present in the Indian
market since 1999. Looking at the
rate at which the pharmaceutical
sector was growing in India, IKA decided
to explore the opportunities that the
Indian market has to off er. It set up its
manufacturing plant in Bengaluru, India
in 2009. “As a company we felt that
the Indian market was doing very well.
We also noticed the gradual growth of
business in India and so we decided to set
up a manufacturing plant here. We chose
to enter the Indian market also because
we wanted to provide our support as well
as services to the Indian market that was
welcoming us and our products and also
provide support to our distributors in
India,” explains Suren Dixit, Managing
Director, IKA India Pvt Ltd.
The growth storyTh e Indian market has been one of the
biggest markets along with China over
the last 10 years. Th ough IKA did not
have a facility in India its products were
being sold in the Indian market for over
a decade. “We felt that the Indian market
is growing. Th e cost factor is high in the
Asian region and so to save on capital
spent in transporting goods from one
country to another we thought that
having a manufacturing unit in India
would be a good idea. We make sure all
the quality standards are met as per the
policies of our German manufacturing
facility,” explains Dixit.
Th e facility of IKA is an assembly
line unit; all parts of the machines are
imported from their other centres and
are assembled in India, and are then
sent back to various parts of the world
according to the requirements. “We
have not done much in the machines
aspect as we do not have people and
land in India. We are hiring people
and training them as well but it would
take time to bring them to our facility
in India as the training takes place
in Germany. What we do in India is
import parts from all over the world and
assemble them. About 50 per cent of the
assembled products are sent to Germany,
US and Europe and the rest is used in
India to meet the requirements of the
industry here,” informs Dixit.
Other geographical locationsFive years prior to setting up the facility
in India, IKA set up a facility in China.
Today, there are approximately 250
people working in the unit in China,
where IKA has set up a huge laboratory
production facility. Once the China
facility was constructed, IKA set up
a facility in Malaysia to manufacture
process machinery, which today takes
care of most of the requirement of IKA.
Th e facility in India has been set up over
35, 000 sq ft of land and has an application
lab, sales team and regional managers in
each region. “We are also in the process
of setting up a calibration laboratory and
are setting our roots fi rmly in India. Out
of our complete product portfolio, few of
them are manufactured in India and few in
other countries. Overall, we are present in
eight countries - for us the manufacturing
of the machines that we assemble and sell
to our Indian clients are manufactured by
our facility in Malaysia. We have facilities
in Germany, the mother country, and a
facility in the US, Belgium, China - where
we have three units, Malaysia, India and
Japan,” says Dixit.
High quality is maintained not just in
the products that are manufactured in India
but also in all the other units of IKA. To
ensure safe and high quality products IKA
is ISO 9001 and ISO 17 027 certifi ed.
Challenges facedTh ere are cultural and commercial
IKA India Pvt Ltd, a part of 100-year-old German company, set up its fi rst assembling unit in the country in 2009. Since then it has been bringing unique technologies to the country and leveraging on the Indian advantage.
Capitalising on the India advantage
Jasleen Kaur Batra
Phot
o: S
hrik
anth
Facility Visit: IKA India Pvt Ltd
Th e assembly line Orbital shaker
IKA India Pvt Ltd
41March 2012 I Modern Pharmaceuticals
challenges that one needs to face with
every new set up. As IKA has entered the
Indian pharma industry there is one major
challenge it is facing. “Our main challenge
was brand equity. Every international
player has been in the country for the past
20 years. Th e Indian population today
is very well educated and has in depth
knowledge of the market. So having a
German product holds no value today. Th e
diff erences are reducing and one needs to
give value for money. We are enhancing
our service capabilities, our calibration
support, sales support and are investing
in marketing. We are participating in
seminars, symposiums etc as we need to
create a brand. We are also redoing our
website for IKA, as web is a growing
space today,” explains Dixit. Adding to
this he says, “Th e Indian market is price
sensitive. As of now, costumers expect a
lot and try to push as much as possible to
get the maximum in the most economical
price. So, we did have to mend our
ways to meet the demands and expectations
of the competitive Indian market.
What we do is try to sell our products
in bulk as it helps us gain our revenues
as well.”
As a company, IKA tries to provide price
reduction to its costumers and dealers. “We
want to set our foot in India; hence, we are
looking at selling more products and want
to create a population of IKA products in
India. Today, we are above the local prices
and are trying to be a little below the
international prices,” informs Dixit.
USP of the companyIKA is one of the leading companies in
pharma in the world today as it is present in
the spaces of R&D, laboratory and producing
products in pilot as well as production scale.
“We are an instrumentation company and
are known for homogenisers. We make
a wide range of homogenisers that cater
to all requirements. What we do is create
software and machines that are capable
of mixing elements such as liquid to
liquid as well as liquid to solid in all sizes.
We provide scaling up options to companies,
as we have the technology to mix quantity
as small as 50 litre to 2,000 litre or more.
Th ere can be companies who would mix
such elements in 50 litre and few in 5,000
but the numbers of companies providing
mixing technologies for scale up projects are
very rare, and that is where our expertise in
the industry comes into place,” says Dixit.
“Our USP lies in going from laboratory
to process and having total inhouse
international validated solutions right
from R&D to the production fl oor. We
are heading towards further refi ning this
with a lot of technical support, sales and
marketing support along with a strong
service support,” says Dixit.
What’s in store?IKA has plans of expansion as well as
launching new products to explore the
various options that India has to off er.
“Th e future is almost endless. In India, we
have a strong R&D team, a calibration
laboratory, various assembly units and
QA and QC labs. We plan to explore
these verticals and make the most of it.
We are also in the process of setting up
offi ces and showrooms in all the cities
in India. In the future, we would be
defi nitely focussing on brand equity,”
informs Dixit. Elaborating on the future
plans of IKA he says, “In future, setting up
a process factory is also on the cards and
so is developing new products. But there
is time for all that to happen. What we
are doing in the near future is launching a
whole new range of products, which will
give IKA a leap in terms of the products
it has. Th e products will be launched in
June. A few products with an upgradation
of the products available currently and a
few would be new according to the trends
in the pharma.”
Over the years, IKA has invested
a huge amount of capital and would
not shy away from doing the same in
future as its main motive is to provide its
products and services to as many companies
as possible.
41
Suren DixitManaging Director, IKA India Pvt Ltd
Our USP lies in going from laboratory to process and having total inhouse international validated solutions right from R&D to the production fl oor.
The facility in India has been
set up over 35, 000 sq ft of land and has an application lab, sales
team and regional managers in each
region.
Testing of electronic contact thermometer ETS-D5
Dear Reader,
‘Modern Pharmaceuticals’ solicits original, well-written, application-oriented, unpublished articles that
reflect your valuable experience and expertise in the pharmaceutical industry.
You can send us Technical Articles, Case Studies and Product Write-ups. The length of the article should not
exceed 1,500 words, while that of a product write-up should not exceed 100 words.
The articles should preferably reach us in soft copy (either E-mail or a CD). The text should be in
MS Word format and images in 300 DPI resolution & JPG format.
The final decision regarding the selection and publication of the articles shall rest solely with
‘Modern Pharmaceuticals’. Authors whose articles are published will be sent a complimentary copy of that
particular edition.
Published by Infomedia 18 Ltd, ‘Modern Pharmaceuticals’ is one of the leading monthly magazines
exclusively meant for producers and user fraternities of the pharmaceutical industry. Well supported
by a national readership of over 80,000 and our strong network of 26 branch offices across India, this
magazine reaches out to key decision makers among the Indian manufacturers of pharma products,
machinery and allied sectors. Brought out in association with Hong Kong-based Ringier Trade Media Ltd
(one of the world’s largest trade publishing houses with more than 200 special interest titles and offices in
every major country), it ensures that advertisers are able to promote their products and services across the
globe at no extra cost.
So get going and rush your articles, write-ups, etc…
Thanking you,
Yours sincerely,
An invite that rewards as well...
Manas BastiaSenior Editor
Infomedia 18 Limited‘A’ Wing, Ruby House,J K Sawant Marg, Dadar (W)Mumbai 400 028 India
T +91 22 3024 5000F +91 22 3003 4499E [email protected] www.infomedia18.in
D +91 22 3003 4669
43March 2012 I Modern Pharmaceuticals
SMEs growth story Withering tales! .................................................................44
Role of bankers and governmentAbout time to have a synergistic relation .............................46
SMEs in South India Need for government reforms .............................................48
SMEs in spotlightWaiting for the right push ...................................................50
Interface Jagdeep SinghSecretary-General, SME Pharma Industries Confederation, India (SPIC) ...........................................................................52
RoundtableAre the current government schemes for SMEs satisfactory? ..................................................................54
Th yroid cancer therapeutics marketVictim of weak competition ................................................55
Case Study - Fighting counterfeitsJust an SMS away! ..............................................................56
Insight & Outlook
Pharma SMEs
44 Modern Pharmaceuticals I March 2012
During the 1960s, the Indian
pharma market was heavily
dominated by multinationals,
which aff ected the price of
medicines. However, during the 1970s and
80s we saw a slow entry of Indian companies
in the market. “With encouragement from
the government Indian companies started
penetrating the market and during 70s and
80s we saw several small scale companies
and SMEs coming into the picture,”
refl ects G D Chhibber, Chairman, Mcneil
and Argus Pharmaceuticals Ltd. Over
a period of time, many SMEs of yester
years have become national companies and
by hard work and their entrepreneurial
abilities, many have grown to be large
pharma companies with manufacturing
units in India and abroad. At present, there
are around 8,000 pharma companies in
the SME sector in India. Th ese SMEs laid
stress on quality and provided medicine
at aff ordable prices. Many of the MNCs
slowly used the services of SMEs in India
to manufacture their product. “With its
low cost and high quality, pharma products
of the SMEs have made its presence felt
both in domestic and overseas market, thus
enabling them to conquer the market,” says
Daara Patel, Secretary General, IDMA.
Th ere were various factors that had
propelled the infl ux of SMEs in the pharma
market. First, the initiative was taken by
the government to give Indian companies
at that time the opportunity to enter the
market. “In the beginning government was
the biggest buyer of medicines produced
by the SMEs,” informs Chhibber. Second,
the advent of revised Schedule M around
the turn of the 21st century triggered the
modernisation of SME pharmaceutical
plants. Although the SMEs had to
undergo fi nancial hurdles, many of them
have overcome the same and have created
pharmaceutical plants of good standards.
“Also, with the maturing of SMEs into
Schedule M-compliant companies, more
and more SMEs are becoming WHO-
GMP compliant units. It is estimated that
there are over 1,000 SMEs, which will
be WHO-GMP certifi ed by the end of
2012,” believes Patel.
The present scenarioIt has been over a decade that the pharma
market has been witnessing declining
numbers of SMEs entering the market.
“Th ere are hardly any SMEs that have
entered the market since the past fi ve
years. Instead, we are seeing the closure of
existing SSI and SME units in pharma,”
says Chhibber. Patel adds, “Compared
to the scenario witnessed in the 80s and
90s, there is hardly any growth of SMEs
in the pharma industry. Although the
Titash Roy Choudhury
Insight & Outlook: SMEs growth story
The SMEs in general, and pharma SMEs in particular, are considered the ‘growth engine’ of Indian economy. But since the past few years we have not seen many SMEs coming up in the pharma sector, which makes one wonder how something once considered the backbone of the industry is degenerating. We look at the initial stages of growth and how the scenario changed so drastically.
Withering tales!
SMEs growth story
45March 2012 I Modern Pharmaceuticals
pharma SME market is very large and
has tremendous potential, it is yet to be
tapped to its full potential.” Th ere are
various reasons that have worked towards
creating an environment that was not
conducive for new SMEs to enter. For
instance, the revised GMP norms that led
to the closure of many SSIs as they refused
to modify their manufacturing practices.
One of the main reasons why the SMEs
were not able to comply with Schedule
M norms was their perennial fi nancial
problems. “Th e profi tability of many of the
surviving units is not that attractive and
the credit availability to them is restricted
as the banks and other funding agencies do
not lend them easily. Most of the SMEs
are also not getting due share of tender
business of various government agencies
and establishments, as many governmental
organisations have stringent clauses that
keep SMEs from participating in the
tendering processes and bulk supplies,”
informs Patel.
Th e Indian pharma market has also
become extremely competitive. However,
many SMEs have started looking beyond
regions to supply nationally and even to
international markets. SMEs are now
participating in contract research, clinical
trials and biologicals, which are said to
have a good scope in the future. Also, few
decisions of the government made their
survival diffi cult. “Initially any company
that got the licence for manufacturing could
supply products to the government. But
since last 10 years from when government
had put a turnover clause, we have seen a
decline in the growth of SMEs in pharma.
Th e government decided that a company
with a particular turnover, which varied in
diff erent states, can supply medicine to the
government. And this decision according
to me is an unjustifi ed action taken by the
government,” believes Chhibber.
Challenges faced and measures requiredTh e contribution of SMEs to the economy
of any country is indispensable and for a
developing country such as ours, SME plays
an even greater role. “With the coming up
of any new SME it helps in increasing the
employment of a country, not only directly
but also indirectly and employment
generation directly aff ects the economy of
the country,” remarks Chhibber. However,
this sector is facing several challenges that
needs to be addressed immediately to
mend the present situation.
Th e major challenges include
organisational costs with limited resources
and their ability to retain capable and
trained employees, and at the same time
hiring professionals. “An SME’s continued
ability to market products while facing
fi nancial and technological challenges will
determine its survival. Th e limitations and
problems in raising funds as most banks tend
to be biased with cumbersome procedures/
collaterals, lack of venture capitalists,
etc,” says Patel. While Chhibber believes
that government should provide more
incentives to the SMEs and such clauses as
the turnover of any company deciding the
supplying factor for medicines should also
be mended. “Th ere is an increasing access to
fi nances for SMEs, thanks to government
policies. Of course, more needs to be done
by the government to ensure availability of
fi nance to the SME sector without much
hassle,” believes Patel.
Various steps have been proposed,
which if followed can change the slow
growth rate. SMEs should tap the small
towns and rural market. In today’s
environment, synergy approaches are
very important and benefi cial to all
partners. Also, partnering with bigger
companies can benefi t the SMEs and
make their survival easier. “SMEs can
engage in contract manufacturing
and provide quality products to these
large enterprises. Th ey can also do
regional marketing for large enterprises.
And in turn, these large enterprises
can encourage SMEs to grow with
their expertise so that they can get
continued quality support from them,”
suggests Patel.
Another avenue for SMEs would be
co-marketing. Pharmaceutical marketing
in India is a highly resource intensive
activity and many SMEs are regionally
well established in marketing activities.
“Many large pharma companies and
even foreign companies are eager to tie-
up with SMEs to utilise their local fi eld
force for marketing activities. Th e benefi t
of obtaining high quality and well-
researched marketing aids for product
promotion from the big companies and
foreign partners will defi nitely go in
favour of the SMEs and help them in
improving the market support of their
local products,” informs Patel.
Patel further adds continuous eff orts
are also made by organisations, such
as IDMA, who have approached the
Planning Commission to seriously
consider a separate scheme for all SME
units in the Indian pharmaceutical
industry, to enable their rapid growth
and development into world-class
manufacturing units.
G D ChhibberChairman, Mcneil and Argus Pharmaceuticals Ltd
There are hardly any SMEs that have entered the market since the past fi ve years. Instead, we are seeing the closure of existing SSI and SME units in pharma.
Daara PatelSecretary General, IDMA
The profi tability of many of the surviving units is not that attractive and the credit availability to them is restricted as the banks and other funding agencies do not lend them easily.
46 Modern Pharmaceuticals I March 2012
Insight & Outlook: Role of bankers and government
The pharma industry is growing
exponentially. “Enormous
opportunities are provided to
the SMEs through not only
globalisation, but also by the domestic
market, which is growing at a rate of over
15 per cent,” says T S Jaishankar, Chairman,
Confederation of Indian Pharmaceutical
Industry (CIPI). Th ere have been few
schemes by the Indian government, but
almost two decades after we are seeing
how this sector is struggling to survive.
“Competition from international generic
players is increasing. MNCs are also trying
to capitalise on India’s status as one of
the fastest growing emerging markets
by formulating country-specifi c pricing
and marketing strategies. Big pharma
companies are launching drugs and vaccines
in India at substantially low prices than
their home countries. Th is trend is going
to change the scenario of SME segment.
Hence, it is time for the government to
ensure that such activities are restricted to
encourage SME. Otherwise it is going to
be a game of bigger companies and small
companies will be compelled to wind out
their workshop,” believes Bodh Raj Sikri,
Co-Chairman, Federation of Pharma
Entrepreneurs (FOPE).
Analysing the government schemesIt would be unfair to say that the government
has not introduced schemes for the SMEs.
Several schemes are developed to support
SMEs. Small companies are increasingly
facing tough business environment due
to marketing and regulatory constraints,
pressure from buyers in regards to high
eligibility barriers, and also from suppliers
as SMEs cannot negotiate prices through
bulk purchase resulting in high procurement
costs. “SMEs are increasingly looking atthe
government for support for upgrading
manufacturing technology, brand promotion
and marketing to enhance domestic sales and
exports. Given the huge business opportunity
available for contract manufacturing, SMEs
need to have capabilities that comply with
manufacturing standards such as GMP,
WHO to be able to capture this. Th is
requires liberal funding from government
along with fi nancial incentives. Lack of
support from select banks authorised by the
government to issue the incentives has also
aff ected the free fl ow of funds allotted under
this scheme to SMEs,” informs Sikri. Th us,
there are certain schemes in favour of SME
but implementation of such schemes at a
later time when actually needed has become
a futile exercise. “Moratorium should also be
for a longer period and the rate of interest
should be at par with Chinese pattern, which
is around 6 per cent. China has converted
their weakness into strength, ie population,
by giving them ample opportunities to
become small industrialists, whereas in
India common man is deprived of such an
opportunity,” avers Sikri.
Bank’s role All banks in India have a mandate by RBI
to help the SMEs with adequate funds.
“Banks are looking positively towards
funding the SME sector in India. And for
the pharma sector we have been funding
various companies in locations such as
Dehradun, Hyderabad or Ahmedabad and
helping them in setting up a new unit or
expanding their present services,” informs
Ramesh Dharmaji, Chief General Manager,
Small Industries Development Bank of
The Small and Medium Enterprises (SME) sector requires government and fi nancial support for having an impactful existence in the competitive market for any industry. The government of India has launched various schemes along with fi nancial institutions, but the lack of implementation is hindering the growth.
About time to have a
Titash Roy Choudhury
synergistic relation
Role of bankers and government
47March 2012 I Modern Pharmaceuticals
India, (SIDBI). Th e pharma sector has been
undergoing modernisation and changes
such as gaining WHO-GMP certifi cation
and upgradation under Schedule M, and for
most of these changes non-asset creating
funding is required. He adds, “Under this
scenario, SIDBI has come out with a scheme
few years back titled ‘Growth Capital
Equity Assistance’ scheme under which
intangibles such as marketing, branding,
quality improvement and R&D initiatives,
improving technical know-how and others,
are covered. Th is scheme has received good
response from the companies and will help
the pharma companies in the coming years
to meet the global requirement without
fi nancial hassles.”
“Too many guidelines are at times
creating bottlenecks in establishing
new SMEs, particularly when young
entrepreneur wants to start a unit,”
believes Sikri.
At present, there are various fi nancing
options for pharma industry such as Venture
Capital, Private Equity, Initial Public
Off ering, debt funding from fi nancial
institutions and banks public funding.
Some of the other schemes available at
present are Credit Linked Capital Subsidy
Scheme, which was launched in 2001 by the
Government of India and has been revised
in 2005. Under this fi nancing scheme,
SMEs can avail a loan of up to ` 1 crore.
It involves a subsidy rate of 15 per cent,
which is calculated on the purchase price of
plant or machinery. Th e other scheme is the
Credit Guarantee Scheme launched by the
Government of India to make bank credit
available to SMEs without any collaterals or
third party guarantees involved. Th e basic
idea of this scheme is to make the lender
give loan primarily on the basis of asset
security. Th ese are some of the government
fi nancial schemes but in India individual
banks also have their own SME schemes,
but what is required at the moment is fi rst a
pharma priority and proper implementation
of the schemes. “Private sector banks also
provide loans for SMEs but against 100
per cent collateral security. Banks consider
pharma as potential investment sector
and are liberal in fi nancing projects,”
says Jaishankar.
Calling for a changeSME is facing lack of support from the
government. “Th ere is a strong need for
these companies to be brought together on
a common platform and to facilitate co-
ordination among them,” says Sikri. Th e
tender clause of government needs to be
readdressed since the situation has changed
drastically over the years. Tender business of
government institutions should be preferably
routed through SME pharma companies
only. Th ey will be able to off er more
competitive rates than organised companies
or MNCs. “Drugs used for common
ailments should be preferably sourced only
through SME pharma industries. Banks
and fi nancial institutions normally go for
strong credit rating companies to fi nance
them, which falls in the segment of AAA
credit rating. Th ese ratings are normally
done by RBI approved agencies such as
ICRA, Crisil, etc but there is hardly 1 per
cent such companies who qualify for the
AAA rating. Th erefore, while fi nancing
the SME segment, emphasis should be on
the credit worthiness and not only AAA
category,” says Sikri.
At present, the pharma industry
is not considered as a priority sector
lending, whereas education, agriculture
and infrastructure, among others are in
the priority category. “Funding should
be available to the pharma sector at a
special or concession rate after all health
is equally important for the citizens
of our country. Time has come for the
government to include pharma industry
under this policy. Adequate amount of
fi nance through interest subvention on
term loan for technical up gradation of
the plant, including GMP compliance
and getting approvals from overseas
regulatory authorities is required,”
believes Sikri.
T S JaishankarChairman, Confederation of Indian Pharmaceutical Industry (CIPI)
To be considered for eligibility, a long procedure needs to be followed that includes considerable time and money, and several SMEs cannot afford to spend either.
Bodh Raj SikriCo-Chairman, Federation of Pharma Entrepreneurs (FOPE)
Too many guidelines are at times creating bottlenecks in establishing new SMEs, particularly when a young entrepreneur wants to start a unit.
Ramesh DharmajiChief General Manager, Small Industries Development Bank of India, (SIDBI)
Banks are looking positively towards funding the SME sector in India. And for the pharma sector SIDBI is funding various companies and helping them in setting up a new unit or expanding their present services.
48 Modern Pharmaceuticals I March 2012
Insight & Outlook: SMEs in South India
The Indian pharmaceutical
industry has expanded
enormously over the decade.
Today, there are about 250 large
units that control 70 per cent of the pharma
market with market leader holding nearly
7 per cent of the market share and about
8,000 small scale units. Th ese together form
the core of the pharmaceutical industry
in India. Previously, the Indian pharma
market was known for producing generic
market but today it has entered all possible
areas. Th e pharma and biotech companies
in India today produce a complete range
of products and have entered every stage
of manufacturing.
ChallengesSMEs today have challenges in various
forms - land being one of them.
“Getting a piece of land at a good location
and at an aff ordable cost is the biggest
challenge today. Th ere are a number of
pharma and biotech companies that
have come up lately. Hence, space has
become a problem. Only an MNC
or a big pharma company can aff ord
to acquire land in the city. Th e rest
need to go to the outskirts of the city,”
avers Mohideen Kamil, Managing
Director, Concern Pharma. Another
challenge that is connected with
land is the regular supply of water and
electricity. “As we are a few kilometers
away from the city there is considerabe
problem that we face in terms of light and
water. Th ere are no street lights on the road
and no water supply. Th e biggest challenge
is lack of infrastructure and adding to this
there are regular power cuts, which slow
down the process of manufacturing of
products,” informs Th ankachan Th omas,
Director, Navagen Products Pvt Ltd.
Getting the required capital to set up
a unit with high quality instruments and
a team of experts takes a huge amount of
investment, which is a challenge. “Th ere are
various MNCs entering India today and
so the market has grown drastically over a
short span of time. Th is has also increased
the level of competition within the industry.
One of the problems that SMEs face and
MNCs do not is that of capital. For an
MNC it is very easy to get a fi nancial partner
but for a SME it gets extremely
diffi cult to convince companies to invest,”
explains Th omas.
Acquiring labour at the right cost is
another problem that is faced by the
SME sector in India. “Th e shortage of
labour is an issue we face in Karnataka today.
Increasing construction work is one of the
reasons for this shortage. Th e frequency of
turnover of labour puts the SME units into
a standstill. Being in the pharma sector, we
have the disadvantage of location as most
of the pharma industry to whom we cater
to are either in Western or Northern part
of India. Th is adds up to increasing logistic
cost and many times we lose to local
competitors. SME faces lot of challenges
within and outside the industry. To set up
an SME unit and surviving thereafter, lot
of support from the big players is essential,”
remarks Th omas.
Further, gaining trust and building
a brand takes ample of time and work;
SMEs have to be patient and hang in there
amidst not too favourable conditions. “A
small set up company does not just have
to undergo all the above-mentioned
challenges but also has to struggle to make
a name for itself and assure people that the
In the early 70s, Small and Medium Enterprises (SME) were on the rise in India. But off late those falling under the biotech and the pharma industries have withered away due to lack of government support and infrastructure.
Jasleen Kaur Batra
SMEs in South India
49March 2012 I Modern Pharmaceuticals
project would meet the desired quality.
Because of a small set up, convincing
companies about the strengths that we
have as an organisation becomes a task,”
says Th omas.
Government supportTh e Indian pharma sector is growing at
a rate of 8-9 per cent and it is expected
that in the coming years this rate will
continue to increase. To accommodate
this large small scale industry and to
ensure that it is functioning in a good
manner it is important for the government
to step forward and come up with a few
policies that would ease out the burden of
the SME sector to ensure a speedy growth
and it does not saturate and die away. To
ensure this, the government needs to come
up with a few reforms as well as policies
for the SME sector in totality.
Expressing his views on the various
areas in which the
Government of
India needs to create
reforms for the SME
sector Alok Chaudhri,
Partner, Techno
Remedies, says, “Th e
government seems
to be extremely
indecisive when it
comes to taking policy
and reform decisions
for SMEs. Th ere
have been a number
of policies that the
government was in the
process of introducing
such as Credit Linked
Capital Subsidy
Scheme (CLCSS),
but even before it
could be formed it
was withdrawn saying
that the policy was
not apt for the SME
sector of biotech and
pharma industries.
Th e government
needs to stop being so
indecisive and needs to
pay attention on the various challenges that
an SME faces today and needs to provide
reforms accordingly.”
Stability provisionTh e government has recently come
up with a clause called the turnover
clause. According to this a company
needs to generate revenues of minimum
` 20 crore for one product to be
eligible to enter the tender. Th is clause
has worked against the SME sector
instead of working for it. Adding to this
Chaudhri says, “Th e government needs
to understand that SMEs do not have
a lot of capital to begin with and so are
not in the position of producing such
turnover. It is hence the responsibility of the
government to provide a few exemptions in
terms of tax and land to ensure that SMEs
grow. Th ey need to increase the excise duty
from ` 1.5 crore to ` 3 crore. Once the
government makes the necessary changes
only then will the SMEs fl ourish.”
Meanwhile, Th e Department of
Pharmaceuticals, Ministry of Chemicals
& Fertilizers of the Government of India
has been taking initiatives to support the
SMEs through various incentives/facilities
such as CLCSS to SME units - this will
help them in upgrading the facility and
identifying approximately 18 SEZs that
would off er infrastructure, market access
and exports. In the future, the government
will set up a fund to promote R&D. Today,
considering the rapid rate at which the
industry is growing, the government too
needs to be updated and provide facilities,
opportunities and policies for the industry
to grow.
Alok ChaudhriPartner, Techno Remedies
It is the responsibility of the government to provide a few exemptions in terms of tax and land to ensure that SMEs grow.
Th ankachan Th omasDirector, Navagen Products Pvt Ltd
The biggest challenge is the lack of infrastructure and regular power cuts, which slow down the process of manufacturing of products.
Case studiesConcern PharmaConcern Pharma is an integrated research-based pharmaceutical company and produces a wide range of quality medicines.
Th e major problem faced by Concern Pharma during its inception was getting license, experienced manpower, capital, getting all the formalities in place for setting up the unit.Investment: ` 75 lakhLocation: ChennaiYears in the industry: 4
Manan HealthcareManan healthcare manufactures oral liquids and external semi solids/liquid preparations. Th e major problem faced by Manan Healthcare was in fi nding authentic machine suppliers and infrastructural problems such as water and electricity.Investment- ` 50 lakhLocation: BengaluruYears in the industry: 2
Navagen Products Pvt LtdNavagen Products Pvt Ltd provides machines and services to pharma companies. Th e problems faced by Navagen Products were getting electricity supply to the plant and fi nding appropriate labour as well as land.Investment- ` 20 lakhLocation: BengaluruYears in the industry: 9
50 Modern Pharmaceuticals I March 2012
Insight & Outlook: SMEs in spotlight
There are around 7,000 pharma
companies in the SME sector
in India. Out of these, the
ones that have been focussed
in this article include, Fourrts (India)
Laboratories Pvt Ltd, a Chennai-
based company started in 1977 by S V
Veerramani, Chairman & Managing
Director, Fourrts (India) Laboratories
Pvt Ltd with an initial investment of
only ` 2.5 lakh. Avik Pharmaceutical
Pvt Ltd, a Mumbai-based SME started
in 1981 with an investment of ` 88
lakh. “During that time SMEs growth
was high and many new entrepreneurs
were entering the market,” reminds
Anant Th akore, Managing Director,
Avik Pharmaceuticals. Adding to this
Ramesh Arora, Managing Director,
Kwality Pharmaceuticals Pvt Ltd says,
“We started our operations in 1980 with
a meager sum of ` 2 lakh.”
The current scenarioVeerramani points out various factors
that are likely to bring up a number of
winners from this sector in the future.
“Th e advent of revised Schedule M has
triggered the modernisation of SME
pharmaceutical plants. Although the
SMEs had to undergo fi nancial hurdles,
many of them have overcome the same
and have created pharmaceutical plant of
good standards. Th ese plants are likely to
cater to outsourcing in a big way under
contract manufacturing.” He continues,
“Th e SMEs are likely to play an
increasing role in contract manufacturing
to major Indian companies and MNCs.
Compared to metro cities and major
towns in the past, in future the will come
from small towns and rural markets.
Th is is precisely where the SMEs are
operating and they are likely to be in
an advantageous position. Th ere is also
an increasing access to fi nances for
SMEs, thanks to Government policies.”
Veerrammani also adds that more needs
to be done by the Government to ensure
availability of fi nance to the SME sector
without much hassle. Both Th akore and
Arora stresses on the lack of support by
the government. “Th e government has
not been liberal in funding, especially
when it announced the mandatory
upgradation under Schedule M but could
not get the fi nancial support for the same
at that time. Th e fi nancial support of
` 1 crore was extended but at a later stage,
so proper planning and implementation
could not be done. At present, the SMEs
The pharmaceutical sector in India has witnessed a lot of changes, upheavals, trends, and progressed to put the country on a global platform. One such trend that has fuelled the growth further is the emergence of SMEs.
Titash Roy Choudhury
Waiting for theright push
SMEs in spotlight
51March 2012 I Modern Pharmaceuticals
which are already in the market will
grow though it will be a tough time for
them with increasing prices and stiff
competition from MNCs. One has to be
innovative and it will be the survival of
the fi ttest,” says Th akore.
Business model and growth trajectoryMostly SMEs are family business and
may not have any well-established
business model. “Our company is a close
linked family held company and it has
encountered steady growth over the past
few years. Th ere was some setback faced
due to the entrance of Chinese products in
the market but we have survived that and
today we are growing at a rate of 15 to 20
per cent year-on-year,” informs Th akore.
While when it came to the growth of
the company Th akore points out, “At the
time of establishment Government was
pro-active towards SME growth and
loans were available on easy terms. Every
state had fi nancial institutions and these
state government institutions supported
the industry by giving loan on capital
investment, for equipment etc.” He
elaborates, “For buying any equipment
25 per cent of the price was paid initially
and the remaining 75 per cent could
be paid over the next few years. Land
was also made available by the state
government, while working capital was
given by nationalised banks on acceptable
terms of the entrepreneur and, unlike
today, without any collateral security. All
these factors propelled the establishment
and initial growth of the company.” He
continues, “Getting schemes sanctioned
and fi nancial help was not diffi cult.
It was a smooth process, but yes every
bureaucratic process has some pre-
defi ned procedures and once I had gone
through them and applied. Asfter my
interview I got the necessary help.”
Fourrts has the vision to become
an international pharmaceutical
organisation of repute. “Fourrts’ initial
activities were towards marketing
its products in Tamil Nadu and
neighbouring states from its plant at
Perungudi, Chennai. From the initial
plant at Perungudi in 1977, we built a
GMP compliant plant at Kelambakkam
near Chennai in 1985. From a regional
marketer, we became an all India
company in 1995. Now we are exporting
formulations to more than 30 countries.
Fourrts has grabbed many awards in its
journey of excellence. To name a few,
IDMA Quality Excellence Awards 7
times, outstanding Export Performance
Awards 2 times from Pharmexcil,
Government of India among few,”
informs Veerramani. Arora talks about
how government has been a major
obstacle in the company’s growth path.
“I had taken loan from the public sector
bank. But when it came to help from
government schemes they never got
fulfi lled. Th ere is a subsidy scheme and
we had applied for it which came to us
almost 10 years later. Hence, there are
a lot of bureaucratic hazards in the way
that lengthens the process and makes it
troublesome.” Th e model that they use is
that of marketing their products in the
generics market, mainly outside India.
“At the time when I started my company
there was not much competition since
there was not much of a demand. But
today there is cut-throat demand and
competition making the situation very
challenging. Government has been
implementing new laws and policies but
not supporting them at the same time,”
beleives Arora.
Competition and challenges Th e pharmaceutical industry is under
acute competition from more than
20,000 pharma companies. Th ere
are various challenges towards their
growth. As Arora points out, “Today,
cost is the increasing for everything;
land has become so expensive. Rather
than continuing any unit selling the
land becomes more profi table.
Also, SMEs are always blaming the
government, but to make some defi nitive
changes all SMEs should come together
and collectively try to improve the
situation.” While Veerramani informs
how his company is facing growing
competition, “A major challenge for
SMEs will be from MNCs due to the
signing of WTO agreement by India.
We are planning to overcome the
same by entering in niche segments
where multinationals will not be
operating. We have planned to work
for tie-ups and collaborations with
MNCs in our core segments.” When
asked about their plans of growing
into an MNC themselves Veerramani
replies, “Fourrts has laid the foundation
of a good manufacturing plant,
has a strong national marketing team,
besides exporting to 30 countries. It is
only a question of time for Fourrts to
become an MNC.”
A major challenge for SMEswill be from MNCs due to the signing of WTO agreement
by India.
S V VeerramaniChairman & Managing Director, Fourrts (India) Laboratories Pvt Ltd
Although the SMEs had to undergo fi nancial hurdles, many of them have overcome the same and have created pharmaceutical plant of good standards. These plants are likely to cater to outsourcing in a big way under contract manufacturing.
52 Modern Pharmaceuticals I March 2012
You have been part of SPIC for more than 6 years now. How has been the journey? I have been the Secretary General of
SME Pharma Industries Confederation
(SPIC) since inception and the journey
has been full of struggle for survival of
industry. SPIC had come up because of
the consequences of changes in law for
pharma SMEs and it has been struggling
over the years for the growth of pharma
SMEs in India.
Elaborate on the evolution of the pharma SME segment in India. In 2005, two important events took place
that shaped the pharma SMEs sector.
Amended Schedule M of Drug Act
was implemented to upgrade pharma
SSI to international levels. Around
300 SSI Units in Maharashtra and 90
in Haryana had to close down. Others
faced major problems since government
provided no technical support
With the objective of higher revenue and
to discourage printing of higher MRP
on labels by companies, government
changed excise modality whereby excise
was levied on MRP (less 40 per cent)
abatement instead of the ex-factory
clearance value, which was the basis
earlier. Owing to anomalies in change
of modality, the burden of excise on SSI
increased manifold rendering it unviable
at a time when they were mandated
up gradation under Schedule M costing
crore of rupees for each unit. Over 70
per cent of production of medicines
migrated to Excise Free Zones (EFZ) of
Himachal and Uttarakhand in existence
since 2003. Not only they evaded the
high burden of excise but became free
to print higher and higher MRP on
labels causing an unprecedented price
rise in medicines. NIPER recorded a
price rise of 326 per cent from EFZ
in 2006. With shifting, 70 per cent
production revenue was lost instead
of a gain as envisaged while changing
the policy.
Th ese issues were taken to the government.
Th e Prime Minister then intervened and
sought recommendations of Economic
Advisory Council, which were approved
but never implemented by the Ministry
of Finance.
What are the challenges faced by the Indian pharma SMEs?Till this day, India is saddled with
unnecessary price rise and loss
of revenue, which is contrary to
stated objectives of the change
in policy.
Further, the excise duty on medicines
that was reduced in 2008 has not brought
production back to non-EFZ, which means
revenue is lost and price rise continues,
while 5,000 pharma SMEs outside EFZ
continue to struggle.
Millions of shopkeepers across the
country are sourcing their brands
from EFZ at MRP of choice and pushing
them through doctors after bribing
them. 5,000 SSI elsewhere in the country
are out of contention as excise on MRP
prevents them to print higher MRPs
as compared to EFZ and cannot bribe
doctors. Th e fact that the consumer
has become a hapless victim is of no
consequence to government because
price rise of medicines was never an
election issue.
With 70 per cent population earning
less than ` 90 per day it is a hopeless
situation. Th ere are reports of people
dying or slipping into poverty owing to
high cost of medicines. Goverment has
been unable to provide any relief even
when the problem is essentially caused by
change of policy.
Insight & Outlook: Interface - Jagdeep Singh
“Pharma SMEs are on the decline, which is a dangerous trend in a country like ours”…says Jagdeep Singh, Secretary General, SME Pharma Industries Confederation India (SPIC). Starting his career in 1979 by setting up a small scale industry unit for injectibles and eyedrops, he has been instrumental in driving the SMEs in pharma sector. He highlights the current state of pharma SMEs in India.
Titash Roy Choudhury
Jagdeep Singh
53March 2012 I Modern Pharmaceuticals
A plan to cut down prices of medicines
to less than half was submitted to the
government around two years ago. It has
been unable to criticise the plan in several
meetings but large industries/MNCs do
not allow its implementation as it is averse
to any price control. All these facts are
mentioned in the plan and we have been
following up with the same for years now.
How have the Indian pharma SMEs grown over the years?Around 5,000 pharma SMEs in
non-EFZ have not grown over the last
5 years; their sales have declined instead.
Most of those who migrated to EFZ in
2005 and created huge units have become
unviable because they face stiff competition
from each other. Central Drugs Standard
Control Organization (CDSCO) offi cials
have also confi rmed that the highest
number of spurious drugs is produced
from EFZ. Th is happens not only because
they provide 70 per cent production but
because they cut corners on quality owing
to an unhealthy competition. Pharma
SMEs whether in EFZ or outside have
suff ered over the years. And when it
comes to government support to pharma
SMEs it is only on paper despite the fact
that it is the only regulated industry under
price control. Ask any pharma SME
whether it has ever got any support from
the government?
Future of pharma SMEs in India...Pharma SMEs are on the decline, which is
a dangerous trend in a country like ours. If
you go through the Aff ordable Medicines
Plan you can see that only pharma SMEs
are ready to bring down prices. If they are
removed from the scene, which is likely if
the present trend continues, not only prices
of medicines will skyrocket but the capacity
of the country to produce aff ordable drugs
will be lost forever.
Around 25 per cent market has already
been taken over by six MNCs alone.
Government is showing worry but
is unwilling to help SMEs or even
implement consumer-friendly Aff ordable
Priced Quality Medicines Plan submitted
by us, which could be a solution
for both SMEs and consumer in times
to come.
SME classic growth story:One the classic growth stories is that of Torque Pharmaceuticals Pvt Ltd, a pharmaceutical company started in 1956. Th rough its product developments and advertisements the company has grown signifi cantly over the years. Today, it has a varied product portfolio and almost everyone knows about Torex cough syrup. Th is company has seen a phenomenal growth story, which has been possible due to good product development strategies and effi cient advertisement campaigns to reach the masses and make its product well-known.
54 Modern Pharmaceuticals I March 2012
Th e SME scenario has changed drastically from the time when government pushed the growth to today where
it is not the same. Present government schemes are insuffi cient to meet the demands of SMEs and more eff orts should be taken
to fuel the further growth of this sector.
Are the current government schemes for SMEs satisfactory? Government initiatives have propelled the growth of the SMEs in the pharma sector. The question is, are these schemes, though available in large numbers, satisfactory to meet the need of the SMEs in the country?
Editorial take
V S ChakravarthiManaging Director,
Hi-Tech Pharmaceuticals Pvt Ltd
Th e government schemes are mostly
pro MNCs and the government is
making eff orts to make large and
medium companies and MNCs
grow while the SMEs have taken a
backseat. Th e SMEs in the pharma
sector can easily be termed as the
neglected lot and we are afraid
that we will soon become extinct.
At one point the government in
public forum proclaims its continued
support for the SMEs, while on
the other had all the purchases by
government organisations are from
medium-large and MNCs. During
the initial growth of SMEs in 70s
and 80s government did extend
support towards their growth but
the scenario has changed in the past
few years. Th ere is an urgent need for
government attention that needs to
be paid towards the Indian pharma
SMEs, to help them become MNCs
of tomorrow.
Vinod KalaniChairman, MSME,
Sub-Committee, IDMA
Th e government is not doing what is
required for the sector. Pharmaceutical
sector in India is highly regulated
and SMEs should be given individual
attention. At present, the schemes
and policies of government are
inclined towards large companies
and MNCs. Government should
make a separate task force to look
into pharma SMEs alone and
bring out changes that are more
supportive of this sector. Many causes
are taken up by the government that
are restricting the growth of the
SMEs, like the ` 20 crore turnover
clause or no concession in pricing
for the SMEs or no separate
platform for the SMEs to apply for
any new drug. Subsidies are also
diffi cult to get since there are many
requirements to be fulfi lled. Th ere is
no co-ordination between a scheme
passed and its requirement at that
particular time.
Rohan HedeChairman, SME Pharma
Industries Confederation India
I had applied for CLSS scheme from
the government, but I was not given
the same since the scheme would only
be given to companies having profi ts
during the last 3 years. Th ere was an
overriding clause on the scheme and
even after doing the upgradation under
Schedule M and investing money I did
not get the subsidy. Th e establishment of
EFZs has also aff ected the growth of the
SMEs and especially the ones who were
involved in contract manufacturing, who
hve all shifted to EFZs. Before 2005 my
annual business was about ` 10 crore,
which today has gone down to ` 2 to 3
crore since most of my clients for contract
manufacturing turned to EFZ. In reality,
the changes in government schemes
are all done in behest of the MNCs.
Th e government has been indiff erent
to the growth of the SMEs and if there
are no SMEs the country will loose the
capability to provide aff ordable drugs and
that is a situation we should try to avoid.
Insight & Outlook: Roundtable
Titash Roy Choudhury
55March 2012 I Modern Pharmaceuticals
The report by GlobalData
provides valuable insights
on the pipeline products
within the global thyroid
cancer therapeutics sector. It is formed
using data and information sourced
from proprietary databases, primary and
secondary research and inhouse analysis
by GlobalData’s team of industry experts.
Th e report also provides insights on the
prevalent competitive landscape and the
emerging players expected to alter the
thyroid cancer market signifi cantly and
change the positioning of the current
market leaders.
Forecast: A steep growth for thyroid cancer therapeutics marketGlobalData estimates that the thyroid
cancer market was worth $ 54.8 million
in 2010. Th e major reason for the limited
market revenues in 2010 was the lack
of approved drugs for the treatment of
thyroid cancer.
However, Zactima (vandetanib) was
approved by the US Food and Drug
Administration (USFDA) on April 6,
2011 for the treatment of metastatic
Medullary Th yroid Cancer (MTC). It
is the fi rst approved drug for thyroid
cancer. It is registered in Europe as well.
Also, doxorubicin is used as an off -label
drug for treating patients with anaplastic
thyroid cancer. Th e high growth forecast
for the thyroid cancer therapeutics market
is primarily attributed to the infl uence of
recently approved drug Zactima, and the
strong pipeline.
Th e upcoming three pipeline molecules
in Phase III stage of development, and
Zactima, are expected to take a steep rise
in the market in the next seven years.
Overall, between 2010 and 2017, the
thyroid cancer market is expected to
grow at a Compounded Annual Growth
Rate (CAGR) of 27.3 per cent, to reach
$ 297.5 million by 2017.
Strong pipeline candidates: Intense future competitionGlobalData found that the pipeline of the
thyroid cancer market is strong, as there
are 26 molecules in diff erent stages of
development. Th ere are three promising
molecules in Phase III stage.
Th ese drugs are expected to get
approved in the next seven years.
Zybrestat (combretastatin A4 phosphate)
and XL184 have been granted an orphan
drug status by the FDA.
Th ese new molecules (Zybrestat and
XL-184) with novel mechanisms of
action are expected to meet the current
unmet needs and give physicians a better
choice for the treatment of thyroid
cancer. Once these molecules get
approved they are expected to intensify
competition in the market. Hence,
the global thyroid cancer therapeutics
market is heading towards a strong
competitive landscape.
Weak competitionGlobalData found that the current
competition in the thyroid cancer
market is weak, as the market has just
one drug (Zactima), which was recently
approved for the treatment of metastatic
MTC, and the rest are off -label
drugs used for other types of thyroid
cancer. Th ese off -label drugs are aimed
at managing the conditions that
contribute to thyroid cancer. Th ere is
an open space for companies to enter
into this market and take substantial
market share.
High unmet needsTh e thyroid cancer market poses high
unmet needs due to the moderate effi cacy
and safety of the available treatment for
thyroid cancer, however, the recently
approved drug Zactima satisfi es some
unmet needs. To fulfi ll the remaning
unmet needs, pipeline drugs will need to
overcome the effi cacy and safety concerns
of the current products.
Courtesy: GlobalData
The following analysis is an essential source of information and study on the global thyroid cancer therapeutics market. The report identifi es the key trends shaping and driving the global thyroid cancer therapeutics market.
Victim of weak competition
350
300
250
200
150
100
50
02005 2010 2017
CAGR (2005-2010): 6.4%
Rev
enues
($ m
illi
on
)
CAGR (2010-2017): 27.3%
Th yroid cancer therapeutics market, global, revenue and forecast ($ million), 2005-2017
Source: GlobalData, GLOBOCAN 2008,The Lancet Oncology, New England Journal of Medicine, Annals of Oncology, GlobalDataEpidemiology-based Market Forecasting Model, Primary Research Interviews, Key Opinion Leader (KOL) Interviews, ProductPrescribing Information, Company Reports
Insight & Outlook: Thyroid cancer therapeutics market
56 Modern Pharmaceuticals I March 2012
The incidences of duplication
of drugs have increased and
one might never know when
they are being cheated with a
spurious drug. According to a report by
Th e Associated Chambers of Commerce
and Industry of India (ASSOCHAM), a
staggering 20-30 per cent of drugs available
in the market are spurious. Th e impact
of selling these in the market is huge; it
aff ects not only the costumer but also the
pharma industry. “Bringing out a drug to
the market involves a lot of revenue right
from R&D, manufacturing, marketing,
branding and more. When a company
faces competition from a spurious drug,
the entire image of the company as well
as the brand suff ers. Th ere is a huge loss
in terms of revenue and brand,” explains
Rajesh Varrier, Founder & Chief Executive
Offi cer, Activecubes. Adding to this, he
says, “To try and lessen the occurrence of
counterfeit drugs we have made a product
that might not completely remove spurious
drugs from the market but the numbers
will defi nitely reduce.”
The technologyOver the years the government as well as the
pharmaceutical industry has proactively done
considerable work to check the duplication
of drugs. Th e government has appointed a
Drug Development Offi cer to check the
drugs that are being made and exported.
Pharma industry too has adopted measures
such as sophisticated packaging that would
reduce the chance of duplication of drugs
as the people who perform such acts lack
fi nance to have a large manufacturing and
packaging unit to themselves.
In the initiative to reduce counterfeit
drugs in the market Activecubes, an
analytical company, has formed an SMS
software, which will educate the costumers
and provide them the knowledge on whether
they have purchased a fake or a genuine
drug. Explaining the technology Varrier says,
“Counterfeit drugs are a serious problem in
India and other developing nations. Th is not
only presents a signifi cant health hazard but
also revenue loss; not to mention the hit the
brand takes. In order to reduce the menace
of spurious drugs, it is important to be able
to track the drug at the level of a strip or
a vial. Bar coding them at the box level is
really of little impact. Hence, we have come
up with a unique identifi cation number for
every strip or vial that is manufactured.”
Adding to this technique, he informs,
“Th e unique identifi cation number would
be printed on each strip of the drug that a
company manufactures. Th e code is generated
with an algorithm, which is proprietary to us.
So, there is an algorithm that can read the code
and decode it when required. When the drug
goes out to the market, the number goes with
the medicine. Th e customer can then send a
SMS with the code printed on the strip to us
and within three seconds the customer will
receive a message from our end stating that
the drug is genuine. How this will help stop
spurious drugs? A person can duplicate one
strip, but without his knowledge the number
will also get duplicated. A counterfeiter can
try to replicate it, but when we get a message
of an alteration of the code we can check it
and most importantly inform the costumer
that the drug is fake.”
Dual solutionTh ere are two parts to the solution:
Unique Identifi cation Number (UIN) on
strip/vial level: A unique identifi cation
number on every strip of medication is
generated and linked to their database.
Th e numbers are not simulated, hence,
when a customer buys the medication
all he/she does is SMS the code to the
number on the strip. Th e code is received
by the system and it is cross checked in the
database. If it fi nds a match it issues a reply
about the validity of the drug, if a SMS
Insight & Outlook: Case Study - Fighting counterfeits
Counterfeiting of drugs has become one of the major concerns of the pharmaceutical industry. To help reduce the production and sale of such drugs, Activecubes has come forward with a unique SMS technique to help determine the genuineness of the drug.
Just an SMS away!
Jasleen Kaur Batra
Case Study - Fighting counterfeits
57March 2012 I Modern Pharmaceuticals
with the same code is already received
then the consumer is informed that the
drug is not genuine.
QRCode/2D code: A QRCode/2D
code is also printed on every vial as an
added mechanism for validation of the
authenticity of the strip. Th e customer
needs to download the mobile app once
for free and key in the QR code post,
which the application will communicate
with the database at the backend and
revert with the authenticity of the strip
or vial. QR codes will be an additional
level of security since they are not easy
to replicate.
Growth opportunitiesAlthough there are not many analytical
companies present in India, the
industry defi nitely has a lot of potential.
“Th ere is signifi cant space to grow
and excel in the market abroad. If you
consider the US market - it is mature in
multiple ways. From an industry growth
perspective, US does not have growth
rates like that of India. For instance, if
you consider the top companies is India
one would notice that their growth rate
is anything between 10-30 per cent,
whereas in the US it might be 4-5 per
cent year on year,” says Varrier. Explaining
the analytical market further he said,
“When an industry grows at slow rate
the competition defi nitely gets stiff .
Th e companies want to understand every
bit about the costumers, the buying
pattern, what is selling and what is not.
But the Indian market does not function
in the same manner as the growth rate of
companies is tremendous high. In India,
the question is not about fi nding ways
to understand the costumer better; it is
but to fi nd ways of reaching the market
in the least possible time. Hence, India
is still a few years away from reaching a
state where pharma companies want to
analyse all their data to fi nd ways of doing
better than their competitors.”
However, there a few leaders in the
Indian pharma industry who feel the
need to analyse data to stay a step
ahead. Th e India pharma sector needs
the help of analytics for tackling
spurious drugs, and hence, this
technology has a lot of potential to
turn the industry of counterfeit drugs
upside down.
Rajesh VarrierFounder & Chief Executive Offi cer, Activecubes
In India, the question is not about fi nding ways to understand the costumer better; it is but to fi nd ways of reaching the market in the least possible time.
58 Modern Pharmaceuticals I March 2012
The US Food and Drug
Administration (USFDA)
defi nes Process Analytical
Technology (PAT) as a
mechanism to create, analyse and
calibrate the drug manufacturing process
through the measurement of certain
parameters called as ‘Critical Process
Parameters’ (CPP). “Th e USFDA
had approved and implemented this
technology a few years ago for production
of medicines in batches. PAT technology
analyses and measures the CPP, which
aff ects the quality of the product. Th us,
in turn this process helps to analyse the
quality of the end product,” says Sumeet
Kad, Analyst, Synovate Healthcare. Th is
process holds more prominence while
manufacturing a generic version of
any Active Pharmaceutical Ingredient
(API), since that requires modifi cations
and certain changes in the composition,
and here in PAT helps to analyse how
certain modifi cations are going to aff ect
the quality of the fi nal drug. “Th e basic
methodology for the process is to test
the critical parameters of the drug being
manufactured while in line without
disrupting the production fl ow. Th e
analyses and the calibration happen on
the line as well. Also the testing is done
subsequently on the production line as
well,” informs Dr Vikram Venkateswaran,
Healthcare and Lifesciences Professional.
“Th is technology analyses each and
every process and helps in determining
the properties of the end product,” says
Arunabha Bhaduri, General Manager
- Process Control Solutions, Rockwell.
According to ARC Research, some of the
leading suppliers of PAT are ABB, Aegis
Analytical, GE, Perkin Elmer, Rockwell
Automation, Siemens and Solvias.
Use of PAT in the pharma industryTh e pharmaceutical drug development
process is a highly regulated mechanism
starting from drug discovery to
commercialistaion. In the traditional
manufacturing line, the drug has to
be taken off the line to be tested. Th is
is a long process and delays the fi nal
manufacturing time. Under PAT, the
drug need not be taken off the line,
instead using the PAT equipment the
drug is monitored and tested for critical
process parameters. Th is is to ensure that
the manufactured drug meets the critical
quality attributes.
“Implementing PAT consists of two
broad categories. Th e fi rst step is to
design the PAT roll out framework. Th is
would depend on the nature of the drug
being manufactured and the process
that is currently running. Th ere are two
critical steps in designing the framework,
deciding what information needs to be
collected to qualify the critical quality
attributes and deciding which stage in
the manufacturing process does one need
to collect that information. Th e second
step involves selecting the right tool for
the analytical process. Th e three main
sets of tools that are an integral part of
any PAT system include: Multivariate
Data Analysis tool - some common
tools are SPSS, SAS, Spotfi re and Excel;
Process Analytical Chemistry tools
such as Bio Sensors, Near Infra Red
Spectroscopy and Raman Spectroscopy;
and Knowledge Management tools - this
can be done through standard MES tools
and Electronic Content management
tools,” informs Dr Venkateswaran.
Advantages of PATTh is technology has been used in other
industries such as petrochemicals, food
processing but in pharmaceuticals it
has received a mixed response. Th is
Titash Roy Choudhury
The
A technology that has proved its importance in other industries is still at a nascent stage in the pharmaceutical sector. Though implemented by regulatory bodies, PAT is yet to enter the pharma market full-fl edged and prove its potential.
Automation Trends: Process Analytical Technology
less exploredopportunities
Process Analytical Technology
59March 2012 I Modern Pharmaceuticals
technology has several advantages,
which if implemented in this sector,
will give better results. One of the main
advantages of this technology is that in
manufacturing of the drugs, “Th e cycle
times and the production time will be
lowered substantially. Also, the inline
testing will result in lesser changes in
the line, which will fasten turnaround
times,” informs Dr Venkateswaran.
With reduction in production time, the
drugs can also be marketed sooner. “It
reduces the production cycle which in-
turn reduces the marketing time and
gives the company a chance of getting
a drug faster to the market,” says Kad.
Th e second biggest impact area is supply
chain. “With the shortening cycles
of manufacturing, supply chains will
become a closed loop and inventory
planning would be faster and more
accurate. According to research done
in 2009, the implementation of PAT
would create a one-time release of
$ 79 billion, which otherwise is locked
up in inventory due to production
delays,” says Dr Venkateswaran. Th is
technology will also assure the quality
of the fi nal drug. “Th rough PAT, quality
assurance on manufacturing would
be met almost always - 100 per cent
- once the quality parameters are set,”
says Dr Venkateswaran and this will
prevent rejection of batches of drugs
due to quality issues. “Th ere are various
advantages of PAT like, higher through
put, faster time to market, reduction in
manufacturing cost, higher recall and
better output,” sums up Bhaduri.
Challenges in implementationTh e implementation of this technology
has been slow in Indian pharma market
since there are various challenges that
need to be overcome before the market
can fully integrate this technology.
“Th is technology is gradually coming
to India. Th e entry was so late because
Indian pharma market is not technology
driven but controlled more manually.
Th is technology requires an initial
high cost of investment so many
companies have not yet invested in
PAT, but it is going to prove immensely
important for a generic market like
India,” feels Bhaduri. Th us, the biggest
challenge to PAT implementation is cost.
“Not only is it expensive to implement
PAT, it would also require a lot of
modernisation to do the same. Th e current
manufacturing process would not allow
for PAT to be implemented so business
process re-organisation would have to
be done and the manufacturing line re-
assembled. Also, some of our processes
are still manual and paper based, and
PAT requires a relatively high degree of
automation for the best results,” informs
Dr Venkateswaran. To implement this
technology Indian market will also
require trained professionals. “Th e know-
how and technical expertise for the same
is also required and so investment has
to be done in training. Also, the return
on investment is diffi cult to measure,”
says Kad.
Attraction for manyMany global pharmaceutical companies
such as GSK have implemented PAT
at their manufacturing sites including
Ireland, US, UK and Singapore. PAT
has also been implemented by Merck
and Pfi zer. But the absence of a
compulsory mandate has resulted in
many pharma companies ignoring
this process. Th e Indian pharmaceutical
industry is no diff erent. All these
factors have resulted in companies
in India putting this issue on the
back burner.
“For a country such as India, selective
implementation is a better way of
incorporating this technology, where
instead of utilising PAT through the
entire manufacturing process it is
installed for few processes. In that
way, they will understand the nuances
of the technology while the initial
investment will also not be very high,”
suggests Kad.
It is undoubted that this technology
will be helpful for generics market
like India. “It is slated that in the
next 5-6 years PAT would become
a regulatory mandate. Till then,
PAT for the Indian pharmaceuticals
looks like a distant reality,” believes
Dr Venkateswaran.
With the shortening cycles of
manufacturing, supply chains will become a
closed loop and inventory planning would be faster and more
accurate.
Sumeet KadAnalyst, Synovate Healthcare
PAT reduces the production cycle, which in-turn reduces the marketing time and gives the company a chance of getting a drug faster to the market.
Dr Vikram VenkateswaranHealthcare and Lifesciences Professional
According to research done in 2009, the implementation of PAT would create a one-time release of $ 79 billion.
60 Modern Pharmaceuticals I March 2012
The term carbon neutrality is
gaining widespread recognition.
It has become more recognisable
as companies attempt to
demonstrate their environmental and carbon
management credentials.
Carbon neutrality, or having a net zero
carbon footprint, indicates achieving the
net zero carbon emissions by balancing
the measured amount of carbon released
with an equivalent amount sequestered or
off set, or buying enough carbon credits in
order to make up the diff erence. Th erefore,
it is used in the context of carbon dioxide-
releasing processes, associated with
transportation, energy production, and
industrial processes.
Th us, the carbon neutral concept may
be extended to include other Greenhouse
Gases (GHG) measured in terms of their
carbon dioxide equivalence — the impact
a GHG has on the atmosphere expressed
in the equivalent amount of
CO₂. Further, it can be clarifi ed
that the term ‘climate neutral’ is
used to refl ect the fact that it is
not just carbon dioxide (CO2)
that is driving climate change.
Even though carbon dioxide
is present in huge dimension,
there are also other greenhouse
gases regulated by the Kyoto
Protocol, namely: methane
(CH4), nitrous oxide (N
2O),
hydrofl uorocarbons (HFC),
perfl uorocarbons (PFC) and
sulphur hexafl uoride (SF6).
What is carbon neutral?According to several documents and
reports, carbon neutrality refers to the
completion of the following phases:
Measuring emissions: Measuring carbon
emissions is the essential fi rst step in
eff ecting behaviour change and managing
emissions. According to Shruti Pande,
Clinical Team Lead, Wockhardt Ltd,
“Agencies gathered accurate information
on the greenhouse gas emissions linked to
their energy and electricity use, transport
(including domestic and international air
travel), and waste was sent to landfi ll. Th e
credibility, transparency and reporting
methods used aligned with international
public and private sector carbon
neutrality eff orts.”
Reducing emissions: Reduction
planning is an essential part of the carbon
neutrality process. It involves identifying
opportunities to reduce emissions. Pande
says, “Th e six lead agencies aimed to
reduce the amount of greenhouse gases
they released by putting in place: energy-
effi ciency measures, which included
conducting energy use audits, educating
staff on using less electricity, installing
low-energy lighting systems and more
effi cient heating and cooling systems, and
buying equipment that used less electricity
travel measures, which included creating
workplace travel plans to eliminate
unnecessary journeys, buying more fuel-
effi cient vehicles, and using transport
alternatives such as videoconferencing
facilities waste reduction and
recycling systems.”
She continues, “Agencies were expected
to lower their carbon emissions, not
reduce them to zero which would have
been impractical with the available
technology. Agencies did not undertake
emission reductions that lessened their
eff ectiveness. More emphasis was put on
making procurement decisions that had the
lowest overall cost in the long term, rather
than a low initial purchase cost but high
running costs.”
Off setting residual emissions: Th e third
stage necessitates the acquisition of carbon
credits to off set any residual emissions
and achieving internal reductions. When
off setting, considerations should be given
to the type of off sets bought to ensure
that they are of sound quality and thereby
represent real emissions reduction.
Essential elementsDiscussing the important attributes
of carbon neutrality, H G Koshia,
Commissioner, Food & Drugs Control
Administration, Government of Gujarat,
says, “Controlling the existing processes
Energy Management: Carbon neutrality
Over a period of time it has become the need of the industry to maintain a net zero carbon footprint by balancing the measured amount of carbon released. We take a closer look to determine the importance of carbon neutrality.
Chandreyee Bhaumik
Inching closergreen dream
to the
Name:___________________________________________________Designation:_________________________________________
Company:_______________________________________________________________________________________________
Address:_______________________________________________________________________________________________
City:_________________________________________Pin:_______________________State:__________________________
Tel:________________________________________Mob:_______________________________Fax:_________________________
Email:__________________________________________________Web:_______________________________________________ 03/2
012
EASY STEPS TO GET PRODUCT INFO
Product Inquiry Card
FILL IN THE BOXES
WITH PRODUCT
NUMBER/S OF YOUR
CHOICE AND SEND
TIP-15
Product Sourcing Just Got Simpler
1 See the index page in this issue. Every product carries a number.2 Choose products of your choice from the list.3 Write their serial numbers (as per the index page) of your chosen product/s one-by-one in the boxes.4 Fill in your complete contact details. 5 Send it to us at the address printed overleaf.
PLEASE ENSURE
THAT YOU FILL IN
ALL THE DETAILS
REQUIRED
TIP-2
POSTAGE WILL BE PAID BY
ADDRESSEE
NO POSTAGE STAmP
NEcESSARY If POSTED IN INDIA
Business Reply InlandBR Permit No. 555
Bhavani Shankar Post Office,mumbai 400 028.
Special Projectmodern Pharmacuticals
‘A’ Wing, Ruby House, 1st floor, J K Sawant marg Dadar (W), mumbai 400 028 INDIA
InfomedIa 18 LImIted
Carbon neutrality
63March 2012 I Modern Pharmaceuticals
with appropriate technology, effi cient
maintenance and providing for renewable
energy sources to reduce the carbon
footprint is extremely important. Th is
includes re-designing the existing
processes for identifying the steps that
can be eliminated.” Further, according
to him developing newer processes
that are targeted to achieving zero
carbon emission is also signifi cant. He
highlights, “Identifying the areas of
indirect emissions which on an individual
level or at the organisational level can be
reviewed for reduction of carbon emission,
application of renewable energy resources
such as solar energy for domestic as well
as industrial usages, use of biogases for
mass canteens, etc is important. Th e basic
approach is to work on both direct and
indirect emissions, which in a planned or
co-operative manner can be attended.”
Koshia avers, “One needs to account
for the sources of emission generation,
quantify each source for its potential for
emission and draw a balance sheet against
the steps and quantities of emissions
reduced or eliminated.” Continuing this
strain of thought, he highlights, “Th e net
balance must be targeted towards off setting
the debits-emissions, completely by the
credits –elimination of emissions.”
Pharma contextTh e pharma sector broadly consists of
two segments - Active Pharmaceutical
Ingredient (API) and formulations.
According to Koshia, the direct carbon
emission control is a bigger challenge
for API facilities and this is achieved
by migration from synthetic processes
to biotechnology-based processes.
Koshia avers that carbon neutrality has
huge importance in the pharma sector
for following reasons:
Th e signifi cant investment in the
pharma facilities is towards the
creation of controlled environment for
manufacturing areas. Th is is achieved by
installation of HVAC systems. Carbon
neutrality would contribute signifi cantly
towards reduction of DELTA factor,
ie, the factor of control of ambient
parameters to desired parameters such
as dust/particle control, temperature
control, etc
Th e safety and health hazards reduction
is feasible with adoption of technology
and concepts of carbon neutrality
Pande says, “Temperature excursions are
serious because non-compliance with the
manufacturer’s storage recommendations
and the MHRA’s guidelines on general
storage can lead to expensive product
recalls, may prompt the destruction of
aff ected products and, ultimately, could
cause a health risk to patients. Issues
relating to temperature control will cost the
distributor in a number of ways, especially
since they can lead to a loss of confi dence
in the distributor by manufacturers,
the MHRA and pharmacists.” She
continues that glossing over temperature
control issues is not an option since the
MHRA’s Orange Guide makes it clear
that distributors must comply with the
regulations or face sanctions if their
facilities are found to be wanting. Adverse
inspections will trigger recommendations
for corrective action and if it is not
taken the MHRA can take regulatory
action. Th is may include suspension of a
manufacturer’s or wholesale distribution
licence, compulsory variation of licences
to exclude certain activities and sanctions
against the responsible person. She
highlights, “It is not the general conditions
that aff ect product quality, but extremes of
temperature within the operational space.
As global warming is widely accepted as
a reality, temperature control issues are
likely to become even more of a problem
in warehouses that are not equipped with
appropriate cooling.”
Maintaining carbon neutralityPande says that unlike traditional systems,
which pump more greenhouse gases into
the environment, exacerbating the problem
over the long term, to engineer systems to
maximise ‘free’ cooling so that the chiller
plant is only operational when daytime
external temperatures are exceptionally
high.” Signing off she adds, “HVAC
solutions utilise technologically advanced
‘Balanced Jet’ air induction systems. Air
fl ow and temperature throughout the
operational space is maintained at ± 1°C
of the desired level, as the systems are
purpose-designed to entrain and recycle
heat outputs from MHE; cope with tall,
densely racked aisles, mezzanine areas and
loading bays and integrate aesthetically
with ancillary systems such as lighting,
fi re curtains and sprinklers. Importantly,
engineer systems to deliver free cooling
via a night time purge, when external
air temperatures are lower, reduces the
reliance on mechanical cooling and helps
to reduce operating costs over the system’s
life cycle.” Th ese are the steps that a
pharma company should follow in order
to maintain carbon neutrality.
Shruti PandeClinical Team Lead, Wockhardt Ltd
Agencies were expected to lower their carbon emissions, not reduce them to zero which would have been impractical with the available technology.
H G KoshiaCommissioner, Food & Drugs Control Administration, Government of Gujarat
Controlling the existing processes with appropriate technology, effi cient maintenance and providing for renewable energy sources to reduce the carbon footprint is extremely important.
64 Modern Pharmaceuticals I March 2012
Spurious drugs have been aff ecting
the Indian pharma market for
many years now and today the
country has become a major
source of these drugs globally. Further, this
problem gains serious momentum when it
comes to healthcare as it directly aff ects the
health of the patient and at times may lead
to death. Also, the issue of economic loss to
the manufacturing companies holding the
rights for particular products pertains. Th e
Drugs and Cosmetics Act has been in force
since 56 years but the enforcement in many
states has not yet reached the desired level.
Penetration of such laws in the interior parts
of several states is lacking. It is therefore
imperative that eff orts should come from
all the stakeholders to ensure that safe and
genuine drugs reach the public. Th e law for
curtailing this menace exists and so is the
regulatory authority; the only thing missing
is the strong will from the government to
implement the same. “Th e law has been
amended and many committees have been
formed to look into the matter, but when
it comes to implementation and taking
concrete steps we see little action,” avers
Bejon Misra, Founder, Partnership for
Safe Medicines (PSM) India. Along with
an overview of the current market scenario
we need to look at the policies and what
measures need to be taken to make the
government more pro-active.
Market scenarioTh e pharmaceutical industry in India
is approximately $ 24 billion
(` 120,000 crore) while the World Health
Organization (WHO) estimates that
counterfeit drugs make up to 20-30 per
cent of the market. According to the
WHO, counterfeit drugs include medicine
with wrong ingredients, insuffi cient active
ingredients or illegitimate packaging.
Th is has a range of negative eff ects - drug
resistance, poisoning, allergic reactions,
prolongation of treatment and even death.
“India is the world’s third largest drug
producer by volume and 14th by value, and
is increasingly being identifi ed as drug
manufacturing hub for rest of the world.
Th e size and value of the industry attracts
counterfeiters to the space and low barriers to
entry make it an easy market to access. Low
barriers include weak supply chains, multi-
level distribution channels and unregulated
systems,” says Kishore Kar, Vice President-
Sales & Marketing, PharmaSecure. Other
major factors that are fuelling the spurious
drug market are lack of enforcement in
existing laws, lack of co-ordination between
various agencies among others. “Weak
penal action is also another factor that has
been reported by the Mashelkar Committee
Report. Th ey had proposed death penalty
for the culprit that has been changed to
life-imprisonment. Th e prosecution
methods for crime of drug counterfeiting
also has various technical faults,”
informs Misra.
Policies & Regulations: Policies governing drug counterfeiting
Globally, the counterfeit drug industry is estimated to be around $ 75 billion; although no exact fi gures are available for the Indian market the number of fake drugs is about 46 per 1,000. And this number will be increasing if proper measures are not taken. Although there are various policies and amendments to stop this menace their effective implementation is an issue.
Titash Roy Choudhury
Rigorous implementation:
Theway forward
Policies governing drug counterfeiting
65March 2012 I Modern Pharmaceuticals
At the helm of affairsHealth is ultimately a state aff air and the
state government is responsible for licensing
of drug manufacturing establishments and
sales premises, carrying out inspections of
licenced premises for ensuring compliance
to conditions of licences, drawing samples
for test and monitoring the quality
of drugs & cosmetics moving in the
state, taking appropriate action such as
suspension/cancellation of licences and
instituting legal action wherever needed
as provided under the Act and Rules. Th e
Drugs and Cosmetics Act 1940 is dealing
with unlicensed medicine and this law
has been amended over the years. Various
committees have been for looking into
the issue of spurious drugs such as the
Mashelkar Committee, which looked into
the spurious drugs market in India. “Th en,
there was the P N Tandon Committee that
looked into the incorporation of technology
for detecting spurious drugs, but all that
report is doing today is catching dust!
A sub-committee was also setup under
Dr VK Katoch but even that was not
focussed. More eff orts need to be
taken; the policy exists but due to lack
of implementation it is falling short”
says Misra.
As a strategic drug manufacturer and
exporter in the Asia Pacifi c region, India
plays a crucial role in fi ghting counterfeiting.
Th e growing counterfeit drug mafi a poses
a huge threat to India’s image as a reliable
exporter. “Hence, the Director General
of Foreign Trade (DGFT) in India has
mandated a step-by-step implementation
process of serialisation as the fi rst move
against counterfeit drugs. Th us, providing
the foundation for a track and trace system
that can monitor the supply chain at all
points of distribution. Serialisation is a
widely prevalent measure being used across
the globe and the DGFT notifi cations
help Indian manufacturers comply with
global standards. Th is helps pharmaceutical
companies standardise operations and
logistics for eff ective international trade.
By July 2012 all tertiary packages must
be serialised followed by secondary (boxes
typically at chemist shops) and primary
packages (blister packs and vials) by 2013,”
informs Kar.
Measures to be takenTh e reason behind widespread counterfeit
drug prevalence in India is due in part
to weak regulations, loopholes in the
distribution chain and lack of enforcement
at the ground level. “Th e entire system
requires an eff ective overhaul at the
policy and implementation level. Hence,
a collective eff ort from manufacturers,
distributors, retailers, industry bodies and
the government is needed to restrict the
growth of counterfeit drugs in India,” Kar
believes. While according to Misra the
government needs to be more pro-active
and demonstrate the seriousness of the
situation in a time-bound manner. Th ere
is a huge dearth of trained professional to
detect the crime and government should
help in building the capacity of the state
authorities. “Th ey should look into capacity
within state government adequately
supplemented, which means manpower
up gradation, and people should be given
adequate incentive among others,” says
Misra. Technology integration is also a
major hurdle to the proper implementation
of the law and nothing concrete has been
taken in that direction. India still has a
long way to go in adopting such security
measures within the system and hence
the need for authentication measures is
even higher. “Mobile authentication has
high relevance in a country such as India,
because it has leapfrogged the landline
culture and mobile usage has become
a way of life. Th e ease of use is another
advantage in popularising the concept
and its benefi ts. Appropriate measures
have been taken at the manufacturing and
packaging stage to ensure only authentic
medicines reaches the market place. Th e
logistics management at the manufacturers
end and policy regulations from the
governing bodies together construct an
adverse environment for counterfeit drug
makers,” says Kar.
Th us, what India needs right now
are more concerted eff orts towards
implementation of the suggestions made
by various committees, and strengthening
the state regulatory authorities. More than
changes or amendments in the existing
policy, the need of the hour is to look into
proper execution of the same.
Bejon MisraFounder, Partnership for Safe Medicines (PSM) India
The law has been amended and many committees have been formed to look into the matter, but when it comes to implementation and taking concrete steps we see little action.
Kishore KarVice President - Sales & Marketing, PharmaSecure
By July 2012 all tertiary packages must be serialised followed by secondary (boxes typically at chemist shops) and primary packages (blister packs and vials) by 2013.
The Drugs and Cosmetics
Act has been in force since 56 years but the enforcement in many
states has not yet reached the desired level.
66 Modern Pharmaceuticals I March 2012
Pharmaceutical companies are
always looking out for innovations
to rev up their sales. Traditionally,
like all other businesses, the
pharma industry too, built up its trade brick
by brick. It was well accepted that for any
product that is launched there would be
an initial sluggish phase in its sales fi gures
before it hits pay dirt.
Today, the scenario is completely
diff erent. Due to skyrocketing cost of
land, rentals and capital, investments have
gone up. Raw materials are costlier, prices
of transportation have multiplied and
therefore overheads are higher. Besides,
in a growing economy clubbed with high
infl ation, personal aspirations are much
higher than that in the past. Th erefore,
the qualifi ed executive as well as skilled
workers demand better pay. Industries are
mostly set up with funds borrowed at high
interest rates. All these factors shoot up
the cost of research, manufacturing and
trading of pharmaceutical products.
High stakesWhen drugs are researched, manufactured
and sold at a high price; when funds are
available at a premium, the obvious thing
that the manufacturer needs is quick
and huge returns. Unless the bottom-
line zooms northwards immediately, the
industry’s survival itself appears to be
under threat. Just like a $ 100-million
movie must fetch huge box-offi ce returns
in the fi rst week of its opening itself so
that the substantial amount paid to artists,
technicians, theatres, etc is recovered
immediately to fetch profi ts for the
producer; the pharmaceutical industry also
desires a quick buck.
Any delay in building up sales and
amassing profi ts becomes a drain on the
organisation because it continues to pay
high interest rates on funds borrowed
from fi nancial institutions. Th erefore, a
drug launch must immediately be followed
by a spike in sales. Moreover, the growth
in profi ts should remain sustained for a
reasonably long period so as to prevent a
close competitor from overtaking it.
Traditional strategiesIntensive training as well as greater
incentives to the sales force, off ering higher
margins to chemists, trimming avoidable
expenses, diluting the non-sales workforce,
etc are the standard operating procedures
for pharma companies to achieve their
sales target.
Appointing senior physicians and
consultants as Key Opinion Leaders
(KOL) to speak to august medical
audiences is among the modern methods
of pharmaceutical marketing. Th e senior
practitioner discusses his views and
experiences with the molecule in question
and the audience gradually gets infl uenced
by the underlying message. While this
technique was considered to be fairly
‘scientifi c,’ it has its share of detractors who
feel that the contents of most of the talks
by these KOL are ‘doctored!’
Th e latter approach was a tough
proposition, since zeroing upon a KOL is
by no means an easy task. Th e KOL had to
be an expert with over a decade and a half
in practice or who worked as a professor
at a high-profi le medical college hospital
/research institute. Some of these KOL
tend to be too demanding by insisting on
elaborate scientifi c information, greater
compensation as appearance fee or for
conducting clinical trials etc.
Modern trendsIdentifi cation of genuine KOL is a
complicated task as it not just involves
approaching people with impeccable
integrity and scientifi c knowledge. Besides,
these leaders must be those who are
popular, respectable and have an inherent
ability to infl uence the rest of their
Pharmaceutical companies resort to several tactics to meet their initial sales target in the shortest possible time. This is attempted through several time-tested techniques. Here’s providing a unique method to effectively use the industry for successful marketing.
Strategy: What’s new in pharma marketing?
Selective pampering
What’s new in pharma marketing?
67March 2012 I Modern Pharmaceuticals
fraternity. Moreover, these senior experts
are naturally available at a premium that
only large corporations can aff ord.
Moving away from the KOL ‘game plan’
is the latest modus operandi, particularly of
the smaller players in the pharmaceutical
market. Instead of focussing on a few,
major, pricey KOL, these companies
‘enlist’ a large number of Supporters Or
Loyalists (SOL). Th ese cohorts are usually
physicians across age and personality
barriers but who either have already built
up a thriving practice or show promise
in the growth of their patient load. Th e
peer-holding capacity of the physician or
his ability to address a gathering is not a
criterion for being enlisted so long as the
company can ‘deal’ with him comfortably
and their mutual needs are met! Th ese
prescribers are wooed with clinic inputs
such as textbooks, clinical equipment,
hospital supplies, stationery or may extend
up to personal utilities / gadgets, tours,
sponsorships, etc.
ComparisonsBoth methods have its pros and cons
for the company as well as the persons
benefi tted. Th e KOL system was originally
intended to be a scientifi c system wherein
astute, senior consultants were invited
by drug-research majors to provide an
insight into therapeutic approaches, both
for the benefi t of the company as well as
his subordinates in the specialty. However,
this system favoured few physicians and
most of them tended to be academicians
or retired professors from major
medical colleges.
With the gradual lowering of moral
standards of society in general and the
added suspicion about collusion of the
KOL with the company’s fi nancial needs,
the fraternity has begun to lose faith in
the system. Consequently, KOL have lost
their authority on prescribing patterns of
the rest of the members of the speciality.
Moreover, since the general members do
not gain anything other than knowledge
from KOL-led meetings, they have lost
their charm.
KOL have to be handled at all times
by senior members of the marketing
team only. On the other hand, the SOL
system works well for smaller companies
with shoe-string budgets as it does not
have to handle big guns! Th e National
Marketing Manager fi nds it easier to divest
responsibilities among the junior cadre to
identify reclusive, budding doctors. Instead
of providing intense training to the
Professional Sales Representative (PSR)
and the Area Manager on technical product
information, they are taught to handle
specifi c personal needs of the physician,
similar to the hospitality industry. In these
cases, demands from SOL are of minor
nature and the senior marketing staff need
not be involved in processing the request
so long as the prescriptions keep fl owing
thick and fast. Th e quarterly review of
the PSR will speak more about the way
the SOL is performing rather than the
PSR. Since the prescribing pattern of the
doctor can be directly monitored by the
PSR, the loss incurred in the case of ‘non-
cooperation’, if any, is minor.
Since KOL are visible across the industry
as well as the medical fraternity, they are
identifi ed as being part of a particular
company. Th erefore, should things not work
out the way a company desires, dumping
a KOL is not an easy task, In comparison,
SOL being imperceptible outside the
known group, not everyone is aware of the
nexus. If one group of SOL does not work,
the company simply switches to another
band of supporters in the next quarter.
Boomerang!Until the past decade, only a small number
of people were chosen as KOL and the rest
of the fraternity found the system working
well. Th is was because not everyone with
a busy practice could boast of the scientifi c
thinking that a senior medical teacher
or an aged consultant possessed. Except
for a few disgruntled voices, everyone
listened to the speaker with rapt attention
and went back to their clinics with the
take-home message.
Under the present system of pampering,
SOL with personal tours, excursions and
the like, many companies are alienating a
signifi cant section of sincere, conscientious
prescribers. Doctors, who are not part of
the SOL-circle and yet, have been regularly
prescribing good products of companies
may gradually begin to go for alternative
brands. Th is is a new development
that SOL-based companies have yet
to understand!
Companies who have started
mollycoddling SOL are progressively
distancing away sensitive, genuine physician
who keep their patient’s interest supreme.
Th ese quiet-prescribers are not showered
with any goodies since they have an image of
maintaining their individuality, “It is unfair
to provide incentives to others to prescribe
the same brands that we have already been
doing without any expectations,” said a senior
consultant on the condition of anonymity.
Such physicians, who feel that they have
been ignored, will form another cartel to
switch loyalties to another brand. Over a
period of time these hostile physicians
infl uence their like-minded colleagues and
they deviate from all brands introduced
by such pharmaceutical companies.
Eventually, while the SOL brings in
revenue, the original, genuine loyalists’
reluctance to prescribe could erode into the
drug company’s bottom line.
When drugs are researched,
manufactured and sold at a high price; when funds are available at a premium, the obvious thing that the
manufacturer needs is quick and huge
returns.
Dr Rajan T DPharma Consultant & Practising Dermatologist
Tips & Tricks: Patent prosecution tips
68 Modern Pharmaceuticals I March 2012
before fi ling
Patent prosecution is the exchange of information, between the patent examiner and the applicant, in determining as
to whether the invention is eligible and satisfies the requirements for grant of a patent. It involves writing and filing a patent application with the Patent Office
and pursuing protection for the invention as disclosed in the patent application.
The global pharmaceutical market has been encountering significant growth over the years and filing patent for drugs is a
crucial component for fuelling that growth.
But there are various factors that should be considered before filing a patent.
Co-ordinate foreign applications: Th e applicant may amend the application in view of the prosecution in
a corresponding US or EPO application. An applicant must fi le it in Form 3 either along with the application or within six months from the date of fi ling application.
8Tips&Tricks
Ask for hearing: Th e applicant may request for a hearing when possible. It can help applicants and
patent examiners quickly identify points of disagreements and correcting them and hopefully fi le for an early patent.
7Tips&Tricks
Respect deadlines:Th e Patent Offi ce’s position is that when the Act itself prescribes timelines, it must
be treated as a fundamental aspect of the process for granting patents.
9Tips&Tricks
to be
Kamakhya SrivastavaHead-Group on Research Publication and Programme, LEX ORBIS IP Practice
Checklist: An exhaustive checklist covering legal and technical points must remain at hand to
fi nalise the application and make any corrections before submitting with the Patent Offi ce.
10Tips&Tricks
Highlight limitations: During the course of prosecution, when limitations are added to
the claim to narrow down its scope, it is always better to include a brief note to that eff ect citing the location in the specifi cation or drawings from where the support is derived for that limitation.
4Tips&Tricks
Claim set from broad to narrow: Draft your claim beginning with the broadest scope to which you feel
you are entitled and concluding with the narrowest scope that merits protection. A claim set that is graduated in scope assists in performing a complete and focussed search.
2Tips&Tricks
Comprehensive reply: An applicant must ensure that thorough responses are fi led addressing the
specifi c objections set forth in the patent examiner’s offi ce action. Th is on one hand may reduce the chances of a second examination report and on the other also provide time to respond to the second examination report, if issued.
5Tips&Tricks
Number of claims: It is always better to avoid fi ling excessive numbers of claims and keep the number of
claims manageable. An optimal number of claims enable the patent examiner to enhance the quality of prosecution by focussing the search and examination eff orts at the core of the applicant’s invention.
3Tips&Tricks Early amendments/
arguments: File arguments and amendments at the earliest stage of prosecution,
and prior to a fi nal rejection if at all possible. Amendments submitted after fi nal are more diffi cult to deal with procedurally and extend prosecution.
6Tips&Tricks
considered
Claim drafting: Claims should be drafted towards the invention. Knowing what you want to protect
before fi ling the application is the primary requirement of drafting claims. A poorly drafted claim set may not capture the protection needed or desired. Misdirected claims may create diffi culties and diffi cult to anticipate what might be claimed in the future.
1Tips&Tricks
patent
Factors
a
Projects
69March 2012 I Modern Pharmaceuticals
Alembic Pharmaceuticals LtdProject type
New facility
Project news
Alembic Pharmaceuticals Ltd is planning
to set up a new pharmaceutical facility that
would involve manufacturing of diene.
Project location
Panchamahal, Gujarat
Project cost
Unknown
Implementation stage
Construction
Contact details:
Alembic Pharmaceuticals Ltd
Alembic Road
Vadodara, Gujarat- 390003
Tel: 265-2280550
Fax: 265-2281508
E-mail: [email protected]
Aries LaboratoriesProject type
New facility
Projet news
Aries Laboratories is in the process of
setting up a new facility for bulk drug
manufacturing. The project is scheduled for
completion in April 2012.
Project location
Ahmedabad, Gujarat
Project cost
Unknown
Implementation stage
Construction
Contact details:
Aries Laboratories
18, Natraj Industrial Estate
Sanand Dist
Sanand- 382170, Ahmedabad
Tel: 079-26926689
E-mail: [email protected]
Celestial Biologicals LtdProject type
New Facility
Project News
Celestial Biologicals Ltd is planning to set
up a new pharmaceuticals project which
would involve manufacturing of Albumin
Factor Viii Immunoglobulin.
Project Location
Ahmedaad in Gujarat
Project Cost
Unknown
Implementation Stage
Construction
Contact details:
Celestial Biologicals Ltd
Saekethej Bayla Highway
Village Matoda, Sanand
Ahmedabad, Gujarat- 382210
Tel: 2717-662103
Fax: 2717-662126
E-mail: [email protected]
Eisai Pharmatechnology and Manufacturing Pvt LtdProject type
New facility
Project news
Eisai has announced expansion of the
existing facility to increase manufacturing
and research capabilities. Expansion of the
facility will increase annual production
capacity to 60 tonnes of formulations and
two billion tablets by 2013.
Project location
Vishakhapatnam, Andhra Pradesh
Project cost
$20 million
Implementation stage
Construction
Contact details:
Eisai Pharmatechnology and
Manufacturing Pvt Ltd
Eisai Knowledge Centre
Ramky Pharma City (SEZ)
Andhra Pradesh
Tel: 891-3047100
Fax: 8924-282500
E-mail: [email protected]
Epsilon PharmaceuticalsProject type
New facility
Project news
Epsilon Pharmaceuticals is implementing
a sterile injectables manufacturing unit,
which would be spread over a land of
5 acres.
Project location
Mahabubnagar, Andhra Pradesh
Project cost
Unknown
Implementation stage
Construction
Contact details:
Epsilon Pharmaceuticals Ltd
6th Floor, Midtown Complex
Road No. 1
Banjara Hills
Hyderabad - 500 035, Andhra Pradesh
Tel: 040-44609000 / 44609020
Fax: 040 44609007
E-mail: [email protected]
Hyacinths Pharma Pvt LtdProject type
New facility
Project news
Hyacinths Pharma Pvt Ltd is planning
to set up a new pharma project that
would involve manufacturing of
ethambutal.
Project location
Srikakulam, Andhra Pradesh
Project cost
Unknown
Implementation stage
Construction
Contact details:
Hyacinths Pharma Pvt Ltd
H. No 8-3-678/60
Park View apartments
Yousufguda
Hyderabad- 500045, Andhra Pradesh
Fax: 040-23756566
E-mail: [email protected]
New projects and expansion activities are the barometers of industrial growth. These also present business opportunities to service providers like consultants, contractors, plant & equipment suppliers and others down the value chain. This feature will keep you updated with vital information regarding new projects and capacity expansions being planned by companies in the pharma/lifesceinces industry.
Projects
70 Modern Pharmaceuticals I March 2012
Igen Labs Pvt LtdProject type
New facility
Project news
Igen Labs Pvt Ltd plans to set up
an active pharmaceutical ingredients
unit. The completion is targeted in
1.5 years.
Project location
Hassan, Karnataka
Project cost
` 10 crore
Implementation stage
Construction
Contact details:
Igen Labs Pvt Ltd
Venkateshwarlu
CTO, Plot 106A
Road 7 Jubliee hills
Hyderabad- 500033
Tel: 040-40114001/02
Fax: 040-40114004
E-mail: [email protected]
Lupin Healthcare LtdProject type
New facility
Project news
Lupin Healthcare in planning to set
up a new pharmaceutical project
that would involve manufacturing of
pharmaceutical formulations based on
pepsin 12.50.
Project location
East Sikkim
Project cost
Unknown
Implementation stage
Construction
Contact details:
Lupin Pharmaceuticals, Inc
Harborplace Tower
111 S. Calvert Street
21st Floor
Baltimore, MD 21202
Tel: 866-587-4617
Fax: 866-587-4627
E-mail:[email protected]
Symbiotec Pharma LabProject type
New facility
Project news
Symbiotec Pharmalab is in the process
of setting up a new fermentation
facility to produce corticosterioids.
The facility is expected to be ready
in 2014.
Project location
Dhar, Madhya Pradesh
Project cost
` 450 million
Implementation stage
Construction
Contact details:
Symbiotec Pharmalab Ltd
Off A B Road
385, Pigdamber Rau
Indore- 453331
Tel: 731-4200052
Fax: 731 4201222
E-mail: [email protected]
Torrent Pharmaceutical LtdProject type
New facility
Project news
Torrent Pharmaceutical, which has
interests in pharma and power, is in
the process of expansion. It is going
to expand its facility at Kadi and will
be setting up a green field project at
upcoming Dahej SEZ.
Project location
Kadi, Mehsana district
Project cost
` 300 crore
Implementation stage
Construction
Contact details:
Torrent Pharmaceutical Ltd
Off Ashram Road
Ahmedabad- 380009
Gujarat
Tel: 079-26585090
Fax: 079-26582100
E-mail: [email protected]
Ushma Technologies Pvt LtdProject type
New facility
Project news
Ushma Technologies is in the
process of implementing an
API and formulation project in
Madhya Pradesh to develop anti-cancer
drugs.
Project location
Dhar, Madhya Pradesh
Project cost
Unknown
Implementation stage
Construction
Contact details:
Ushma Technologies Pvt Ltd
301, Evershine Mall
Off Malad Link Road
Malad (W)
Mumbai 400064
Tel: 022- 42172222
Fax: 022 4003 8925
E-mail: [email protected]
Zydus CadilaProject type
New facility
Project News
Zydus is setting up a new unit in SEZ
near Ahmedabad. This facility will
manufacture transdermal patches and
various injectables.
Project location
Ahmedabad
Project cost
` 1000 million
Implementation stage
Construction
Contact details:
Zydus Cadila Ltd
Zydus Tower
Satellite Cross Road
Ahmedabad- 380015
Gujarat
Tel: 079-26868100
Fax: 079-26862365
E-mail: [email protected]
Event List
71March 2012 I Modern Pharmaceuticals
3rd Annual BiosimilarsWith a 2-day strategic conference and
post-conference workshop on clinical
trials, Biosimilars India 2012 will bring
together key stakeholders in the
biopharmaceutical industry to learn about
the latest industry developments
and innovative commercialisation
strategies that will propel your biosimilar
strategies to the next level; March 27-29,
2012, Hyderabad
For details contact:
UBM India Pvt Ltd
Tel: +91 22 4046 1466
Fax: +91 022 4046 1477
Email: [email protected]
Website: www.biosimilars-india.com
Herbal International SummitHerbal International Summit-cum-expo
on medicinal and aromatic products is a
mega event showcasing continental,
regional & local competence in this
industry & to promote worldwide
upcoming business of herbals, spices
and finished products. More than
100 prominent companies will be
participating in this event including
foreign companies. There will be
manufacturers, suppliers, exporters,
traders of medicinal plants, herbal
plants, herbal seeds and products.
Further, product development boards
and associations related to herbal plants,
products, manufacturers and traders; April
14-15, 2012, NSIC Exhibition Complex,
New Delhi
For details contact:
ASSOCHAM
Tel: +91 11 46550555
Fax: +91 11 46536481
Email: [email protected]
Website: www.assocham.org
Lab Expo & Conferences PuneFor many years the Indian government
has been conducting this expo in
different cities of India. Exhibitors
of various lab commodities from all
over the world will come to display
their newly launched products.
Exhibitors will exhibit their products,
instruments and equipment. It will
play an immense role for broadening
their investment market and technology.
The participants will also be able to
exchange their experiences with the
viewers; April 20-22, 2012, Auto
Cluster Development & Research
Institute Ltd, Pune
For details contact:
Paramount Exhibitors
Tel: +91 172-2274801
Fax: +91172 2274803
Email: [email protected]
Website: www.paramountexhibitors.com
Lab Expo & Conferences CoimbatoreThis is an event that focusses on
various aspects related to lab equipment
manufacturing as well as promoting
good lab practices among the fellow
professionals. The trade show will
be a two-day affair and will witness
attendance from a considerable number
of professionals who have been involved
with this profession for a long time.
This expo will also be supplemented
with informative sessions and
workshops, which will benefit the
participants in a great way. This is an
excellent platform for the lab equipment
manufacturers and distributors to
display their latest technological
innovations and creations in front of
an international audience. Moreover,
this event also takes care of a number
of important issues related to lab
automation and labware equipment;
June 15-17, 2012, Codissia Intec
Technology Centre, Coimbatore
For details contact:
Paramount Exhibitors
Tel: +91 172 2274801
Fax: +91 172 2274803
Email: [email protected]
Website: www.paramountexhibitors.com
Automation 2012All leading companies in industry will
showcase their latest products and help
one find the solutions at the show.
The show brings latest technologies
from an interesting array of fields
such as: factory automation, process
automation and control systems,
robotics & drives, field instrumentation
& smart sensors bus technologies,
software solutions, wireless technology,
building automation, and hydraulic &
pneumatic automation in renewable
energy. From technocrats to solution
providers, vendors and tech-buffs,
the fair is all set to draw every one
alike; September 7-10, 2012, NSE
Complex, Mumbai
For details contact:
IED Communications Pvt Ltd
Tel: + 91 22 22079567
Fax: + 91 22 22074516
Email: [email protected]
Website: www.iedcommunications.com
NATIONAL
India’s premier industrial trade fair on products and technologies related to Machine Tools, Hydraulics & Pneumatics, Process Machinery & Equipment, Automation Instrumentation,
Packaging & Auxiliaries, IT Products, Electrical & Electronics, Material Handling and Safety Equipment.
AHMEDABADGujarat,
Oct 5-8, 2012
For details
Infomedia 18 LtdRuby House, 1st Floor, J K Sawant Marg, Dadar (W), Mumbai 400 028.
• Tel: 022 3003 4651 • Fax: 022 3003 4499 • Email: [email protected]
PUNEMaharashtra,
Nov 2-5, 2012
CHENNAITamil Nadu,
Nov 22-25, 2012
LUDHIANAPunjab,
Dec 21-24, 2012
INDOREMadhya Pradesh, Jan 11-14, 2013
AURANGABADMaharashtra, Feb 1-4, 2013
RUDRAPURUttarakhand,
Feb 23-26, 2013
Event List
72 Modern Pharmaceuticals I March 2012
INTERNATIONAL
The information published in this section is as per the details furnished by the respective organiser.
In any case, it does not represent the views of Modern Pharmaceuticals
Adaptive Designs in Clinical Drug DevelopmentAdaptive Designs in Clinical Drug
Development conference will focus a
spotlight on the industry in this rapidly
advancing novel technique. There will be
discussion on case studies from leading
pharma companies on their use of adaptive
clinical trials, maximising the benefits
of an adaptive design through effective
management, tried and tested - case
studies of successful adaptive design trials
and many others; March 26-27, 2012, The
Grange Holborn Hotel, London, UK
For details contact:
SMi Group Ltd
Tel: +44 0 20 7827 6000
Fax: +44 0 20 7827 6001
Email: [email protected]
Website: www.smi-online.co.uk
Bio IT World 2012The 2012 Expo plans to unite 2,000 life
sciences, pharmaceutical, clinical, and
IT professionals from 30+ countries.
The expo provides the perfect venue to
share information and discuss enabling
technology that are driving biomedical
research and the drug development
process. Spanning three days, the meeting
includes 12 parallel conference tracks and
16 pre-conference workshops; April 24-
26, 2012, World Trade Center, Boston,
Massachusetts, US
For details contact:
Cambridge Healthtech Institute
Tel: +781 972 5400
Fax: 781 972 5425
Email: [email protected]
Website: www.bio-itworldexpo.com
Anti-Counterfeiting for Pharmaceuticals 2012There will be discussions on the global
threat of counterfeit medicines and
brainstorming on how to best confront
the problem and provide insights into
establishing and implementing an anti-
counterfeiting programme in the global
pharma market to ensure that one is in
a better position to secure the products
against counterfeiters and most of all
ensure consumer safety. This will be a
unique opportunity to exchanges ideas
and address anti-counterfeiting and brand
protection matters in an open forum;
April 30-May 01, 2012, Philadelphia,
USA
For details contact:
IQPC
Tel: +91 80 4322 4100
Fax: +91 80 4322 4103
Email: [email protected]
Website: www.anticounterfeitingpharma.com
US-India BioPharma & Healthcare Summit 2012The event will witness a congregation
of biopharma, medical devices, healthcare
companies, venture capitalists, policy
makers from Europe, the US and
India. Panel discussions will cover areas
like drug discovery and collaborative
research, restructuring R&D in order o
maximise productivity and innovation,
therapeutic areas like oncology
(research areas, investor perspective,
market opportunities, challenges and
so on). Further, there will be discussion
on emerging market opportunities,
strtageies, funding innovation, cross
border investments, M&A trends in the
biopharma & healthcare and so on; May
11, 2012, Hyatt Regency Cambridge
Massachusetts, USA
For details contact:
USAIC
Tel: +781 586-1212
Email: [email protected]
Website: www.usaindiachamber.org
Biomarkers World Europe
This event aims to discuss how to
support target identification and
eliminate dead-end candidates,
how to understand the range of
biomarker candidates, how to create
sophisticated animal models of
human disease to develop biomarkers
for proof-of pharmacology, how to
facilitate clinical trial stratification
and employ early surrogate end
points of efficacy, how to define the
correlation between biomarker and
disease/therapeutic intervention;
May 22-24, 2012, Business Design
Centre, London, UK
For details contact:
Health Network Communications Ltd
Tel: +44 0 207 608 7055
Fax: +44 0 207 608 7050
Email: skhamissa@
healthnetworkcommunications.com
Website: www.
healthnetworkcommunications.com
CPhI WorldwideThe event hosts over 1900 exhibitors
and is the market leader for the
global pharmaceutical ingredients
industry. CPhI Worldwide has three
co-located events: ICSE, P-MEC
Europe and InnoPack. These events
focus on specific sub-sectors of the
pharma ingredients industry and
provide visitors and exhibitors
with additional capability to network
and do business in dedicated
areas; October 9-11, 2012, Feria de
Madrid, Spain
For details contact:
UBM India Pvt Ltd
Tel: +91 22 6612 2600
Fax: +91 22 6612 2626-27
Email: [email protected]
Website: www.ubmindia.in
73March 2012 I Modern Pharmaceuticals
With the theme ‘Optimising
Opportunities’, BioAsia
2012 was seen in a new
avatar in its 9th edition
as an advocacy and networking platform.
Th e event was held from February 09-
11, 2012 at Hyderabad International
Convention Centre. It was inaugurated by
N Kiran Kumar Reddy, Honourable Chief
Minister, Andhra Pradesh; Dr J Geeta Reddy,
Honorable Minister of Major Industries
GoAP; Tissa Vitarana, Honourable Senior
Minister - Scientifi c Aff airs, Government
of Sri Lanka; Dr Seth Berkley, CEO, GAVI
Alliance, Geneva; and Kevin Ali, President,
Merck & Co Inc, NJ, USA. Talking about
the developments made in the industry of
biotechnology and the plans for the future
Kumar Reddy said, “Biotech companies have
a crucial role in the society and will have to
keep the quality and aff ordability of medicines
in mind. To support the industry grow better
we are in the process of improving our
policies to make the industry more industry
friendly.” Highlighting on the footfall of the
event Karikal Valaven, IAS, Convener of the
event, remarked, “Th e precise number of
registered delegates for the event was 598;
in addition over 450 visitors also thronged
the three-day global bio-business event. Sri
Lanka participated as the country partner for
the event and more than 40 countries took
part in BioAsia 2012 with major delegations
from USA, Korea, Belgium, Pennsylvania,
Germany, Iran, Singapore, Nepal and Africa.
Th e international tradeshow at BioAsia
2012 attracted about 75 companies from
across the globe wherein the Biobazaar
(International Buyer Seller Meet) had over
45 sponsored international buyers from 17
countries. We are extremely grateful for the
support received from the Government of
India through Department of Biotechnology,
Department of Pharmaceuticals, Department
of Commerce, Department of Science &
Technology etc.”
A congregation of industry stakeholdersWith panel discussions instead of technical
sessions, the event was an instant hit with the
industry primarily as the panels had industry-
focussed deliberations while encompassing
the research and academia elements as well.
Th e panel discussions held at the event
included Vaccine policy: Recommendations
and challenges; Vaccines grand challenges
programme; Investing in Asia: Enabling
vaccine industry success; Supply chain
importance in the vaccine market: Impact
of cold chain logistics and more. Th e other
panel discussions held were on Vaccine
exports – will highly regulated markets
be on the radar? Rising importance of
contract research organisations, innovative
partnership models in outsourcing:
CROs, CRAMs, CMOs and research
cost eff ectiveness – long term solution to
the industry?
Furthermore, about 50 high profi le
speakers shared their thoughts at this event.
Focussing on vaccines, BioAsia 2012 was
successful in assembling the key stakeholders
of the sector both globally and from India.
Prominent participation of the Indian
vaccine manufacturers such as Bharat Biotech
International, Shantha Biotech, Biological E,
Serum Institute of India, Panacea Biotech,
Indian Immunological Ltd, etc in addition
the global vaccine majors such as GSK,
Sanofi , Pfi zer, Novartis, etc highlighted
the importance of the event. Hyderabad
companies such as Bharat Biotech Intl,
Biological E and Shantha contribute to
more than 60 per cent of the Indian vaccine
produced. It was perhaps therefore befi tting
that vaccines was one of core focus areas for
this year’s event.
On the second day of the event, a CEO
Conclave in partnership with Frost & Sullivan
was held with focus on Mega trends: Th e new
frontier. Th e objective of the conclave was to
provide focus to companies on the evolution
of the global trends and help them drive
growth and innovation in a rapidly changing
environment. A white paper from Frost &
Sullivan on the mega trends of the industry
is being prepared based on the deliberations
during BioAsia 2012 Conclave and will be
released during end of March 2012.
A platform for manyTalking about their association with BioAsia,
Manni Kantipudi, CEO, GVK Bio, said,
To further strengthen the biotech industry and the players entering the space of new drug discovery, BioAsia 2012 stepped into its 9th edition with a focus on vaccines and the potential that the Indian market holds.
Targetting the vaccine and drug discovery market
Jasleen Kaur Batra
(L-R): Dr K V Raghavan, Vice President, Federation of Asian Biotech Associations; Ali;
Dr Berkley; Prof Vitarana; N Kiran Kumar Reddy; Dr Reddy; Dr Ella; Dr Raja Sekhar Vundru,
Joint Secretary, Dept of Pharmaceuticals; Kantipudi; and N R Munjal, Chairman, Pharmexcil
Event Report: BioAsia 2012
BioAsia 2012
74 Modern Pharmaceuticals I March 2012
“BioAsia provides a platform for companies to exhibit, launch and
showcase their products and services. GVK Biosciences has been
associated with BioAsia for the past several years as it provides an
opportunity to network and forge new business relationships. BioAsia
2012 was well attended this year due to greater industry participation
(domestic and international) and better marketing by the organisers.”
Adding to this Dr Krishna Ella, Chairman and Managing Director,
Bharat Biotech said, “Over the years, BioAsia has become an industry-
oriented event while the Bangalore India Bio event has remained
research oriented. Hyderabad is the biggest manufacturer of biotech
products and vaccines in the country and this explains the focus of
BioAsia on elements such as strategy and markets, while the Bangalore
event is focussed on research.”
For the fi rst time, BioAsia also hosted one of its kind workshop on ‘
labs of the future’ workshop in addition to limited group workshops like
Bio-manufacturing and Cleaning Validation in association with Hyde
Engineering, Workshop on Bioinformatics for students in association
with NIPER and a Tech Transfer Summit in association with MSME
& ICICI Knowledge Park were also conducted which received an
overwhelming response from the industry and academicians. But the
most novel factor of BioAsia 2012 was the Power 20 Breakfast meeting
with Dr Seth Berkley, Chief Executive Offi cer, GAVI Alliance as the
guest and the Indo-German Power Breakfast meeting.
Promoting young mindsIn order to promote investigative spirit in young school children and
scientists, BioAsia instituted ‘Innovation and Young Minds’ award
in areas of Biotechnology/Life sciences including Biomedical/
Pharmaceutical technology, Bioinformatics, Biomechanics, etc. Th is
year, out of 61 proposals received from India and from 7 countries
abroad, 13 proposals were short listed.
BioAsia Innovation Award for 2012 consisting ` 1 lakh cash
and a memento was presented by Dr T Ramasami, Secretary to
Government of India, Department of Science & Technology, during
the event. Th e award was shared between Dr Shailaja Tiwari from
Dr H S Gour Central University, Sagar, MP for her project titled-
‘Recombinant protein based liposomal combination vaccine for intranasal
immunisation against Hepatitis and Infl uenza’ and Dr Nooruddin
Khan from the Dept of Biotechnology, University of Hyderabad for his
project titled- ‘Development of ELISA based approach to detect active
Tuberculosis including smear-negative pulmonary and extra-pulmonary
TB cases’. Th e BioAsia Young Minds award for 2012 was presented to
N Koushika from Th e Ashok Leyland School for her project titled -
‘Comprehensive health check up kit.’
Regarding plans for BioAsia 2013, Shakthi M Nagappan, CEO,
BioAsia 2012 said, “Our attempts to re-strategise the 2012 edition
has been successful and is evident from the overwhelming response
received so far. We are currently evaluating the areas that need
improvement and are also in discussions with various stakeholders
on their interests including the structure, theme, etc. Based on these
discussions the 2013 event will be announced. Th e event will be
designed in tune with the demands and expectations of the biotech
and bio-pharma industry.”
FORM IV
Statement about ownership and other particulars aboutModern Pharmaceuticals, as required to be published in the fi rst issue every year after the last day of February.
1. Place of Publication: Ruby House, ‘A’ Wing, JK Sawant Marg, Dadar (W), Mumbai-400028
2. Periodicity of Publication: Monthly 3. Printer’s Name: Mr Mohan Gajria Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,
JK Sawant Marg, Dadar (W), Mumbai-4000284. Publisher’s Name: Mr Lakshmi Narasimhan Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,
JK Sawant Marg, Dadar (W), Mumbai-4000285. Editor’s Name: Mr Manas Bastia Nationality: Indian Address: Infomedia 18 Ltd, Ruby House, ‘A’ Wing,
JK Sawant Marg, Dadar (W), Mumbai-400028 6. Names and addresses of Individuals who own
Modern Pharmaceuticals & partners or shareholder holding more than 1% of total capital: Infomedia 18 Limited (formerly known as Infomedia India Limited), Ruby House, ‘A’ Wing, JK Sawant Marg, Dadar (W), Mumbai-400028 is the owner of Modern Pharmaceuticals.
Details of the shareholders of Infomedia 18 Limited who are holding more than 1% of the paid up equity share capital of the company as on 20-02-2012:
1. Network18 Media & Investments Limited, 503,504 & 507, 5th Floor, Mercantile House, 15 Kasturba Gandhi Marg, New Delhi - 110001
2. Acacia Conservation Fund LP, Citibank N A, Custody Services 3rd Flr, Trent House, G Block, Plot No. 60, BKC, Bandra (East), Mumbai - 400051
3. Pramod Premchand Shah, Kalpana Pramod Shah, Agra Building, 1st Floor, 121/4 M.G.Road, Mumbai - 400023
4. Acacia Institutional Partners, LP, Citibank N A, Custody Services 3rd Flr, Trent House, G Block, Plot No. 60, BKC, Bandra (East), Mumbai - 400051
5. SPS Capital & Money Management Services Pvt Ltd, 66,Tamarind Lane, 4/5,Haji Kasam Bldg, 1st Floor, Fort, Mumbai - 400023
6. Sanjiv Dhireshbhai Shah, 201-203, Sapphire Complex, Nr. Cargo Motors, C.G. Road, Ahmedabad - 380006
7. The Oriental Insurance Company Limited, Oriental House, P B 7037, A-25/27, Asaf Ali Road, New Delhi - 110002
8. Accurate Finstock Pvt Ltd, 9th Floor, Shikhar, Adani House, Nr. Mithakhali Six Road, Navrangpura, Ahmedabad - 380009
I, Lakshmi Narasimhan, hereby declare that all particulars given above are true to the best of my knowledge and belief.
Dated: 20th February 2012
Lakshmi NarasimhanSignature of the publisher
Book Review
75March 2012 I Modern Pharmaceuticals
Reviewer: Dr Mandar Kubal Consultant - Infectious Diseases and HIV AIDS, Infectious Diseases and Pulmonary Care (IDPC)
HardKnocks For the GreenhornAuthor: Anup Soans
Price: ` 599
Supervision for the Superwiser Front-Line Manager
Author: Anup Soans
Price: ` 799
Th e Indian pharma industry has seen a phenomenal growth in recent years. Th is
has created employment opportunities in the fi eld with respect to sales, marketing,
research and management. Th is book brings forth the necessary skills required by
Pharmaceutical Sales Representatives (PSRs) in performing their daily duties.
Th e author has in a clear and lucid language tried to elucidate the application of
basic principles of marketing to the job of these PSRs. Th e book tries to focus
on bringing out the fi ner skills hidden within an individual with the help of
illustrations and examples and their importance in sales.
Th e fi rst part of the book is an introduction to the Indian healthcare delivery
system and the pharma industry in detail. Th e second part outlines the roles and
functions of PSRs and their importance in the marketing chain. Th e next parts try
to inform the PSRs on the knowledge that they should possess anytime during
the performance of their duties. Th e concepts of industry, customers, territory and
competitor’s knowledge have been put forth in a brilliant yet simple way. Th e PSR
being the next frontline manager in future, there is a section product position,
diff erentiation, branding, pricing, new product launch and public relations. Th e
book ends with a section on personal skills like presentation, dressing, attitude,
communication skills, personality, ethics, etc, which assist in holistic development
of a PSR. Overall an excellent read for aspiring pharma sales professionals,
existing PSRs, pharma trainers, and pharma management students.
Th e second book in the series for pharmaceutical sales professionals, ‘Supervision
for the Superwiser Front-Line Manager’ is dedicated to the roles, responsibilities
and skills of a front-line manager in the pharmaceutical sector. Th is makes a unique
reading as unlike management books the principles of management are illustrated
via anecdotes, stories, case studies and cartoons, etc. Th e book begins by illustrating
the importance of the front-line manager in the growing pharmaceutical industry
and the important link that they are in between the sales force and the management.
It then expands into the ideal qualities of a good front-line manager and ways to
achieve them.
Th e stress of the book is on the leadership role, managerial role, motivational
role and teaching role played by a front-line manager towards his team of sales
representatives. Th e section on how to manage customers and how to achieve
breakthrough performance uses simple life skills and management principles
applied to the job of the front-line manager. Th e concept of emotional intelligence
and its application in team management and customer management is of practical
use to existing and potential front-line managers. Th e concluding section on
progression in the chain of management beyond front-line managers and grooming
of successors serves as an inspiration to front-line managers. Overall, a unique book
dedicated specifi cally to the needs of a front-line manager and utilising all the
principles of management towards personal and professional growth.
76
Products
76 Modern Pharmaceuticals I March 2012
Industrial panel PCTo satisfy the stringent
standards required
in food, beverage,
clinical, chemical or
pharmaceutical applications, Advantech off ers the IPPC-8151S
15” XGA TFT LCD Celeron M fanless industrial panel PC
designed with 316L stainless steel, food-safe sealing materials and
an anti-corrosive and chemical resistant touchscreen. Its fanless
design and NEMA4X/IP66 waterproof and dustproof protection
ensure reliable operation in most hazardous environments. With
the optional enclosure kit and IP66 I/O connector kit, the IPPC-
8151S can provide a fully enclosed IP66 protection for all sides.
Advantech India
Bengaluru - Karnataka
Tel: 080-23374567
Email: [email protected]
Website: www.advantech.in
Walk-in-cooling chamberTh e walk-in-cooling chamber has double
walled insulated PUF modular panels,
which can easily be assembled at site
without any major hassles. Interior is made
of stainless steel and exterior is either made
of mild steel fi nished with powder coating
or stainless steel. Th e unit is provided with
perforated stainless steel trays.
Newtronic Equipment Company Pvt Ltd
Mumbai - Maharashtra
Tel: 022-28679326, Mob: 09821089932
Email: [email protected]
Website: www.newtronic.in
Gas fl ow adsorption analyserTh e model SGA-100 is a continuous gas fl ow
adsorption instrument specially designed for
the study of water or organic vapour isotherms
at temperatures ranging from 0°C to 80°C
(standard version), 250°C (high-temperature
version), at an ambient pressures. Th e term
symmetrical refers to a design feature where
by both the sample side and the reference side of the microbalance
is subjected to identical temperature, relative humidity and fl ow
rate. Th is provides signifi cant stability and accuracy and allowing
the possibility of performing absolute or diff erential adsorption
experiments. Th e instrument is used in industries such as catalyst,
chemicals, pharmaceuticals, foods, electronics, etc.
Smart Instruments Company
Th ane - Maharashtra
Tel: 0251-2801123, Mob: 09323509969
Email: [email protected]
Website: www.smartinsrument.com
Liquid fi lling/capping and sealing machineTh e monoblock piston fi lling/ROPP-cum-
sealer is a combination of rotary multi-
heads volumetric liquid fi lling and rotary
multi-heads RO/ROPP capping and
sealing machine. Due to its compact model
it reduces space and manpower utilisation.
A single synchronised drive mechanism couples the multi-heads
fi ller and sealer on a common base. It is suitable for glass, tin and
PET bottles/containers. Th e machine is provided with no-bottle-
no-fi ll and no-bottle-no-cap mechanism and with attachments
suitable for any one size bottle and cap.
Th e Master Mechanical Works
Mumbai - Maharashtra
Tel: 022-26493459
Email: [email protected]
Liquid-ring vacuum pumpTh e single and double-stage
liquid-ring vacuum pump is
silent in operation. Design
of the mechanical shaft seal
ensures adequate protection
to the shaft and provides for
ease of maintenance. Th is leads
to minimal time required for
servicing thereby cutting down
time to the barest minimum. Th e pump is rugged in design, reliable
in performance and easy to maintain.
Acmevac Sales Pvt Ltd
Mumbai - Maharashtra
Tel: 022-28375837, Mob: 09223388105
Email: [email protected]
Website: www.acmevac.com
PelletTh e multi-unit pellet of vitamins and minerals
and medicine in capsules include those of
vitamins and minerals, pellets of cough and
cold preparations, pellets of hyperacidity, anti-
ulcer, anti-fl atulant, anti-emetic preparations,
pellets of cardiovascular drugs, pellets of anti-
microbials & adjuvants, pellets of anti-asthamatic drugs, pellet of
NSAIDS, pellets of anti-malarial drugs, etc.
Pelltech HealthCare
Mumbai - Maharashtra
Tel: 022-28662980
Email: [email protected]
Website: pelltech-healthcare.com
Products
77March 2012 I Modern Pharmaceuticals
Hydraulic orbit motorTh e hydraulic orbit motor is available with
maximum peak power rating of 20 kW. It
provides high-torque low-speed performance
with limited overall dimensions. Th e orbit motor
is made with a system of lobe shaped geroter/
geroller. Some of the features include well-designed compact
structure, good weight to power ratio, reversible rotation direction,
excellent effi ciency, uniform torque, standard mounting fl anges,
etc. Th e orbit motor is used in applications like road sweepers,
agricultural and forestry machines, plastic injection moulding
machines, wood working machinery, printing machines, conveyor,
mining equipments, food & textiles processing, etc.
Pioneer Transmission Solutions
Bengaluru - Karnataka
Tel: 080-51273369
Email: [email protected]
Ointment manufacturing plantTh e ointment, cream, toothpaste,
shampoo, gel and lotion
manufacturing plant has all contact
parts made out of SS-316 and all
pipelines electro-polish from inside. Joints are DIN standard, with
easy openable fi ttings after cleaning. Th e plant is provided with
inline fi lters to ensure fi ltration and PLC-based control panel for
process automation. It is equipped with CIP and SIP facility and
loadcell for online weighing. All transfers are done under vacuum
to avoid any hand touch and contamination. Th e intensive mixing
by semi-contra design anchor stirrer avoiding dead zones by tefl on
scrapper and bottom entry angular homogeniser for micronising.
Arsee Engineering Works
Navi Mumbai - Maharashtra
Tel: 022-56053602
Email: [email protected]
Website: www.arsee.com
Suspension centrifugeTh e four-point suspension centrifuge is
mounted on an inertia plate with anti-
vibration mounts, thus eliminating the
cost of heavy foundation. It also eases
relocation of the machine. Only a few
bolts are to be grouted to prevent lateral movement of the machine
during operation. Maintenance of suspension system associated
with pendulum suspension machine is eliminated. Th e centrifuge
is employed in medium-to-high output processes in bulk durgs,
pharmaceuticals, food, fl avours and chemical industries. It is
off ered in complete stainless steel construction and conforms to
GMP standards.
United Engineering Enterprises
Mumbai - Maharashtra
Tel: 022-23083990
Email: [email protected]
Website: www.united-centrifuges.com
Continuous band sealerTh e is a versatile and high-production pouch
sealing machine for plastic heat sealable
materials like PP, LDPE, HMHD, polyester,
polylaminates, etc. It is provided with nitrogen
gas fl ushing arrangement for chips, wafers,
savouries, fl our, food items, etc. Th e machine is
a tabletop model suitable for pouches up to 2 kg weight and consists
of Tefl on belt used for driving the already fi lled pouches at fi xed
speeds through heating and cooling zones. At the bottom is a height-
adjustable conveyor for up to 16” height pouches.
Ace Industries
Mumbai - Maharashtra
Tel: 022-28732530, Mob: 09324481285
Email: [email protected]
Website: www.aceindus.com
Insulation materialsTh ese insulation materials include fl exible
foam produced from melamine resin. Th e three
dimensional structure of the foam is made up
of a microscopic, slender skeletal structure
that delivers insulation properties. As a result of its unique design
and inherent nature of the design, it off ers properties such as high
temperature resistance, low bacterial growth, 25/50 fi re rating,
ASTM C-1410, etc.
IUS Equipments Pvt Ltd
Navi Mumbai - Maharashtra
Tel: 022-56116626, Mob: 09960110373
Email: [email protected]
Website: iusequip.com
Horizontal pull-action clampTh e model PA-H horizontal pull
action clamp has holding capacity
with easy operation. Th e treated U-
bolts permit easy simple adjustment
and provide a positive connection with
the supplied latch plate. Th e clamp fi nds application in machine
tool positioners, welding fi xtures, production fi xtures, inspection/
gauging fi xtures, chemical machinery, lathes of container lids,
pharmaceutical machinery, assembly jigs and fi xtures, etc.
Chamunda Equipments
Ahmedabad - Gujarat
Tel: 079-27522437
Email: [email protected]
Website: www.chamundaequip.com
78
Products
78 Modern Pharmaceuticals I March 2012
Temperature and process controllerFuji Electric’s self-tuning
temperature and process controller
has low-cost options that include
RS485 communications, digital
input, timer function, heater
burnout alarm, dual outputs,
and programmable alarms.
Th e faceplate is watertight
and corrosion-resistant. Th e
three-button keypad allows
programming and the screw-terminal on the back eliminates the
need for sockets. In addition to auto-tuning and fuzzy control, it
has self-tuning control, which automatically retunes the controller
under certain conditions, without the need to revert to auto-
tuning. It accepts temperature & process inputs and off ers two
control outputs and two programmable alarms.
Procon Technologies Pvt Ltd
Ahmedabad- Gujarat
Tel: 079-27492566, Mob: 09824310188
Email: [email protected]
Website: www.procon.co.in
SpheroidiserTh e spheroidiser consists of a round disc
mounted on a vertical shaft spinning at
high-speed at the bottom of a cylindrical
chamber or drum. Th e cylindrical drum
is called the bowl and the spinning
disc is called the chequered plate. Th e
chequered plate has a grooved pattern
to increase the friction with the product
and break the extrudates to length.
When the extrudates are charged into the spheroidiser, they are
thrown on the edge of the spinning plate by centrifugal forces.
Umang Pharmatech Pvt Ltd
Dist Th ane - Maharashtra
Tel: 0250-6450835, Mob: 09764998260
Email: [email protected]
Website: www.umangpharmatech.com
Digital temperature indicatorTh e digital temperature indicators is available with
features, such as auto shut-off circuit, built-in-lineariser,
open sensor indicator, low battery indicator, 3½ digital
0.5” LCD display, low power cosumption, compact
moulded ABS cabinet, etc.
Instrument Research Associates Pvt Ltd
Navi Mumbai - Maharashtra
Tel: 022-61484000
Email: [email protected]
SpectrophotometerTh e spectrophotometer is designed for
versatility in various applications. It is a
portable integrating sphere spectrophotometer
incorporating numerical gloss control. It
simultaneously measures specular component
included and specular component excluded
and displays the data on the LCD in only 1.5 seconds. Th e relativity
gloss value can be displayed by using numerical gloss control.
Th e spectrophotometer fi nds applications in pharmaceuticals,
cosmetics, printing, building materials, textiles, food, etc.
Jay Instruments & Systems Pvt Ltd
Mumbai - Maharashtra
Tel: 022-23526207
Email: [email protected]
Website: www.jayinst.com
Pallet shrinking toolTh e pallet shrinking tool is used for
shrink wrapping. Shrink wrapping of
export pallets, giant pallets, giant articles,
big articles/machinery are used to avoid
damage during transportation. Boxes on
pallets and other products can be shrink-
packed within minutes. It provides fi ve-sided protection for any
size or shape load from small uneven pallets to large machinery
and more strength than stretch wrapping. Th e tool is compact,
portable and handy weighing 950 g.
Dharmesh Enterprises
Mumbai - Maharashtra
Tel: 022-55233591
Email: [email protected]
Website: hotairguns.com
Lyophiliser Th e lyophiliser is used for pharmaceuticals,
biotechnology and allied industries. Lyophilisation
is the preferred drying process, for heat labile
substances or where any physical, chemical or
enzymic changes are detrimental to the products
and its applications. Sublimation of frozen ice
directly in the form of vapour under high vacuum is the basis
of lyophilisation process. Th e system off ers optimal fl exibility in
programming the recipe to suit a wide variety of products. Th e
drying chamber is designed for full vacuum and overpressure of
2.5 bar.
Machinfabrik
Mumbai - Maharashtra
Tel: 022-25555596
Email: [email protected]
Website: machinfabrik.com
Products
81March 2012 I Modern Pharmaceuticals
Remote I/O system Th e RIX CANopen remote
I/O system is designed to be
mounted near fi eld elements
like junction boxes and
in push-button panels for
individual I/O connections.
RIX units are connected to
Messung’s Nexgen-5000
PLC Master using a network cable. So, there are no snaking wires
and no unnecessary loss of space and productive time. Th ese are
compact in size and easy mounting. Auto network baud rate can
be detected by RIX base units. Th ere is data transmission on I/O
status change to reduce network traffi c. Diagnostics and I/O status
LEDs are there on each module.
Messung Systems Pvt Ltd
Pune - Maharashtra
Tel: 020-27102000
Email: [email protected]
Website: www.messung.com
Vibratory fi nishing systemTh e vibratory fi nishing system
incorporates a rubber or
polyurethane lined bowl of
U-cross section mounted on
precisely calculated springs.
Th is system is driven by a highly
effi cient vibratory motor. Th e
open top of the bowl can be
loaded with suitable ceramic/
plastic or steel media and parts to be processed. Vibratory fi nishers
shake parts and media at high speeds, causing the media to scrub
the surface of the parts in an action similar to lapping. Since the
parts and the media are moving at small increments on each stroke,
the parts are not subject to severe stress or damage.
Niraj Optical Machinery
Ahmedabad - Gujarat
Tel: 079-29295747, Mob: 09909904148
Email: badrakia@rediff mail.com
Website: www.nirajopticalmachinery.com
Rotary cone vacuum dryerTh e rotary cone vacuum dryer
consists of a jacketed double
conical shell rotating around
6 rpm with provision for
application of vacuum inside
the shell and circulation
of heating media in the
jackets during the rotation
of the cone. Large
heating surface area presented by the internals of the cone
ensures uniform drying of the product, as the product gently
tumbles while the cone rotates slowly. Th e diff usive action
induced by the tumbling cone constantly presents a fresh
layer to come into contact with the indirectly heated walls of
the shell.
Bhuvaneswari Pharmach Pvt Ltd
Chennai - Tamil Nadu
Tel: 044-22641267
Email: [email protected]
Automatic powder fi lling machineTh e automatic powder fi lling machine is used in fi lling of
pharmaceutical powder medicine. It fi lls any type of powder/
granules and is made of stainless steel. Th e technical output of
machine is 20-60 fi lls per minute depending upon the material
characteristic and fi lling volume. Filling volume is 5 gm to
500 gm with diff erent size of auger and funnels. Th e power
consumption is 3 phase/440 V, 1 hp, with four core wire system
and the 25 ltr hopper capacity.
Virajka Machinery Mfg Co
Ahmedabad - Gujarat
Tel: 079-25894985
Email: [email protected]
82
Products
82 Modern Pharmaceuticals I March 2012
High-pressure washing unitTh e high-pressure washing unit consists of a robust and sturdy
high-pressure tripled plunger pump. Th is unit is designed to
perform under extreme duty condition. Th e benefi ts of the
machine are product quality greatly increased by eff ective and
through cleaning of the system, simplicity makes the cleaning less
tedious task, where a layman can operate it easily, reduces energy,
water, manpower and time consumption, etc.
Dupoly Marketing Pvt Ltd
Ahmedabad - Gujarat
Tel: 079-26577389
Email: [email protected]
Website: www.dupoly.com
Radial drilling machine Th e heavy-duty high precision all-geared drill
head radial machine comes with forged steel
gears and toughened spindle. Th is drilling
machine has automatic vertical movement of
arms. It also provides horizontal automatic
movement of man spindle head for face
milling as well as keyway milling operations.
Th e machine has arm titling at 360-degrees to
get inclined drilling. Accuracy is as per ISI chart. Th e main spindle
runout is within 0.005 mm, ie, within 5 microns. Drilling capacity
of the machines is 38 mm in steel.
Poly Kraft Machines
Ahmedabad - Gujarat
Tel: 079-22743639, Mob: 09898003625
Email: [email protected]
Website: www.polykraftmachines.com
Cooling chamberTh ese cooling chamber is provided with
perforated stainless steel trays for sample
mounting. Th is unit has full-length inner
glass door and outside metal door with
magnetic gasket and lock. It has forced
air circulation for uniform temperature,
safety thermostat, hermetically sealed
compressor, with electronic time delay to
safeguard compressor.
Newtronic Equipment Company Pvt Ltd
Mumbai - Maharashtra
Tel: 022-28679326, Mob: 09821089932
Email: [email protected]
Website: www.newtronic.in
Fluid bed dryerTh e fl uid bed dryer includes short drying time, uniform drying,
low drying temperature, electric or steam heated, SS heater, digital
temperature controller and indicator. Th is dryer is available from
10 kg to 120 kg capacity. It comes with a digital timer. Technical
specifi cation include: for 30 kg, 60 kg and 120 kg it is 100, 220,
430 container volume (in ltr), batch capacity (in kg) is 30-40, 60-
75, 129-140, heating load (in kW) is in the range of 18, 36, 60,
electrical heating motor (hp) of the range 5, 10, 15, etc.
Sunmach Machinery
Ahmedabad - Gujarat
Tel: 079-25840230; Mob: 09825008365
Email: [email protected]
FRP cooling towerTh e maintenance-free crossfl ow
FRP induced draught cooling tower
provides higher range (cooling) with
the advantages of minimum water
loss. It is suitable for any type of water
cooling application. It eliminates
maintenance of rotating sprinklers,
spray nozzles, choking of fi lls, changes
in water pressure, etc. Higher air volume aluminium fan with
lower power consumption and special design fi ll packing gives
maximum cooling effi ciency. Water distribution with non-clog
water splitting polymer nozzles work eff ectively even with gravity
pressure. Th e fi ll packing is reusable and cleanable.
Crystal India
Ahmedabad - Gujarat
Tel: 079-25833965, Mob: 09824013727
Email: [email protected]
Website: www.crystalcoolingtower.com
Pusher centrifugeTh e pusher centrifuge provides
continuous fi ltration for separation of
suspended, fast draining, crystalline,
granular or fi brous solids from
the liquid. Crystalline product has
particle size of 0.1 mm to 20 mm and
feed solids from 30 to 70 per cent by
weight. Solids are washed as they are transported through the
basket. Features include: complete separation of mechanical unit
from the process area, single or multi-stage according to product,
cylindrical/cylindro-conical basket with long and short lengths,
hydraulic pusher mechanism with variable stroke & stroke length,
slurries are fed via feed pipe and non-fl owable products are conveyed
by a screw conveyor into the feed distributor, counter current wash
and wash by displacement for high washing effi ciency.
Rotofi lt Engineers Ltd
Ahmedabad - Gujarat
Tel: 079-25712861
Email: rotofi lt@rotofi lt.com
Website: www.rotofi lt.com
Products
83March 2012 I Modern Pharmaceuticals
Electronic panel timerTh e electronic panel timer is
housed in small industrial grade
plastic box. It gives 5 per cent
setting accuracy and 1 per cent
repeat accuracy. It is available
in 415 V or 230 V with one
changeover contact. Timing
range is 30 sec, 60 sec, and 120
sec. Power and delay indications
are provided on the front side
of the timer. Potentiometer is
provided to set the required
time. It measures 102 mm x 65
mm x 43 mm and weighs 250 gm approximately.
Gelco Electronics Pvt Ltd
Ahmedabad - Gujarat
Tel: 079-22200902
Email: [email protected]
Website: www.gelco-world.com
Closure feeding systemTh e fully-automatic, hygienic
and sanitation-friendly closure
feeding system is used for crowns,
PP caps, aluminium rollon caps,
etc. Th is system is suitable for
high-speed bottle fi ller machines
up to 600 bpm for industries, like
beverages, breweries, distilleries,
pharmaceuticals, dairy, etc, which
ensures the fl ow of closure in gentle
and controlled manner into the
crowner/capper hopper, which nullify the damage and bending
of closures remarkably. Th e system is self-mounted and the dies
do not require any foundation. It is moved anywhere in the
bottling hall.
Alien Fabricon (India)
Ahmedabad - Gujarat
Email: [email protected]
Website: www.bottlingplantconveyor.com
Electronic ballast and fi xtureAcon electronic ballast
and ultra slim fi xture
comes in diff erent
models for tubelights,
T5 complete fi xtures
and HPSV, HPMV and
MH lamps. Th ese are
reliable with minimum
rejection, watt loss and electromagnetic/radio frequency
interference (EMI/RFI). Th e ballast has maximum power factor
Jet millTh e jet mill is increasingly
used in micronisation and
is a critical process for
API manufacturers, as all
bulk actives in order to
go to the next stage of the
production processes like,
tablets, agglomeration,
capsules, creams or
aerosols have to undergo process micronisation. Th is mill has
hourly capacities ranging from 2 gm to 200 kg down to D100<5
or lesser. It accepts feed sizes from 750 microns to 3,000 microns.
It is used to increase the active surface area of pharmaceutical bulk
drugs. A three-dimensional size reduction is also possible.
GR International
Chennai - Tamil Nadu
Tel: 044-22641650,Mob: 09444381252
Email: [email protected]
Drive and inverter Th e Teco-7300 CV inverter has
sensorless vector control, 150 per
cent starting torque, built-in PLC
function, LED/LCD keypad
display, NPN/PNP digital input,
PID function, braking transistor
built-in, copy unit, memory pack
function, PC (Windows)/PDA
(Win CE) link function, RS–485
Modbus RTU/ASCII mode,
fi eldbus communication modules,
built-in EMC fi lter. It complies
with UL, CUL and CE global standards.
Kuna Impex Pvt Ltd
Ahmedabad - Gujarat
Tel: 079-26841523
Email: kipl123@rediff mail.com
and reliability, prevailing over humidity, dust, chemical fumes,
voltage irregularities, etc. In-house standardised testing on each
and every ballast and quality control on the raw material ensure
that Acon ballast do not fail even in neutral fault condition,
where voltage can be nearly 415 V. It is tested at ERDA and
various labs as per IS:13021.
Suveg Electronics
Ahmedabad - Gujarat
Tel: 079-26583994, Mob: 09327002155
Email: [email protected]
Website: www.suvegelectronics.com
84
Products
84 Modern Pharmaceuticals I March 2012
Magnetic drive centrifugal pumpLutz magnetic drive centrifugal
pump is available in two series
range AM and TMR. Th e materials
are in glass-fi lled PP or carbon-
fi lled ETFE. Unique feature of the
TMR series is that the pump can
run dry for up to 15 mins without
damage. Th e inlet/outlet for the
pump is off ered in threaded (BSP/
NPT) or fl anged (ISO/ANSI)
connections. Th e TMR series is disassembled without disturbing
the motor. Maximum fl ow rate that achieved is up to 30 m³/hr
and heads up to 25 mWc. Th e strong magnetic coupling made
up of rare earth materials and three versions of each model allow
pumping of liquids of special gravities from 1.00 to 1.85.
Shanbhag & Associates
Mumbai - Maharashtra
Tel: 022-28346604
Email: [email protected]
Website: www.shanbhags.com
Cartridge sealTh e UE cartridge seal is inherently
balanced, and hence is used for
maximum range of pressure. It has
multi-springs but the spring does
not come in contact with liquid.
Th is seal is used in any kind of
contaminated fl uids. Th e seal comes
with sleeve and gland plate as one
unit. It is easy to install.
Unicorn Engineers
Delhi
Tel: 011-22421640
Email: [email protected]
Website: www.mechseal.com
Programmable logic controller Th e compact size programmable
logic controller (PLC) integrates
the compactness of small-sized
controllers with the modularity
of big-sized PLCs. It off ers
breadth of power (from 14
I/O to 128 I/O). It has 128 I/O capacity in free mix, 128 KB
programme memory and 32 KB data memory. It is provided
with high-speed backplane serial bus, wide range of I/O modules
and embedded intelligence in digital I/O modules. It has IEC-
61131-3 compatible Windows-based programming package.
Th e PLC has unique offl ine, online, debugging features, powerful
function library management, modem communication FBs, and
open serial ports.
Messung Systems Pvt Ltd
Pune - Maharashtra
Tel: 020-27102000
Email: [email protected]
Website: www.messung.com
Ball valveTh is ball valve comes with
pneumatic rotary actuator.
Th e valve is of on/off type
with screwed, fl anged, socket
weld, tri-clover end in three-
piece design. It is available in
SS-304 and SS-316 investment
castings and is fi tted with
double-acting pneumatic rotary
actuator that operators through
90-degrees angular movements
of ball valve or butterfl y
valves. Pneumatic actuator is
mounted directly on the shaft of the valve. Th e actuator is supplied
with solenoid valve mounted on it. It is available in diff erent
sizes up to 4” to control fl uids such as steam, chemicals, oil, air,
and water.
Madho Controls Pvt Ltd
Th ane - Maharashtra
Tel: 022-25883252, Mob: 09820066046
Email: [email protected]
Website: www.madhocontrols.com
Air classifi erTh e air classifi er is a screenless machine
used for grading offl ine powder into
distinct coarse and fi ne grades from
60 mesh down to 40 microns. Th is air
classifi er-type separating machine is
operated in closed circuit with existing
equipment, such as feed from the
hopper, bins pulveriser, cyclone, etc.
It is manufactured in closed tolerance and well balanced to give
trouble-free operation. Th e material is fed through the top input
pipe down on a revolving distributor plate. Th e fl uidised particles
are propelled to the sides of the inner cone by whizzer blades and
separated from the re-circulating air stream between inner and
outer ring.
Premium Vijimech Pvt Ltd
Ahmedabad - Gujarat
Tel: 079-40083450, Mob: 09712987467
Email: [email protected]
Website: www.vijimech.com
Products
85March 2012 I Modern Pharmaceuticals
The information published in this section is as per the details furnished by the respective manufacturer/
distributor. In any case, it does not represent the views of Modern Pharmaceuticals
Fluid control systemsA wide range of precision
fl uid control systems, like
pneumatically operated air
pulse dispensers, and allied
accessories, such as tips barrels,
precision dispense valves (for
various applications) pressure
tanks, etc, are off ered to give a positive control for handling various
fl uids. Dotting, lining, potting, fi lling, doming, encapsulating,
spraying, coating, etc can be done with ease, effi ciency and high
degree of repeatability and accuracy. Th ese systems handle any
type of fl uids like adhesives, anaerobics, light curing, UV curing,
moisture curing (cyanoacrylates), latex based, solvent based, etc
coating fl uids (hard coating of optical lenses), lacquers, dyes, etc.
Metering & Dispensing Technologies
Dist Th ane - Maharashtra
Tel: 022-28042189, Mob: 09833783720
Email: [email protected]
Temperature data logger Th is temperature data logger is used
for pharmaceutical industries. It has
measuring capacity ranging from -
35ºC to 80ºC, accuracy of ±0.5ºC and
resolution at 0.1ºC with sensor Pt-1000.
Th e measuring rate is selected from
1 min to 8 hours. It stores 4,000 value
data in memory. Th e measuring mode is automatic with loop,
start/stop or start with set measuring rate. It comes with a
battery life of three to fi ve years. Th ese data loggers are housed
in stainless steel, PEEK. It has IP68 protection class/housing for
pharmaceutical industries.
Ambetronics
Mumbai - Maharashtra
Tel: 022-28371086
Email: [email protected]
Website: www.ambetronics.com
Moulded parts and componentsTh e machined moulded parts and
components are manufactured
from industrial and engineering
plastics, such as nylon, UHMWPE,
delrin, polycarbonate, acrylic,
polyurethane, abs, Tefl on, PVC,
peek, PPO, PPS and Noryl. Th ese
are available in various size and
shapes in the form of sheets, rods,
tubes, pipes, blocks and profi les. Engineering plastics off ers a
variety of features like light weight, high abrasion resistant, self
lubrication, corrosion proof, noise and vibration dampening and
good dimensional stability. Th ese fi nd applications in various
industries like bottling & beverages, pharmaceuticals, paper
ceramic tiles manufacturing plants, material handling, conveyors,
steel, power, cement and chemical industries.
Arvind Anticor Ltd
Ahmedabad - Gujarat
Tel: 079-32918016, Mob: 07878883400
Email: [email protected]
Website: www.picklingplant.com
Air-cooled single-stage pumpTh e oil-lubricated air-cooled single-
stage pump comes with multi-vane
built-in anti-suck back system. It is
provided with oil recirculation system
having exhaust fi lters to produce mist-
free exhaust. Th e pump is available
with capacities ranging from 15 m³/hr to 150 m³/hr. Th e pump
is used in various applications like packaging, bottle fi lling, pick
and place, leak detection, heat treatment, distillation, suction in
hospitals, oil purifi cation, degassing and drying, etc. Advantages
of the pump are less oil, less power, noise less and pollution free
compared to normal oil seal vacuum pumps.
Toshniwal Instruments (Madras) Pvt Ltd
Chennai - Tamil Nadu
Tel: 044-26252716
Email: [email protected]
Website: www.toshniwal.net
Multi-purpose trolleyTh e specially designed multi-purpose trolley is
used for ICU/hospital/surgery. It comes with
multi-purpose aluminum extruded legs, heavy-
duty designed castor wheels, MDF monitor
top with anti-skid rubber mat, lockable MDF,
scratch-proof painted drawer box. Diff erent
boxes or trays are adjusted according to
needs due to the specially designed profi le of
tapped strip. Because of aluminium metallic structure, earthing
is affi rmative and provides safe working for electrical and
electronic appliances.
Envair Electrodyne Ltd
Pune - Maharashtra
Tel: 020-30688117
Email: [email protected]
Website: www.envairelectrodyne.com
List of Products
86 Modern Pharmaceuticals I March 2012
Sl No Product Pg No
1 AC motors ...............................23
2 Acoustic enclosure .......................25
3 Agitator ........................................19
4 Air classifi er .................................84
5 Air fi lter .................................15, 17
6 Air treatment system ...............FGF
7 Air-cooled single-stage
pump ..........................................85
8 Analytical instruments........88, BIC
9 Automatic powder fi lling
machine .....................................81
10 Ball valve .................................84
11 Batch disperser .............................19
12 Bbl brake motors .........................23
13 Biological safety cabinet ........15, 17
14 Blow-fi ll-seal machine .................11
15 Booklet and leafl et label ............BC
16 Booklet .........................................81
17 Calorimeter ..............................19
18 Cartridge seal ...............................84
19 Chlorine gas cylinder/tonner ......57
20 Chromatography ..........................88
21 Clean attire ....................................6
22 Cleanroom apparel ........................6
23 Cleanroom door.....................15, 17
24 Cleanroom garment ......................6
25 Closure feeding system................83
26 COD analyser ..............................37
27 Column ........................................88
28 Columns and chemistries .........BIC
29 Continuous hand sealer ...............77
30 Cooling chamber .........................82
31 Cooling tower ..........................FGF
32 Counters and power
supplies ...................................FIC
33 DC motor ................................23
34 Digital temperature indicator ......78
35 Dispensing booth ..................15, 17
36 Disperser ......................................19
37 Drive and inverter .......................83
38 Dry vane pump............................25
39 Duo label ..................................... bc
40 Electronic ballast and fi xture ....83
41 Electronic chlorine dosing
system and chloroscope ............57
42 Electronic panel timer .................83
43 Elemental analysis .......................88
44 Empower ...................................BIC
45 Encoder .....................................FIC
46 Fan fi lter unit ..................... 15, 17
47 Flag label ....................................BC
48 Flameproof motor .......................23
49 Flange mounting motor ..............23
50 Fluid bed dryer ............................82
51 Fluid control systems ..................85
52 FRP cooling tower ......................82
53 Gas chlorinator ........................57
54 Gas conditioning and fi re
protection ...................................39
55 Gas detector .................................37
56 Gas fl ow adsorption analyser ......70
57 Geared motor ..............................23
58 General pump ..............................21
59 Hanger label.............................bc
60 Heating bath ................................19
61 Hepa fi lter terminal
housing ................................15, 17
62 High-pressure homogeniser ........19
63 High-pressure washing unit ........82
64 Horizontal pull-action clamp......77
65 Hot plate ......................................19
66 HPLC .................................88, BIC
67 Hydraulic orbit motor .................77
68 Industrial control and sensing
device ..................................FIC
69 Industrial cooler .......................FGF
70 Industrial panel PC .....................70
71 Informatics ................................BIC
72 Injectable manufacturing
line .......................................15, 17
73 Inline disperser.............................19
74 Inspection systems .......................13
75 Insulation materials .....................77
76 Integrityplus attire .........................6
77 Inverter/variable frequency
drive ........................................FIC
78 Jet mill .....................................83
79 Kneading machine ...................19
80 Laboratory reactor ....................19
81 Laboratory software.....................19
82 Laminar air fl ow
workstation ..........................15, 17
83 Level controller .........................FIC
84 Liquid fi lling/capping and
sealing machine .........................70
85 Liquid-ring vacuum pump ..........70
86 Lyophiliser ...................................78
87 Magnetic drive centrifugal
pump ......................................84
88 Magnetic stirrer ...........................19
89 Mass spectroscopy .......................88
90 Measuring and monitoring
relay .........................................FIC
91 Mills .............................................19
92 Molecular spectroscopy ...............88
93 Motion control .........................FIC
94 Motor ..........................................23
95 Moulded parts and
components ...............................85
96 Multi-purpose trolley ..................85
97 Ointment manufacturing
plant .......................................77
98 Overhead stirrer ...........................19
99 Packaging service provider .......53
100 Pallet shrinking tool ....................78
101 Pass box ..................................15, 17
102 Pellet .............................................70
103 Photoelectric sensor ..................FIC
104 Pilot plant ....................................19
105 Pre-engineered and pre-
fabricated modular panel ....15, 17
106 Programmable logic
controller ...........................FIC, 84
107 Programmable terminals ..........FIC
108 Proximity sensor .......................FIC
109 Pump ............................................25
110 Pusher centrifuge .........................82
111 Quick-change terminal
house ................................ 15, 17
112 Radial drilling machine ............82
113 Rapid endotoxin detection
system ........................................81
114 Remote I/O system .....................81
115 Return air riser .......................15, 17
116 RFID .........................................FIC
117 Roots blower ................................25
118 Rotary cone vacuum dryer ..........81
119 Rotary evaporator ........................19
120 Safe change housing ........... 15, 17
121 Safety light curtain ...................FIC
122 Sampling booth .....................15, 17
123 Shakers .........................................19
124 Slipring crane duty motors .........23
125 Solid-liquid mixer ........................19
126 Spectrophotometer ......................78
127 Spheroidiser .................................78
128 Spray analysis ...............................39
129 Spray control system ...................39
130 Spray fabrication ..........................39
131 Spray nozzles and accessories .....39
132 Sterilising/depyrogenating
tunnel ...................................15, 17
133 Suspension centrifuge ..................77
134 Switching relay .........................FIC
135 Technical garments ....................6
136 Tefzel HHS isotactic PP
material ........................................8
137 Temperature and process
controller ....................................78
138 Temperature controller .............FIC
139 Temperature data logger .............85
140 Th ermoplastic valves & piping
system ..........................................8
141 Th ermostats and vacuum dryer/
mixer ..........................................19
142 Timer ........................................FIC
143 Turnkey systems for dust
suppression ................................39
144 UHPLC ...................................88
145 UPLC .......................................BIC
146 Vacuum booster pump ..............25
147 Vacuum system ............................25
148 Vibratory fi nishing system ..........81
149 Vision sensor .............................FIC
150 Walk-in-cooling chamber .........70
BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGF-Front gate fold, FIC-Front inside cover
Sl No Product Pg No Sl No Product Pg No Sl No Product Pg No
To know more about the products featured in this magazine, fax us on 022-3003 4499 or tear and post to us the ‘Product Inquiry Card’ by following the 5 easy steps given there. Alternatively, you may also write to us at [email protected] or call us on 022-3003 4684, and we will send your inquiries to the advertisers/companies directly to help you source better.
List of Advertisers
87
Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No Advertiser’s Name & Contact Details Pg No
Our consistent advertisers
March 2012 I Modern Pharmaceuticals
Aqua Services 57
T: +91-265-2331748
W: www.aquaservicesindia.com
Ask Enterprises 53
T: +91-9860921110
W: www.asktechnopack.com
Charles River 81
T: +91-80-25588175
W: www.criver.com
Dover India P Ltd-Dfm India Division 21
T: +91-44-26271020
W: www.almatec.de
Everest Blowers 25
T: +91-11-45457777
W: www.everestblowers.com
Eng Expo 30
T: +91-09819552270
W: www.engg-expo.com
Fabtech Technologies Intl Pvt Ltd 15,17
T: +91-22-61592900
W: www.fabtecheng.ae
IKA India Private Limited 19
T: +91-80-26253900
W: www.ika.in
J B Sez Pvt Ltd FGF
T: +91-422-3267800
W: www.gemindia.com
Omron Automation Pvt Ltd FIC
T: +91-80-40726400
W: www.omron-ap.com
Plus Ventilation 6
T: +91-40-23812152, 23812153
W: www.plusventilation.com
Reynders Label Printing India Pvt Ltd BC
T: +91-149-3305400
W: www.reynders.com
Salesworth India Pvt Ltd(Rommelag) 11
T: +91-80-25274495
W: www.rommelag.com
Salesworth India Pvt Ltd(Seidenader) 13
T: +91-80-25274495
W: www.seidenader.de
Spraying Systems (India) Pvt Ltd 39
T: +91-80-39853200/01
W: www.spray.com
The Indian Electric Co 23
T: +91-20-24474303
W: www.indianelectric.com
Thermo Fisher Scientific Sid Div 88
T: +91-22-67429494
W: www.thermofisher.com
Uniphos Envirotronic Pvt Ltd 37
T: +91-22-6123500
W: www.uniphos-she.com
UNP Polyvalves India Pvt Ltd 8
T: +91-265-2649248
W: www.polyvalve.com
Waters (India) Pvt Ltd BIC
T: +91-80-28371900
W: www.waters.com
BC-Back cover, BIC-Back inside cover, COC-Cover on cover, FGF-Front gate fold, FIC-Front inside cover
90
RNI No: MAHENG / 2008 / 27125Postal Regd No: G / NMD / 122 / 2011 - 13
Posted at P.C Stg. Offi ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month
Date Of Publication: 16th Of Every Month
Modern Pharm
aceuticals M
arch 2012
Supplement with Modern Pharmaceuticals - March 2012Presents
22 Modern Pharmaceuticals - Supplement I March 20122
3March 2012 I Modern Pharmaceuticals - Supplement 3
44 Modern Pharmaceuticals - Supplement I March 2012
55March 2012 I Modern Pharmaceuticals - Supplement
66 Modern Pharmaceuticals - Supplement I March 2012
77March 2012 I Modern Pharmaceuticals - Supplement
88 Modern Pharmaceuticals - Supplement I March 2012
99March 2012 I Modern Pharmaceuticals - Supplement
1010 Modern Pharmaceuticals - Supplement I March 2012
1111March 2012 I Modern Pharmaceuticals - Supplement
12
RNI No: MAHENG / 2008 / 27125Postal Regd No: G / NMD / 122 / 2011 - 13
Posted at P.C Stg. Offi ce, GPO, Mumbai 400 001 On 19th & 20th Of Every Month
Date Of Publication: 16th Of Every Month